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Abstract 
 
A cells interaction with its surroundings is governed by the flora of the cell surface.  
This complex landscape of structures provides an opportunity for the re-engineering of 
the surface and so the cells properties without the use of genetic modification.  
Applying the principles of supramolecular chemistry; surface proteins can be targeted 
with carbohydrate based ligands to form both stable and metabolite-responsive non-
covalent complexes.  This redecoration of the surfaces of bacteria will make it possible 
to control the interactions that a bacterium makes with its environment, whether in a 
patient or a bioreactor. 
 
In this project the transport protein maltoporin and maltose binding protein (MBP) will 
be utilised in the construction of a maltose responsive switch.  Both proteins will be 
targeted with a maltose-based polymer which can thread through maltoporin on the cell 
surface to interact with MBP in the periplasm.  In addition, the synthesis of molecules to 
probe the binding of maltoporin through biophysical experiments will be investigated. 
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1 Chapter I: Introduction  
2 
 
1.1 Molecular Switches 
 
Molecular switches are molecules or complexes that on interacting with an outside 
force can reversibly switch between two stable states.1,2  This outside force can come 
in the form of light, pH, temperature, electric current or a binding ligand.  The unique 
properties of molecular switches have made them attractive synthetic targets and a 
wide variety of uses have been found for them.3-5 
 
The simplest switches are small molecules such as cis-1,2-dicyano-1,2-bis(2,4,5-
trimethyl-3-thienyl)ethane (CMTE) which is a yellow isomer 1.1 until irradiation with UV 
light at a wavelength of 380 nm which produces a red isomer 1.2 (Scheme 1-1).6  This 
can be converted back to the original yello isomer with irradiation at 543 nm.  This 
switch has subsequently been used for 3D data storage as the photochromatic 
molecule can be absorbed onto a surface and precisely switched between states with a 
laser.7 
 
 
Scheme 1-1 The reversible electrocyclisation of CMTE between a yellow and red isomer 
 
The binding of photochromatic compounds can also be influenced by light-induced 
conformational change.  This is the case with photo responsive crown ethers.8  Crown 
ethers are known to act as hosts for positive ions with the size of the cavity determining 
which ions can act as a guest.9,10  Shinkai et al., bridged the two sides of  a crown ether 
with a trans-azobenzene moiety which on irradiation with UV light converted to the cis-
conformer 1.4 (Scheme 1-2).  The product could be switched back to the trans-form 1.3 
by leaving the molecule in the dark.  This change led to an increase in the diameter of 
the crown and this was reflected in the ability of the crown ether to act as a host to 
cations.  The trans-product 1.3 had a preference for the smaller Na+ ions while the cis-
product 1.4 was selective for the larger K+ ions.8 
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Scheme 1-2 After irradiation with UV light the azo-group switches to the cis-form increasing the 
diameter of the crown ether. 
 
Some of the most complex molecular switches are based on rotaxanes.11,12  Here the 
macrocycle is often locked on a single section of the axle either by switchable steric 
bulk13 or electrostatic interactions.  In the case of Busseron et al., the position of a 
macrocycle 1.6 could be exchanged with a variation in pH (Scheme 1-3).14  At low pH 
the crown ether 1.6 preferentially surrounds the anilinium moiety of the axle 1.5 while at 
a higher pH the crown ether 1.6 switches to the opposite end of the axle 1.7 interacting 
with the triazolium station.  
 
Scheme 1-3 A crown ether 1.6 was switched between from an anilinium station 1.5 to a 
triazolium station 1.7 by the use of DIEA and the process could be reversed by acidifying the 
solution. 
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Molecular machines based on rotaxanes can also be made to change state dependent 
on solvent.  Coutrot et al. developed a molecular switch 1.8 where a ‘rope’ could swing 
around the macrocycles (Scheme 1-4).  This was found to occur on a fast timescale in 
non-dissociating solvents but when the solvent was exchanged for a dissociating 
solvent the speed at which the ‘rope’ swung round was reduced to enable two distinct 
rotamers 1.8-C and 1.8-D to be seen by NMR.15  In this experiment a dissociating 
solvent is one which can solvate the hexafluorophosphate ions.  When these ions are 
solvated the positive charges on the triazolium ions repel each other keeping the two 
‘ropes’ of the molecule 1.8-A and 1.8-B untangled allowing for the rope to rotate easily.  
Once in a non-dissociating solvent the hexafluorophosphate ions can sit in-between the 
two triazolium ions causing the ‘rope’ to tangle and therefore it can no longer rotate. 
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Scheme 1-4 The ‘jump rope’ mechanism.  In sections A and B the molecule 1.8 is in a 
dissociating solvent therefore the hexafluorophosphate ions are solvated and the ‘rope’ can 
swing freely around the macrocycles.  In C and D the hexafluorophosphate ions are not 
solvated so they interact with both triazolium ions tangling the ‘rope’ meaning it swings much 
more slowly. 
 
As well as solvents external stimuli such as different cations can be used to induce a 
change in conformation of rotaxanes.  In an example by Sauvage et al. two interlinking 
rotaxanes 1.9 are used with the macrocyle of one attached to the axis of the other.  
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Here two binding sites are included in the axis one with a tridentate binding motif and 
the other a bidentate.  When copper (I) is added to the solution the bidentate site is 
preferred forming the expanded conformer 1.9-A while the introduction of zinc (II) leads 
leads to binding of the tridentate site and a contracted conformer 1.9-B.16  This change 
in binding leads to a widening and shortening of molecule 1.9 much like a muscle cell 
(Figure 1-1). 
 
 
Figure 1-1 A molecular muscle.  In the expanded conformation 1.9-A a copper (I) ion is bound in 
a tetradentate site.  When the copper is replaced with a zinc (II) ion it is instead chelated by five 
sites contracting the molecule 1.9-B. 
 
These kinds of rotaxanes can act as sensors for specific cations and this research has 
also extended to anions.17-19  Molecular switches using proteins have also been 
created.20,21  These switches have the advantage of the selectivity being built into the 
proteins and can therefore be used to sense much more nuanced changes in the 
ligand than simply the size of the ion. 
 
A maltose sensor has been developed with the use of MBP and β-lactamase (BLA).  β-
lactamase was circularly permuted in a random fashion and then randomly inserted 
into the gene encoding maltose binding protein.  This created a library of proteins from 
which one was found where the catalytic activity of BLA was dependent on MBP 
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binding maltose.  This was due to the conformational change of MBP on binding 
maltose which resulted in a subsequent change in conformation of BLA restoring its 
enzymatic activity (Figure 1-2).22,23 
 
 
Figure 1-2 An MBP BLA fusion switch.  A) When maltose (red) is not bound to MBP (blue), MBP 
is predominantly in the open conformation this causes the binding site of BLA (purple) to close 
turning off its enzymatic activity.  B)  When MBP binds maltose it changes to the closed 
conformation this induces BLA to also change conformation opening its binding site.  C)  With 
BLA in a functional conformation it is able to bind lactose (orange). 
 
The use of proteins in a molecular switch conveys a large degree of selectivity such as 
the ability to differentiate between maltose and lactose.  Whereas molecular switches 
based on synthetic molecules are typically only able to detect more distinct differences 
in ligands such as the radius of an ion.  Although the degree of complexity and fine 
tuning that can be achieved using synthetic rotaxanes is impressive and a molecular 
switch implementing both proteins and synthetic molecules would yield the best of both 
worlds.  The aim of this project is to investigate whether a combination of synthetic 
molecules and natural proteins can be used to make a functional molecular switch. 
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1.2 Protein-Carbohydrate interactions 
 
Now the concept of a molecular switch has been introduced the specific interactions 
that lie behind the fundamental design of a maltose-responsive switch will be 
investigated. 
 
Protein-carbohydrate interactions are involved in many different processes in biological 
systems including signal transduction24, host-pathogen recognition25,26 and 
inflammation.27,28  Carbohydrates are found on the surface of all cells and act as the 
recognition system through which other cells, viruses and toxins may interact.  
Carbohydrate binding sites are typically shallow indentations on the protein surface, 
and thus protein-carbohydrate interactions are inherently weak.29  Binding is driven by 
a favourable enthalpy: interactions typically involve a multitude of hydrogen bonds to 
carbohydrate hydroxyl groups and van der Waals interactions between the faces of the 
carbohydrate rings and aromatic residues in the protein.30  However, this is offset by an 
unfavourable entropy term which may stem from losses of carbohydrate flexibility.31 
 
Nature has many examples of protein-carbohydrate interactions that overcome these 
limitations on binding strength. Concanavalin A (ConA), the best studied of the 
lectins32,33 (i.e., proteins which can specifically recognise oligosaccharides but which 
are neither an enzyme nor an antibody34) interacts with many cell receptors and has 
been shown to agglutinate red blood cells and some cancer cells.35  ConA commonly 
binds non-reducing terminal and internal -D-mannosyl and -D-glucosyl groups.  The 
requirements for a saccharide to bind in ConA’s binding site are referred to as the 
Goldstein Rules and require the sugar to have free equatorial hydroxyl groups in the 3 
and 4 positions and a free primary hydroxyl group in the 6 position (Figure 1-3).36  For 
disaccharides such as man(1–2)man 1.10 this allows either sugar ring to bind in the 
monosaccharide binding site.  This ability for the disaccharide to bind in more than one 
conformation has been proposed to increase the probability of binding and gives a 
more favourable entropy contribution so in part overcoming the inherent weakness of 
protein-carbohydrate interactions.34,37  
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Figure 1-3 Schematic diagram of the bonding between ConA and Man 1-2 Man in the two 
possible conformations.  The monosaccharide binding site is highlighted in the box and the 
positions of one of the mannose rings have been labelled. 
 
Mannose-binding lectin (MBL) is another important carbohydrate-binding protein and is 
part of the innate-immune system; it recognises and binds to patterns of carbohydrates 
found on the surface of a range of pathogens.38-40  MBL forms a variety of multimers 
(Figure 1-4) with the larger multimers having lower dissociation constants than smaller 
ones.  Each MBL monomer contains three carbohydrate recognition domains (CRD) 
which mainly bind mannose and fucose residues.  Multimers increase the number of 
binding sites on the MBL allowing it to take advantage of multivalent effects and so 
improve binding strength.41  HIV has been shown to contain many high mannose 
carbohydrate clusters on its surface which MBL can recognise.42  Once the pathogen is 
bound by MBL it activates the lectin pathway, a system similar to the classic 
complement pathway but not antibody dependent; or simply by binding MBL can render 
some viruses inactive.43,44 
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Figure 1-4 Schematic of MBL binding HIV, the MBL monomers (blue) are bound by sulphide 
bridges (yellow) in the cysteine rich domain to form a trimer.  The MBL binds an area of high 
mannose (red) concentration on the surface of HIV. 
 
Multivalency in carbohydrate-protein interactions is also used by some bacterial toxins 
to gain entry into cells.  A classic example is Shiga toxin which compromises two 
subunits; the toxic A-subunit and the B-subunit which delivers the A-subunit into the 
cell.45  The B-subunit binds to the glycolipid globotriaosylceramide (Gb3) which is found 
on the cell surface and allows the A-subunit to enter the cell by receptor-mediated 
endocytosis.46  The binding between the B-subunit and Gb3 is enhanced by 
mulitvalency as the B-subunit has five binding domains that can interact simultaneously 
with the cell surface (Figure 1-5).47  Furthermore, the five subunits in the Shiga toxin 
each have three binding sites for Gb3 giving the B-subunit a total of 15 binding sites.
48 
In this way, individual interactions with Kd = 1 mM can reinforce one another to achieve 
a sub-nanomolar avidity. 
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Figure 1-5 The structure of Shiga-like toxin (cyan) binding to Gb3 (red) with the three different 
binding sites per protomer illustrated.  (PDB: 1BOS). 
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1.3 Multivalency 
 
As is evident from the examples above, multivalency is a frequent feature of protein-
carbohydrate interactions.  While monovalent interactions are typically very weak, 
multivalent interactions are often found to increase the effective affinity of binding to a 
point where the interaction is functionally useful.  
 
Clusters of carbohydrate epitopes are common in many naturally occurring 
glycoconjugates.49  Lectins have been shown to have higher affinities for clusters of 
carbohydrate epitopes compared to a single oligosaccharide.50-52  The binding of a 
lectin with multiple subsites to a carbohydrate cluster is relatively well understood as is 
the increase in binding affinities.  An example is the binding of the asialoglycoprotein 
receptor to a trivalent carbohydrate with terminal LacNAc residues (Figure 1-6) which 
results in a ~106 -fold increase in binding affinity relative to a single LacNAc residue.53,54 
 
 
Figure 1-6 Schematic of asialoglycoprotein (green) binding to a trivalent carbohydrate with 
terminal LacNAc residues (blue) in the ‘face-to-face’ model. 
 
In the case of asialoglycoprotein, the increase in affinity is the sum of the free energies 
of binding of the subsites.  This is called the chelation model, and is the basis for the 
enhanced binding of the Shiga toxin mentioned above.55   
  
Increases in affinity have also been shown for the tetravalent lectins ConA and Dioclea 
grandiflora lectin (DGL) binding to multivalent saccharides.49  ConA was shown to bind 
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multivalent carbohydrates 1.11, 1.12 and 1.13 with 6-, 11- and 35-fold increases in 
affinity, respectively, compared to trisaccharide 1.10 (Figure 1-7).  Similar results were 
found for DGL which showed 5-, 8- and 53-fold increases in affinity for 1.11, 1.12 and 
1.13 respectively.56  This could not be due to chelation as the binding sites in ConA and 
DGL are too far apart for the glycosides to bind more than one at a time. 
 
 
Figure 1-7 Schematic representations of 1.10 a trisaccharide and cluster glycosides 1.11, 1.12 
and 1.13.  With the structures also shown. 
 
The increases in affinity for ConA and DGL were also found to be much lower than 
those expected from the chelation model.  The increase in binding affinity in this case is 
proposed to be due to an increase in entropy of binding to the multivalent ligand.  As 
the multivalent ligand has another epitope in close proximity to the bound epitope the 
effective concentration of the ligand around the binding site and so chances of 
rebinding when the first epitope dissociates is increased (Figure 1-8).56 
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Figure 1-8 Schematic representations of binding of a tetravalent ligand 1.13 to ConA (green), in 
A ConA binds one epitope which then disassociates (B).  ConA can then either rebind the 
original epitope (A) or bind a different epitope (C), this increase in entropy leads to an increase 
in binding strength. 
 
This use of repeated epitopes to improve binding by recapturing the ligand is repeated 
elsewhere in biology but with affinities much closer to those achieved in chelation 
binding.  An area where this process has been investigated is in the binding between 
DNA regulatory proteins and DNA.  Evidence suggests that the DNA regulatory 
proteins bind at a non-specific sequence and then diffuse along the backbone of the 
DNA until reaching the site for which the protein has the highest affinity.57,58  The 
energy barrier for moving from base pair to base pair is so small that the regulatory 
protein can traverse 10,000 base pairs every second.  This is called the ‘bind and slide’ 
mechanism  (Figure 1-9).59  This mechanism allows the regulatory protein to find faults 
in the DNA and repair them before mutations occur and is much faster than if it was to 
detach from the DNA and then reattach at each different site along the strand, which is 
referred to as ‘bind and hop’. 
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Figure 1-9 Schematic of (a) the ‘bind and slide’ mechanism and (b) the ‘bind and hop’ 
mechanism.  The regulatory protein is shown in green/grey and the DNA backbone in 
orange/brown. 
 
A similar bind and slide mechanism has been observed for lectins binding to mucins, 
these are heavily glycosylated gel forming proteins produced in epithelial cells intrinsic 
to most gel-like secretions.  In this interactions it was shown that an increase in 
carbohydrate chain length led to a greater affinity.60,61  The enhancement arises from 
the lectin having a much greater length of mucin to travel along before either reaching 
the chain end or meeting another lectin and thus having to dissociate and rebind.62 
 
These three multivalent effects; chelation, repeated epitopes and ‘bind-and-slide’ are 
some of nature’s most efficient methods of increasing the strength of protein-
carbohydrate interactions. 
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1.4 Maltoporin 
 
Maltoporin is a bacterial outer membrane protein that forms a trimeric channel through 
the membrane to allow starch fragments to enter the periplasm of the bacterium.  The 
protein was first identified in 1973 as the receptor for bacteriophage-, hence it also 
being referred to as LamB.63  Maltoporin is a maltodextrin-specific channel as well as 
acting as a diffusion pore for ions and other small hydrophilic solutes.  Its structure has 
been determined by X-ray crystallography.64  Maltoporin is a trimeric channel with C3 
symmetry, in which an 18-strand beta-barrel forms each channel (Figure 1-10).  The 
beta-sheet has an all next-door neighbour anti-parallel fold and is formed of 246 
residues (in Salmonella typhimurium).  At the extracellular edge the beta-strands are 
connected by long loops (L1-L9) averaging 17 residues.  On the periplasmic side the 
beta-strands are connected by much shorter turns averaging only 4 residues. 
 
Figure 1-10 The structure of maltoporin (green) shown from extracellular space showing a 
trimeric structure with the maltotriose (red) bound in all three pores.  (PDB: 2MPR). 
 
Loop L2 is positioned near the trimer axis and reaches over into an adjacent subunit 
placing Trp74 into the adjacent subunit’s pore.  Loops L4, L5, L6 and L9 form a 
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protrusion at the extra cellular edge while loops L1, L3 and the beginning of L6 fold into 
the beta-barrel and pack against the pore wall, creating a constriction within the pore 
(Figure 1-11).  The inner loops L1, L3 and the beginning of L6 are rigidified by the only 
disulfide linkage in the subunit which is found between two cysteine residues of L1.  
This rigid constriction is involved in the selectivity of the pore for maltoligosaccharides 
(MOS). 
 
Figure 1-11 The inside of maltoporin’s (green) beta-barrel shown from extracellular space with 
all the loops labelled.  Loops 1, 3 and 6 can been seen folding into the beat-barrel.  Maltotriose 
(red) is also shown in the constriction site.  (PDB: 2MPR). 
 
Within each pore there is a row of aromatic side chains, beginning with Trp74 from the 
L2 loop of an adjacent subunit.  These side chains follow a left handed helix along 
Tyr41, Tyr6, Trp426, Trp368 to Tyr227 which sits at the periplasmic end of the subunit.  
These residues together are referred to as the ‘greasy slide’ (Figure 1-12).65  It has 
been shown that Tyr41, Tyr6 and Trp426 bind to maltodextrin while the other residues 
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act as the ‘slide’ allowing maltodextrin to pass through the pore and into the periplasm.  
There also exists a multitude of polar residues on either side of the ‘greasy slide’ which 
form hydrogen bonds with the sugar.  The polar residues line the length of the ‘greasy 
slide’ allowing the hydroxyl groups of the sugar to ‘bind and slide’ into the constriction 
site.  When combined with the ‘greasy slide’, the polar residues ensure that there is no 
large energy barrier to be overcome for the sugar to access the pore.  Tyr118, 
separated from the ‘greasy slide’ on the opposite side of the constriction site is thought 
to act as a steric barrier only allowing specific molecules such as maltodextrin to pass 
through the pore. 
 
 
Figure 1-12 The inside of maltoporin’s (green) beta-barrel showing the greasy slide (white) with 
maltotriose bound (red).  Maltotriose is shown interacting with residues Trp426, Tyr6 and Tyr41.  
Tyr118 is not part of the greasy slide instead acting as a steric barrier.  The front face of the 
pore has been removed for clarity (PDB: 2MPR). 
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Crystal structures of maltoporin binding to maltodextrin as well as maltodextrin mimics 
have been determined.64,66,67  It has been shown that maltodextrin enters the pore with 
its non-reducing end leading from the extracellular side.  There are significant van der 
Waals interactions between g4, g3 and g2 (rings of MOSs from g1 at the reducing end 
(Figure 1-13)) and Trp426, Tyr6 and Tyr41 respectively.64,67  Maltodextrins longer than 
three residues do not show additional binding interactions to the greasy slide as the left 
handed helix of maltodextrin does not exactly match the helix of the greasy slide. The 
maltodextrin also binds through a series of hydrogen bonds to polar residues in the 
pore eyelet. When unligated the constriction site is occupied by water molecules which 
are visible by crystallography and are therefore tightly bound.67  As these water 
molecules are displaced on binding, only a ligand capable of replacing the lost 
hydrogen bonds is likely to enter the pore.  There are only minor conformational 
changes in the pore eyelet on binding maltodextrin as the charged residues in the 
constriction site form salt-bridges between themselves adding to the rigidity of the 
structure. 
 
 
Figure 1-13 Here the binding of MOSs (blue), maltose (a) and heptamaltose (b) within 
maltoporin (black) is shown, g4 and g3 bind in a similar manner for both molecules while g2 is 
found twisted towards Arg82 in (b). 
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While g3 and g4 are found to bind in very similar positions whatever the size of the 
MOS, the position of g2 varies depending on the number of glycosyl moieties in the 
MOS (Figure 1-13).  This is due to the large amount of space available in the entrance 
to the pore compared to the constriction site leading to an increased variability of the 
position of the tail end of the molecule.  Interactions of glycosyl moieties on either side 
of g2 thus determine its position in the channel. 
 
The three protomers that form the maltoporin channel bind sugars independently of 
each other.68  Electrical conductance measurements across a black lipid membrane 
have shown that the association rates of maltodextrins are largely independent of the 
chain length while the dissociation constant decreases with chain length (Table 1-1).69  
In other words, the dissociation constants decrease from di- to hexasacchardies. This 
observation appears to contradict the structural data which suggests that all MOS 
make similar interactions with the pore.  However, once the sugar is bound it can be 
thought to behave in a similar manner to the ‘bind and slide’ mechanism:  maltoporin 
can bind equally well to any section of the MOS, and as dissociation only occurs once it 
reaches the end of the sugar, longer MOSs will have lower dissociation constants.  
This is similar to the mechanism previously observed for lectins binding to mucins. 
 
Table 1-1 The affinities of maltoporin and MBP for relevant oligosaccharides.
70,71
 
Kd / µM maltoporin Kd / µM maltose binding protein (MBP) 
10,000   Maltose 1.0  Maltose 
 
75.0  Maltotriitol 
59   Maltopentaose 2.9  Maltohexaitol 
 
Maltotriitol  
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1.5 Maltose Binding Protein (MBP) 
 
Maltose Binding Protein (MBP) is a monomeric protein that binds MOSs in the 
periplasm and transfers them to transporter proteins in the inner membrane.71  MBP 
consists of two globular domains separated by a groove where the MOS is bound.72  
These two domains are referred to as the C- and N-domains, containing the C- and N-
termini respectively, and are connected by three segments that form a ‘hinge’ between 
the C- and N-domains (Figure 1-14).73,74  Both globular domains exhibit similar 
structures that consist of a beta-pleated sheet flanked on both sides by two or three 
parallel alpha helices.75 
 
 
Figure 1-14 An overlay of MBP shown in the open form (blue) and the closed form (cyan), a 
hinge angle of 35° and a rotation of 8° is shown between the two conformations.  Maltotriotol 
(red) is shown bound in the open conformation. (PDB: 1OMB). 
 
MBP binds MOS in two different modes which can depend on the length of the 
oligosaccharide.  The different modes are shown above.  The change between them is 
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characterised as a closing of the two globular domains by 35° around the hinge.  In 
both binding modes the ligand is bound in the cleft between the N and C domains 
(Figure 1-14).  The two modes are referred to as ‘end on’ and ‘side on’.  In ‘end on’ 
binding MBP binds to the reducing terminus of the sugar, allowing the protein to adopt 
a closed conformation.  MBP can also bind to the middle of longer oligosaccharides, 
‘side on’; in this binding mode MBP adopts an open conformation.76  Reduced, oxidized, 
or cyclic maltodextrin derivatives can only bind ‘side on’, only linear maltodextrin up to 
8 glucose units long can bind ‘end on’.71,77  As MBP can only dock to the transporter 
protein at the inner membrane when it assumes the closed conformation it is only these 
linear maltodextrins that can be transported.  In the open conformation the binding site 
is open to solvent while in the closed conformation the two globular domains move 
around the hinge to surround the bound MOS allowing no contact with the solvent 
(Figure 1-15).   
 
 
Figure 1-15 Maltotriitol (red, shown below) binding in the open conformation (left) and the 
closed conformation (right), it occupies nearly identical binding sites except that in the open 
case the C domain (on the right) is not involved in binding.  The glucitol group of maltotriitol 
(Figure 1-16) is shown extending in to the s-1 binding site in the open conformation while it 
bends round in the closed conformation.  (PDB: 1FQC and 1FQB). 
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Figure 1-16 Maltotriitol 
 
Both globular domains contribute to MOS binding by forming a binding site of flat 
aromatic residues on the top and bottom faces (Figure 1-17) with polar residues along 
the edges.  This design is complementary to the shape of maltodextrins which adopt a 
conformation like a twisted ribbon with all their hydroxyl groups along the edges and 
the apolar ring faces making up the flat surface of the ribbon.  Charged side chains line 
the edges of the binding site and hydrogen bond to the sugar.  All the hydroxyl groups 
on glucose residues g1, g2 and g3 (beginning from the reducing end) are involved in 
hydrogen bonding (Figure 1-17).  Residue g4 is partially exposed to solvents and any 
residues beyond this point would be entirely outside the binding cleft.  The aromatic 
residues stack against the apolar ring faces of the MOS creating van der Waals 
interactions.75,78 
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Figure 1-17 Aromatic stacking between maltotriitol and aromatic residues in both the open and 
closed conformations.  Little difference is observed between the stacking of g1, g2 and g3 in 
both binding modes. 
 
The Kd values for MBP binding to three different MOSs (maltose, maltotriose and 
maltotetraose) have been determined as 3.5, 0.16 and 2.3 µM respectively, which are 
some of the tightest protein-carbohydrate interactions known.66  The g1-4 residues 
occupy four distinct subsites in MBP with the glycosyl residues g1 and g2 having the 
greatest interaction with the MBP binding site (Figure 1-18).  These sites are occupied 
in both the closed and open binding conformations.  It has been shown with maltotriitol 
(Figure 1-16) that a -s1 binding site exists beyond the s1 binding site which is bound by 
the glucitol residue of maltotriitol.76 
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Figure 1-18 Hydrogen bonding between MBP and maltotetraose (red).  This is an example of 
closed binding. 
 
In the open conformation the MOSs bind in the same subsites as closed but the two 
globular domains do not move around the hinge to bury the ligand (Figure 1-14).  
Binding to the N-domain is greatly diminished,76 reducing much of the hydrogen 
bonding as the N-domain contains the majority of the polar side chains.  The open 
conformation makes the –s1 binding site more accessible and molecules such as 
maltotriitol can then occupy this site. 
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1.6 Aims and Objectives 
 
1.6.1 Aims 
 
In this project we aim to use maltoporin as a receptor to attach biomolecules at a 
bacterial cell surface.  This approach will use MOSs as part of a ligand taking 
advantage of the multivalent binding models previously discussed as chelation and 
‘bind and slide’.  The chelation effect (Figure 1-19) could be used to anchor a molecule 
to maltoporin through a trimeric ligand while the ‘bind and slide’ mechanism could allow 
for the production of a maltose responsive switch (Figure 1-21) that could be used as a 
sensor for the presence of MOS in solution. Feasibly, such a sensor could be used to 
alter the surface properties of the bacterium, for example to allow it to bind reversibly to 
a surface. 
 
This method would allow for the modification of bacterial cell surfaces without the need 
for genetic modification.  With the development of supramolecular engineering at the 
cell surface, it could be possible to bestow temporary adhesive properties to 
therapeutic bacteria allowing them to colonise a patient during a course of treatment.  It 
may also be possible to attach antigenic groups to “inert” bacteria to create live 
vaccines without the risk of causing serious infections.  New opportunities such as this 
to modify and control bacteria will ultimately lead to the medicines of the future. 
 
 
Figure 1-19 A cartoon representation of a multivalent ligand anchoring a biomolecule to a cell 
surface with malto-oligosaccharide (red), biomolecule (blue) and maltoporin (green). 
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It was anticipated that this molecular switch would be made with a single chain ligand 
that comprises maltosyl units linked together by PEG chains (Figure 1-20) that could 
bind to maltoporin at different points along its length. This ligand would be able to 
thread through maltoporin to form a pseudorotaxane. At the “reducing end”, a large 
molecule of interest could be attached, which would act as a stopper to prevent the 
molecule from passing through maltoporin into the periplasm.   
 
 
Figure 1-20 A schematic of the ligand. 
Once the ligand had passed through maltoporin it would become bound by MBP in the 
periplasm.  As MBP binds more tightly to the MOS than does maltoporin (Table 1-1), 
the ligand would effectively be “pulled” through maltoporin until the stopper comes into 
contact with the cell surface and prevents anymore of the ligand passing through.  This 
arrangement should be relatively stable until the system comes into contact with 
maltose which has higher affinity than MOS for MBP.  In the presence of maltose, MBP 
would thus release the ligand allowing it to move back through maltoporin.  When the 
maltose concentration decreases, for example, after it has been transferred into the 
cytoplasm of the bacterium, MBP would once again bind the ligand bringing the 
appended biomolecule close to the opening of maltoporin. This mechanism would act 
like a switch that can be activated by the presence of maltose (Figure 1-21).  
 
 
28 
 
 
Figure 1-21 Cartoon representation of molecular switch.  Glucose moiety (red), maltoporin 
(green), MBP (blue), maltose transporter (purple), biomolecule (dark blue) and the outer and 
inner membranes (cream).  (a)  The ligand initially binds maltoporin (b) MBP binds the the 
ligand pulling the biomolecule close to the cell membrane.  (c) On addition of maltose MBP 
releases the ligand, preferentially binding maltose.  The biomolecule is free to return to its 
original position.  (d)  Once all the maltose has been removed MBP again binds the ligand 
holding the biolmolecule close to the cell surface. 
 
The design for the molecular switch is based on the different affinities of maltoporin and 
MBP for different MOS.  In the polymeric ligand, the reducing end of each sugar will be 
attached to the non-reducing terminus of the next maltose unit; therefore only the open 
conformation of MBP binding will be possible.71,76  Comparison of binding affinities of 
reduced MOSs to MBP and maltoporin (i.e., in the side-on binding mode) shows that 
MBP should bind with a greater affinity than maltoporin to the MOSs within the ligand 
29 
 
(Table 1-1). For example, MBP binds maltohexaitol 20 times and maltotriitol 130 times 
more tightly than maltoporin binds maltopentaose and maltose, respectively.70,71  This 
means as the ligand threads through maltoporin it will become preferentially bound by 
MBP in the periplasm, effectively pulling the ligand through until the stopper on the 
extracellular side of the ligand prevents any more passing through (Figure 1-21).  The 
result will be a rotaxane-like structure holding the appended biological molecule close 
to the cell surface. 
 
MBP has an affinity 75 times higher for maltose than it does for maltotriitol (a good 
analogue for the maltose mimics in the ligand).  On addition of maltose, the MBP will 
preferentially bind maltose releasing the ligand and allowing the pseudorotaxane to 
move back through maltoporin.  Maltoporin has an affinity 170 times higher for 
maltopentaose than maltose.  The proposed ligand will take advantage of this by 
having a maltopentaose at the non-reducing terminus.  After release by MBP the ligand 
can move through maltoporin in a ‘bind and slide’ manner.30  This allows the ligand to 
assume the position with the greatest binding affinity and so place the maltopentaose 
residue in the constriction site of maltoporin.  As this residue is at the non-reducing 
terminus it places the appended biomolecule as far out into extracellular space as 
possible (Figure 1-21). 
 
After MBP binds maltose it takes it to a transporter in the inner membrane where it is 
removed from the periplasm.79  This means if no more maltose is added to the system 
the concentration of maltose will decrease allowing MBP to rebind the ligand.  Thus the 
absence/presence of maltose can be used as a reversible switch to trigger a change in 
the cell surface of the bacterium.  This movement could be converted into a signal for 
the presence of maltose with use of fluorescence.  If a fluorophore was attached to the 
reducing end of the ligand and its FRET pair attached to maltoporin the fluorescence of 
the fluorophore would change according to their proximity.  
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Figure 1-22 Schematic of a multivalent maltose responsive switch. 
 
As protein-carbohydrate interactions are very weak, the binding of the ligand through 
maltopentaose may be too small to anchor it to the bacterium.  If this proved to be the 
case a multivalent approach could be used, in which a trivalent ligand will bind to all 
three of the channels in maltoporin (Figure 1-19).  A multivalent ligand would have 
affinities in the nM as opposed to mM or M range, greatly increasing the binding 
strength.49  As well as the molecular switch described above, a multivalent approach 
could be used to redecorate the surface of bacteria.  With the use of three MOS ligands 
a biological molecule could be bound stably to maltoporin (Figure 1-22).  This would 
allow the attachment of a wide range of molecules to the surface of bacteria without 
needing to genetically engineer the bacterium. 
 
1.6.2 Objectives 
 
1.6.2.1 Design of the switch axle 
 
The axle for the switch was to be developed based on solid phase peptide synthesis 
(SPPS).  This method would allow for formation of a variety of ligands using simple 
building blocks.80  A retrosynthesis of the axle showed four sections that would need to 
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be synthesised (Scheme 1-5).  They are a maltoheptaose fragment 1.14 at the non-
reducing end, a central maltose fragment 1.16, a capping lysine derivative 1.17 and 
PEG-linkers to connect the fragments 1.15. 
 
 
Scheme 1-5 The switch axle 1.18 with the maltose mimic 1.16 (red), PEG amino acid linker 1.15 
(blue) and the maltopentaose moiety 1.14 (orange) highlighted. 
 
Maltoheptaose was chosen as the high affinity ligand as it could be purified from -
cyclodextrin. 81  Maltoheptaose and the central maltose fragment were designed to be 
preferably C-glycosides or S-glycosides as these avoid any risk of cleavage by 
glycosidases in the periplasm.82  It was anticipated that the axle would be synthesised 
from the reducing to the non-reducing end, therefore the carboxylic acid residues were 
placed at the reducing ends of the sugars. 
 
The central maltose fragment 1.16 was to be derivatised at the 4'-position because 
maltoporin’s natural substrates are connected via this position.  As MOSs are 
connected by -1,4-glycosidic linkages, this motif was to be repeated in the switch axle 
1.18 to give the highest probability of the axle being able to thread through maltoporin.  
Therefore, it was anticipated that the sugars within the molecules would all be  -
glycosides. 
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The PEG-linker 1.15 and similar linkers of different lengths are commercially available 
and therefore could be easily varied.  The final section of the axle would be constructed 
using a Dde-protected lysine 1.17.  This was chosen as it would be resistant to 
piperidine Fmoc deprotection and could be orthogonally deprotected with hydrazine at 
the end of the synthesis.  Once deprotected it could be functionalised with a variety of 
moieties, for example an oxyamine for ligation to larger molecules that would act as a 
cap on the axle. 
 
The modular nature of SPPS would allow for variations in the number of maltose 
fragments 1.16 and PEG linkers 1.15 between them.  This method could be used to 
generate several different ligands which can then be tested separately. 
 
An alternative to SPPS is ‘Click’ chemistry which could be used to link the fragments 
together in an efficient solution-based method.83,84  Copper-catalyzed alkyne amine 
cycloaddition (CuAAC) is a well-documented reaction that has been used to connect 
carbohydrates together.85  This would require the introduction of an azide and alkyne at 
opposing ends of the saccharide and could conceivably be developed to form polymers 
in one-pot-syntheses.  
 
 
1.6.2.2 Synthesis of ligand building blocks 
 
The original synthetic design for the central maltosyl moiety of the axle is shown in 
Scheme 1-6.  Following this route the anomeric position would be derivatised first 
before a regioselective protecting group strategy to functionalise the 4'-position. 
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Scheme 1-6 The important general precursors in the synthesis of the maltose mimic 1.22 
starting from maltose 1.19. 
 
A benzylidene acetal was to be employed to selectively protect and then reveal the 4' 
position for introduction of the amino group.  The benzylidene acetal would only protect 
the 4' and 6' positions as these are the only positions which allow the formation of a 
stable six membered ring.  The benzylidene acetal 1.21 could be opened selectively to 
give a hydroxyl group at the 4' position which could be transformed to introduce the 
equatorial amino group in compound 1.22.86  This amino group could either be used 
directly for the formation of an amide linkage to another maltosyl building block or used 
to attach a linker with another amine group at the end if desired.  
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1.6.2.3 Binding studies 
 
Electrochemical conductance measurements in black lipid membranes made from 
diphytanoyl phosphatidylcholine have previously been used to study sugar 
translocation through maltoporin.70,87  These methods are not routinely used in the 
Turnbull lab so a number of other biophysical methods that would give complementary 
information were to be investigated. 
 
It was anticipated that isothermal titration calorimetry (ITC) would be used to measure 
solution binding affinities of mono-, di- and trivalent ligands using detergent-solubilised 
maltoporin.  A comparison of the enthalpy of binding for mono- and multivalent ligands 
would determine if all the ligand groups in the molecule are binding and therefore the 
optimum length of linker between the ligand groups.56 
 
Another method useful in determining the binding affinities of carbohydrate protein 
interactions is fluorescence anisotropy.88,89  When a fluorophore is excited with 
polarized light its emission is also polarized.  The extent to which the emitted light is 
depolarized is related to the size of the molecule it is attached to due to the speed of 
tumbling in solution. 
 
This effect could be harnessed to gain binding information as the degree of anisotropy 
will change if a fluorophore tagged maltoside binds to the much larger maltoporin.  For 
fluorescence anisotropy experiments, the attachment of a fluorophore to the ligands 
would be necessary. 
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Figure 1-23 Cartoon showing the FRET experiment.  (a) MBP (light blue) binds the ligand 
holding the fluorescein group and the FRET acceptor in close proximity.  (b)  On addition of 
maltose (red) the MBP releases the ligand allowing the fluorescein group to move away from 
the FRET acceptor and light up. 
 
FRET experiments would provide a method to monitor the effectiveness of the maltose 
responsive switch.  One fluorescein group would act as the stopper on the ligand while 
a complementary FRET acceptor would be attached using maleimide chemistry to the 
surface of a G382C mutant of maltoporin via the cysteine residue at position 382. 
Modification of this residue has been shown not to affect the ability of maltoporin to 
bind MOSs.  MBP would be captured within vesicles into which the modified maltoporin 
has been reconstituted.  The ligand would be added to the solution and in the presence 
of MBP should pull the fluorescein group close to the complementary FRET acceptor 
reducing its fluorescence (Figure 1-23).  On addition of maltose, the ligand should be 
released and ‘light up’, thus signalling that it has moved away from the FRET acceptor 
and the cell surface. Ultimately, the FRET experiment will be reproduced in whole E. 
coli cells expressing the maltoporin G382C mutant. 
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2 Chapter II: Expression, purification and 
modification of proteins 
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2.1 Introduction 
 
The design of the switch requires the hijacking of two members of the E. coli maltose 
transport system.  The expression of these two proteins, maltoporin and MBP, have 
been recorded in the literature.90,91 MBP is commonly used as a fusion protein to aid 
solubility and facilitate purification of other proteins, therefore there are standardised 
protocols for its expression.92  In contrast there exist a variety of methods for 
maltoporin with significant differences suggesting its expression and/or purification is 
tempremental. 
 
Maltoporin has been expressed using recombinant methods as well as from wild-type 
bacteria.  Its expression from unmodified E. coli was achieved by solubilising the 
protein with a detergent (lauryldimethylamine oxide) and passing the fraction down an 
amylose affinity column.93  To increase the protein yield, the expression of maltoporin 
can also be induced by using a minimal media with maltose as the carbon source 
which leads to up-regulation of the maltose transport system.94  Although this method 
has proved successful, there is only a finite amount of space in the bacterial outer 
membrane which limits the amount of protein that can be expressed.  Later, groups 
used over-producing E. coli strains which contain the lamB gene in an expression 
plasmid under control of a tac-promoter.95  This method was also transferred to E. coli 
strains which had a number of their outer membrane proteins knocked out to give more 
space in the outer membrane for the recombinant protein.  This strategy was 
demonstrated by T. Schirmer and co-worders who expressed maltoporin from 
BL21(DE3)omp5 cells, a strain of E. coli with the major outer membrane proteins 
knocked out.96 
  
Once expressed, the binding of the proteins will be investigated.  Isothermal 
calorimetery (ITC) was selected to be the primary method for acquiring binding 
information.  ITC has never been performed with maltoporin before and use of this 
technique could provide new insights into the binding thermodynamics of this protien.  
Fluorescence binding studies  were also identified as an alternative and 
complementary strategy for studying the interactions of the protein.  These experiments 
require modifications of the protein in the form of site directed mutagenesis: 97 a 
powerful method to specifically modify and derivatise proteins.   
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2.2 Expression and purification of maltoporin 
 
Expression and purification of maltoporin in high yields was essential for its use in a 
variety of studies.  At the time of taking on the project, expression of maltoporin had 
been attempted by members of the Turnbull group but with no success.  The LamB 
gene had successfully been cloned from E. coli DH5α cells and ligated into pSAB2.2 
vectors (Figure 2-2).  Expression trials had been performed in E. coli BL21 cells using 
autoinduction media, but no overexpression had been seen. 
 
As maltoporin is an outer membrane protein its expression is typically low yielding due 
to the small volume the membrane occupies compared to the rest of the cell.  
Membrane proteins are known to be toxic in high concentrations and it was postulated 
that as the concentration of maltoporin built up in the cell membrane and periplasm, the 
cells were becoming stressed and were ejecting the protein into the media.  This effect 
could be mitigated if maltoporin were prevented from reaching the periplasm.  
Maltoporin’s transportation to the outer membrane is enabled by chaperone proteins, 
which recognise a short peptide leader sequence of the form 
MMITLRKLPLAVAVAAGVMSAQAMA added on to the N-terminus.  Therefore, if 
maltoporin were to be expressed without the leader sequence, the chaperone proteins 
would not recognise maltoporin and so the over-expressed protein would then be 
contained within inclusion bodies in the cytoplasm as unfolded aggregates.98 It would 
then be possible to refold such proteins in detergent.99 
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2.2.1 Expression of maltoporin without the leader sequence 
 
 
Figure 2-1 The pSAB2.2-M5 gene with maltoporin (dark green) and the leader sequence (light 
green) shown as well as the binding sites of the primers.  The use of these primers in PCR led 
to replication of the maltoporin gene without the leader sequence. 
 
The maltoporin gene was amplified from stock pSAB2.2-M5 vectors using forward 
primers that did not contain the leader sequence (Figure 2-1).  The amplified DNA was 
digested with MfeI and Hind III for 1.5 hrs at 37°C to create ‘sticky ends’. 
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Figure 2-2 pMAL-c5X with maltoporin gene inserted in place of MBP 
 
The digested DNA was ligated into a pMal-c5x vector in place of the MBP gene before 
transformation into E. coli XL10 cells (Figure 2-2).  After incubation on an agar plate 8 
colonies were selected.  From these the plasmid DNA was extracted and digested with 
MfeI and Hind-III to separate the inserted LamB gene from the plasmid.  An agarose 
gel of these samples showed six of the selected colonies to have the correct insert of 
~1450 bp (Figure 2-3).  Sequencing analysis of the five cleanest DNA bands showed 
that they all corresponded to the full maltoporin gene. 
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Figure 2-3 Agarose gel showing digested plasmids from lamB without leader sequence ligations. 
Lanes 2, 4, 5, 7, 10 and 11 all have inserts at ~1450, the weight of the correct insert.  Lane 1 – 
100 bp ladder; Lanes 2-7 – ligation digestion; Lane 8 – 1 K bp ladder; 
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Figure 2-4 BL21 cells with plasmid expressing maltoporin minus the leader sequence with 
different incubation times.  Lane 1 – Protein marker; Lane 2 – Inclusion bodies, 4 h; Lane 3 – 
Inclusion bodies, o.n.; Lane 4 – Membrane fraction, 4 h; Lane 5 – Membrane fraction o.n. 
 
One colony with the correct gene for maltoporin without the leader sequence was 
transformed into E. coli BL21 gold cells and expressed in LB media.  Samples from the 
culture were taken 4 h and 24 h after the cells were induced with IPTG.  The samples 
were purified following the maltoporin purification procedure (see experimental section).  
An SDS PAGE showed no over-expression of maltoporin in either inclusion bodies or 
the membrane fraction (Figure 2-4).  The leader sequence may have more important 
roles in the expression of maltoporin than previously thought.  As this route had been 
unsuccessful, a different method for the expression of maltoporin was sought. 
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2.2.2 Expression of maltoporin in E. coli BL21 (DE3) ompX cells 
 
E. coli strains with some of their outer membrane proteins knocked out have been 
shown to increase the yields of maltoporin expression.96  As previously illustrated, the 
over-expression of membrane proteins has two major challenges.  The maximum 
amount of protein that can be expressed is restricted by the small volume of the 
membrane compared to the rest of cell and overloading the membrane with one type of 
protein can lead to toxicity.100  The combination of these factors means that as well as 
each cell containing only a small amount of protein, their exponential phase is cut-off 
resulting in a smaller number of cells.  This results in low yields for the over-expression 
of proteins into the membrane. 
 
To overcome one of these factors E. coli BL21(DE3)omp8 and BL21(DE3)omp9 cells 
were acquired from Ralf Koebnik in CNRS Montpellier (where ompX is used it refers to 
both sets of cells).101 These strains of cells have had the major outer membrane 
proteins knocked out these consist of maltoporin, OmpC102,103, OmpA104 and 
OmpF105,106 all of which allow passive diffusion of small polar molecules. The omp9 
cells also have ompN107 knocked out which fulfils the same function.  This leaves more 
space in the outer membrane into which proteins may be expressed.  
 
To transform the plasmid encoding maltoporin into the ompX cells they first had to be 
made heat competent.  The heat competent cells were transformed using the pSAB2.2-
M5 containing the intact maltoporin gene previously made in the Turnbull group by Dr 
James Ross (Figure 2-2).  Sequencing of two colonies from the transformation showed 
them to be successful. 
 
As over-expressed membrane proteins can be toxic to the cell, an expression study 
was performed with samples taken at different time points to ascertain the point at 
which expression was optimal.  Expression was carried out using LB media and IPTG 
induction.  The cells were induced at an OD600 of 0.6 which corresponds to the 
exponential growth phase of the bacteria.  This optical density has been found to be 
optimal for a variety of membrane proteins.108  Samples were harvested after 0, 2, 3 
and 4 h, collected by centrifugation and stored at -80 °C prior to analysis. 
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Figure 2-5 SDS PAGE of omp8 (lanes 2-9) cells and omp9 (lanes 10-13) cells with expression 
plasmid pSAB2.2-M5 after different periods of time, which shows over expression of a protein at 
~45 kDa (A) after 4h for the omp8 cells.  Lane 1 – Protein marker; Lane 2 –0 h grow up, 
unboiled; Lane 3 –0 h grow up, boiled; Lane 4 –2 h grow up, unboiled; Lane 5 –2 h grow up, 
boiled; Lane 6 –3 h grow up, unboiled; Lane 7 –3 h grow up, boiled; Lane 8 –4 h grow up, 
unboiled; Lane 9 –4 h grow up, boiled; Lane 10 –0 h grow up, unboiled; Lane 11 –0 h grow up, 
boiled; Lane 12 –2 h grow up, unboiled; Lane 13 –2 h grow up, boiled. 
 
The cells were subsequently passed through a Constant Systems cell disrupter and an 
SDS PAGE of these samples showed omp8 cells over-expressed protein at 45 kDa 
which is the mass of the unfolded maltoporin monomer (Figure 2-5, B).  It is known that 
maltoporin runs as the folded trimer on SDS PAGE due to its high stability.  Here, both 
boiled and unboiled samples have over-expression at 45 kDa suggesting that the 
majority of maltoporin being over-expressed in the cell was unfolded.  Although there is 
also a smaller band at 97 kDa (Figure 2-5, A), where the folded trimer runs, which 
disappears on boiling so a proportion of the protein is likely to be folded.99 
 
Samples for omp9 were only taken after 0 and 2 h as it took 5 hours to reach the 
optimum OD600 = 0.6.  Neither of these samples showed any protein (Figure 2-5).  As 
the omp9 cells take a significantly longer time to grow and the omp8 cells had been 
shown to over-express protein it was decided to carry on with only the omp8 cells. 
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Omp8 cells without the maltoporin expression plasmid were cultured using the same 
method as used for the plasmid-containing cells (Figure 2-6).  As no over-expression of 
protein was observed, this control experiment demonstrated that the extra protein 
bands seen in Figure 2-5 resulted from the maltoporin expression plasmid and were 
thus likely to be maltoporin. 
 
 
Figure 2-6 SDS PAGE of omp8 cell control, induced without maltoporin expressing plasmid.  No 
over expression was found after a 4 h incubation. Lane 1 – Protein marker; Lane 2 – Cell pellet. 
 
Maltoporin expression was thus carried out on a larger scale of 8 L.  Here the cells 
were harvested by centrifugation and passed through a Constant Systems cell 
disrupter before centrifugation to remove soluble proteins.  The remaining pellet was 
then resuspended in Triton X-100, a non-ionic surfactant, and shaken overnight at 
37 °C to solubilise any detergent-soluble protein in the pellet.  The suspension was 
pelleted at 48,000 x g for 30 min. The supernatant was retained and the pellet was 
resuspended in TEN buffer containing urea (8 M) before pelleting again at 48,000 x g 
for 30 min.  This procedure produced an initial supernatant of Triton X-100-solubilised 
protein and a secondary supernatant containing urea-solubilised proteins. 
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SDS PAGE was performed on the Triton X-100-solubilised and urea-solubilised 
fractions, as well as the remaining pellet (Figure 2-7).  This gel showed a large band at 
45 kDa in the urea-solubilised fraction.  It also showed a smaller band at 97 kDa in the 
Triton X-100 band which dropped to 45 kDa on boiling the sample before analysis.  
This suggests that only the folded maltoporin was solubilised by Triton X-100, while the 
unfolded maltoporin was only solubilised by urea. 
  
 
Figure 2-7 SDS PAGE of omp8 cells with maltoporin expression plasmid.  The gel shows 
protein which is soluble in Triton X-100 running at 97 kDa (lane 2) and at  45 kDa (lane 5) after 
boiling which is consistent with the expected behaviour of maltoporin.  Lane 1 – Protein marker; 
Lane 2 – Triton X-100-solubilised protein, unboiled; Lane 3 – Urea-solubilised protein; Lane 4 – 
Final pellet; Lane 5 – Triton X-100-solubilised protein, boiled. 
 
The Triton X-100 fraction was purified using an amylose column as maltoporin would 
be able to bind to the maltooligosaccharides at the surface of the resin.  At this point 
the protein was eluted in buffer containing Octyl-POE instead of Triton X-100.  This 
was because Octyl-POE is not UV active allowing for the concentration of the sample 
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to be easily measured.  It also has a critical micelle concentration (CMC) of 6.6 mM 
compared to 0.24 mM for Triton X-100.  This higher CMC allows for easier diffusion of 
the detergent.  The protein at 97 kDa was shown to bind the amylose column indicating 
that this protein was indeed maltoporin (Figure 2-8).  As the amylose column did not 
bind any other proteins from the fraction, the fractions eluted with maltose provided a 
pure sample of maltoporin.  
 
 
Figure 2-8 SDS PAGE showing amylose column purification of Triton X-100 soluble proteins.   
Lane 1 – Protein marker; Lane 2 – Flow through; Lane 3 – Wash fraction; Lane 4 – 1st elution 
fraction; Lane 5 – 2nd elution fraction; Lane 6 – 3rd elution fraction; Lane 74
th
 elution fraction; 
Lane 8 – 5
th
 elution fraction. 
 
Quantification of the concentration of protein collected from the membrane was made 
difficult by the presence of an unknown concentration of Triton X-100 which absorbs 
light at 280 nm.  Following removal of Triton X-100 through dilution and dialyses, a 
concentration of 2.2 mg per L incubation was obtained.  These results are consistent 
with expression of membrane proteins.98  
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2.2.3 Optimisation of the expression of maltoporin 
 
The current method of expression for maltoporin had resulted in 2.2 mg / L grow-up.  It 
was estimated that this project would require more than 50 mg of maltoporin, so 
optimisation of this method was sought.  As this initial procedure also yielded a much 
larger amount of unfolded maltoporin, the refolding and purification of the urea-
solubilised fraction was desirable.  Gradual dilution of this solution should allow the 
refolding of the protein.  The urea supernatant was therefore diluted two-fold with urea 
(8 M) in TEN buffer and then four-fold with Triton X-100 (3% v/v) in TEN buffer.  The 
solution was also subsequently diluted to 1 M and then 0.1 M urea although SDS 
PAGE showed no refolding of maltoporin.  
 
It was considered that the inability of maltoporin to refold may be a result of much of 
the protein still having its leader sequence attached and that this additional strand of 
peptide interferes with refolding.  This hypothesis is supported as when boiled, 
maltoporin runs lower than the urea-soluble unfolded protein on SDS PAGE (Figure 
2-7).  This shows the unfolded protein is of a higher mass than maltoporin and by 
approximately the size of the leader sequence. 
 
The leader sequence could still be attached because the over-expression of maltoporin 
occurred at such a rate that the chaperone proteins that export maltoporin to the 
periplasm were overloaded.  As the leader sequence is removed in the periplasm, the 
failure of the cell to export maltoporin out of the cytoplasm may have resulted in the 
leader sequence not being cut from a majority of maltoporin.  
 
In order to overcome this issue the rate at which maltoporin was expressed needed to 
be more closely matched to the rate at which it is exported to the periplasm.  This could 
be achieved by slowing the expression rate through a reduction in the incubation 
temperature to 16 °C and inducing with a lower concentration of IPTG.  A longer period 
of time was also allowed for expression and as such a more supportive SOC media 
was used.  This media contains a higher concentration and variety of salts increasing 
the cells’ survivability. 
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A SOC media expression was performed with the omp8 cells containing the pSAB2.2-
M5 plasmid in 8 x 1 L cultures.  The flasks were inoculated with cells at differing stages 
of growth allowing them to be induced at different optical densities and an analysis of 
the most advantageous stage to induce them could be carried out.  Five of the flasks at 
induction OD600s of 0.4, 0.6, 1.4, 2.2, and >2.5 were selected to be purified using the 
maltoporin purification procedure.  SDS PAGE of the supernatants and pellets of each 
one showed variations in line with the density of cells when they were induced (Figure 
2-9). 
 
 
Figure 2-9 SDS PAGE showing 12 h incubation of omp8 cells with expression plasmid at 16 °C 
in SOC media induced at different ODs.  Both the membrane fraction and pellet are shown., At 
OD600 = 0.4 and 0.6 a single band can be seen at 46 kDa in the pellet fraction and 97 kDa in the 
membrane fraction.  These bands are lost at higher OD.   Lane 1 – Protein marker; Lane 2 – OD600 = >2.5, 
membrane fraction; Lane 3 – OD600 = >2.5, pellet; Lane 4 – OD600 = 2.2, membrane fraction; Lane 5 – 
OD600 = 2.2, pellet; Lane 6 – OD600 = 1.4, membrane fraction; Lane 7 – OD600 = 1.4, pellet; Lane 8 – OD600 
= 0.6, membrane fraction; Lane 9 – OD600 = 0.6, pellet; Lane 10 – OD600 = 0.4, membrane fraction; Lane 
11 – OD600 = 0.4, pellet; Lane 12 – Protein marker. 
 
 
50 
 
Induction at OD600 of 0.4 and 0.6 led to expression of maltoporin as the folded trimer.  
Induction at OD600 of 1.4 and higher led to no over expression of folded maltoporin 
which is in contrast to the amount of maltoporin produced as the unfolded monomer.  
While induction at 0.4 and 0.6 do show over-expression, there is significantly less 
protein produced in the cells than those induced at 1.4 or higher (Figure 2-10). 
 
 
Figure 2-10 SDS PAGE showing pellets of 12 h incubation of omp8 cells with expression 
plasmid at 16 °C in SOC media induced at different ODs compared to boiled and unboiled 
maltoporin.  The single bands at 46 kDa in the OD600 = 0.4 and 0.6 lanes run at the same 
position as boiled maltoporin indicating that it is maltoporin.   Lane 1 – Protein marker; Lane 2 – OD600 = 
0.4; Lane 3 – OD600 = maltoporin, boiled (100 °C, 10 min); Lane 4 – OD600 = 0.6; Lane 5 – OD600 = 1.4; 
Lane 6 – OD600 = maltoporin, boiled (100 °C, 10 min); Lane 7 – OD600 = 2.2; Lane 8 – OD600 = >2.5; Lane 
9 – maltoporin, boiled (100 °C, 10 min). 
 
More importantly it can be seen that when induction is performed at an OD600 of 0.4 
and 0.6, the unfolded monomer expressed in the detergent-insoluble fractions appears 
as a single band compared to the double bands shown in 1.4 and higher (Figure 2-10).  
SDS PAGE of the insoluble fractions maltoporin shows the band resulting from 
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induction at 0.4 and 0.6 runs at the same weight as the maltoporin unfolded monomer.  
This result contrasts with the previous incubation in LB media at 37 °C which showed a 
marked difference in the weight of the dominant band and the unfolded monomer 
(Figure 2-7).  From this, it appears that the slower expression has allowed the cell time 
to remove the leader sequence from maltoporin. 
 
As it appeared that the leader sequence had been successfully removed from 
maltoporin the refolding of the unfolded maltoporin could be re-attempted. 
 
 
2.2.4 Refolding of maltoporin 
 
Baldin et al. had shown that maltoporin could be refolded when diluted into detergent 
from a denaturant.99  Once diluted below 1 M of denaturant, the protein should 
spontaneously refold, with octyl-POE being the preferred detergent for this method.  As 
maltoporin had been now been expressed without the leader sequence a more 
rigorous attempt at its refolding was embarked upon. 
 
The pellets from a 1 L incubation for maltoporin expressed in SOC media at an OD600 
of 0.6 and >2.5 were dissolved in 7 M guanidine hydrochloride (GdmCl) in 30 ml TEN 
buffer.  The samples were left shaking overnight at 37 °C to solubilise the unfolded 
protein.  Centrifugation at 48,000 x g removed any insoluble protein and the 
supernatant was diluted with TEN buffer and octyl-POE to a final concentration of 1.3 
M GdmCl and 2.5% octyl-POE. A concentration below 1.5 M of GdmCl had been 
shown to cause refolding of maltoporin.99  The solution was left stirring overnight at 
room temperature to refold.  In both samples the protein was found to have aggregated 
as the unfolded monomer and precipitated out of solution. 
 
The refolding experiment was carried out again but with the protein diluted by a factor 
of 3.  The greater dilution should hinder aggregation of the protein.  In this case, no 
precipitation was observed but SDS PAGE did not show any refolding of the protein 
either.  
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As the refolding experiment had shown no refolding a larger systematic testing of 
refolding conditions was undertaken.  The cells induced in SOC media at OD600 = 0.6 
were used in all experiments as these were judged by SDS PAGE to have the least 
contamination by other proteins (Figure 2-10). 
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Table 2-1 Different unfolding and refolding buffers, reagents and detergents 
No. Buffer Unfolding 
agent (conc.) 
Refolding 
Detergent 
Other reagents Dilution 
Factor* 
1a 20 mM HEPES, pH 7.4 GdmCl (7.3 M) 0.5% Octyl-POE 0.02% NaN3 6 
1b 20 mM HEPES, pH 7.4 GdmCl (7.3 M) 0.5% Octyl-POE 0.02% NaN3 10 
2 20 mM HEPES, pH 7.4 GdmCl (7.3 M) 0.5% Octyl-POE 0.02% NaN3 6 
3a 20 mM HEPES, pH 7.4 Urea (6 M) 0.5% Octyl-POE 0.02% NaN3 6 
3b 20 mM HEPES, pH 7.4 Urea (6 M) 0.5% Octyl-POE 0.02% NaN3 10 
4a 50 mM Tris, pH 8.0 Urea (6 M) 0.7% DDM 0.1 mM EDTA 6 
4b 50 mM Tris, pH 8.0 Urea (6 M) 0.7% DDM 0.1 mM EDTA 10 
5 10 mM Borate, pH 10.0 Urea (8 M) 0.7% DDM 2 mM EDTA 4 
6a 50 mM Tris, pH 8.0 Urea (4 M) 0.7% DDM 10% Glycerol, 
0.1 M NaCl 
6 
6b 50 mM Tris, pH 8.0 Urea (4 M) 0.7% DDM 10% Glycerol, 
0.1 M NaCl 
10 
7 50 mM Tris, pH 8.0 Urea (6 M) 0.1% 
Deoxycholic acid 
20% 
Isopropanol 
4 
8a 50 mM Tris, pH 8.0 Urea (6 M) 0.5% SDS  4 
8b 50 mM Tris, pH 8.0 Urea (6 M) 0.5% SDS  10 
9a 50 mM Tris, pH 8.0 Urea (6 M) 0.5% Tween  4 
9b 50 mM Tris, pH 8.0 Urea (6 M) 0.5% Tween  10 
10a 50 mM Tris, pH 8.0 Urea (6 M) 0.5% Triton X-
100 
 4 
10b 50 mM Tris, pH 8.0 Urea (6 M) 0.5% Triton X-
100 
 10 
*The cells from 50 ml cell of cultures were pelleted and re-suspended in 5 ml of denaturing 
buffer.  These were incubated at 37 °C o.n. before dilution and addition of detergent as 
indicated in the table. 
 
A large variety of different buffers and reagents were used in the folding of maltoporin 
to increase the chances of finding successful conditions (Table 2-1). Experiments 1-6 
had been previously shown to refold maltoporin or similar pore proteins109,110 while 7-10 
used four untested detergents.  In each experiment, the protein was first unfolded in 
either urea or guanidinium hydrochloride by overnight incubation at 37 °C before 
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dilution in buffer to a concentration at which maltoporin has been shown to refold.99 
After dilution of the samples SDS PAGE showed none of the conditions were 
successful in folding maltoporin (Figure 2-1).  During these procedures it was found 
that the use of guanidinium hydrochloride caused the protein to precipitate out of the 
denaturant solution while at least 8 M urea was needed to completely solubilise the 
protein, hence the more intense band for sample 5 (Figure 2-11). 
 
 
 
Figure 2-11 SDS PAGE of refolding conditions from Table 2-1 Different unfolding and refolding 
buffers, reagents and detergents.   Lane 1 – Protein marker; Lane 2 – 1a; Lane 3 – 1b; Lane 4 – 
2; Lane 5 – 3a; Lane 6 – 3b; Lane 7 – 4a; Lane 8 – 4b; Lane 9 – 5; Lane 10 – blank; Lane 11- 
Protein marker; Lane 12 – 6a; Lane 13 – 6b; Lane 14 – 7; Lane 15 – 8a; Lane 16 – 8b; Lane 
17 – 9a; Lane 18 – 9b; Lane 19 – 10a; Lane 20 – 10b. 
 
Maltoporin is known to have at least one disulfide linkage in its structure90 which could 
have cross-linked between proteins forming larger aggregates.  The degree of cross-
linking was investigated by removing DTT from the SDS PAGE loading buffer which 
should leave all disulfide linkages intact.  This experiment showed the existence of 
aggregates that were too large to pass into the resolving and stacking gels (Figure 
2-12).  As these aggregates could hinder protein folding, DTT would now be added to 
all refolding buffers as it had also been shown that maltoporin can refold without 
disulfide linkages.99  This may also explain the higher intensity of sample 2 in Figure 
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2-11 (lane 4), as this sample had 1 mM of DTT added which should have disrupted the 
larger aggregates resulting in less protein precipitating out of the GdmCl denaturant 
solution. 
 
 
Figure 2-12 SDS PAGE of omp8 urea-soluble proteins with and without DTT in the loading 
buffer showing large aggregates.   Lane 1 – Protein marker; Lane 2 – Omp8 urea soluble 
protein with DTT; Lane 3 – Omp8 urea soluble protein without DTT. 
 
Another set of refolding experiments was carried out using DTT to reduce disulfide 
linkages and implementing dialysis instead of dilution to reduce the concentration of the 
denaturant (Table 2-1).  Dialysis should change the concentration of urea or GdmCl 
more slowly than dilution, thus minimising the chance of protein precipitating from 
solution.  Octyl-POE was used as it is the preferred detergent for refolding maltoporin 
in the literature99 while Triton X-100 was used as it is a much cheaper, but comparable 
detergent. 
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Table 2-2 Initial conditions used for the refolding of maltoporin before dialysis. 
No. Buffer Unfolding 
agent (conc.) 
Other reagents Refolding Detergent 
11a 10 mM Borate, pH 10.0 GdmCl (7.3 M) 100 mM DTT 0.5% Octyl-POE 
11b 10 mM Borate, pH 10.0 GdmCl (7.3 M) 100 mM DTT 0.5% Triton X-100 
12a 50 mM Tris, pH 8.0 GdmCl (7.3 M) 100 mM DTT 0.5% Octyl-POE 
12b 50 mM Tris, pH 8.0 GdmCl (7.3 M) 100 mM DTT 0.5% Triton X-100 
13a 10 mM Borate, pH 10.0 Urea (8 M) 100 mM DTT 0.5% Octyl-POE 
13b 10 mM Borate, pH 10.0 Urea (8 M) 100 mM DTT 0.5% Triton X-100 
14a 50 mM Tris, pH 8.0 Urea (8 M) 100 mM DTT 0.5% Octyl-POE 
14b 50 mM Tris, pH 8.0 Urea (8 M) 100 mM DTT 0.5% Triton X-100 
*The cells from 50 ml cell of cultures were pelleted and re-suspended in 5 ml of denaturing 
buffer.  These were incubated at 37 °C o.n. before a 10x dilution and addition of detergent as 
indicated in the table. 
 
All of the refolding solutions were dialysed to 0 M urea/GdmCl and 0 M DTT, although 
again no folding of the protein was seen.  Due to the time involved in running the 
folding studies and the availability of folded maltoporin in the membrane, this route for 
purification of the protein was abandoned.  
 
 
2.2.5 The large scale expression and purification of maltoporin 
 
To produce enough folded maltoporin the expression would need to be scaled up 
beyond 1 L flasks.  To do this omp8(DE3)BL21 cells with the plasmid expressing 
maltoporin and media were supplied to Prof Peter Henderson’s lab where a 30 L 
fermenter run was carried out generating a 50 g cell pellet.  The pellet was purified in 
the same manner as before but with the use of a 5 ml MBPTrap column (GE 
Healthcare) which was found to have an increased binding capacity compared to the 
20 mL column of amylose resin (NEB) used previously (Figure 2-13).  Purification still 
required multiple runs as the total amount of maltoporin considerably exceeded the 
capacity of the MBPTrap column, therefore an AKTA FPLC machine was used to 
automate and speed up the process.  The yield of maltoporin was 1.2 mg of protein per 
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litre, or 35.8 mg of protein in total.  The fermenter run was repeated producing 70 mg of 
protein in total which was sufficient for the rest of the project. 
 
 
Figure 2-13 SDS PAGE of maltoporin purification with a 5 ml MBPTrap column from a 30 L 
fermenter run.   Lane 1 – Protein marker; Lane 2 – Flow through; Lane 3 – Flow through; Lane 4 
– Elution fraction 1; Lane 5 – Elution fraction 2; Lane 6 – Elution fraction 3; Lane 4 – Elution 
fraction 1; Lane 5 – Elution fraction 2; Lane 6 – Elution fraction 3; Lane 7 – Elution fraction 4. 
 
 
2.2.6 Circular dichroism (CD) of maltoporin 
 
It is difficult to ascertain the mass of maltoporin using mass spectrometry due to its 
large size and hydrophobicity.  Therefore other methods were employed to determine 
that the protein in question definitely was maltoporin.  It has been demonstrated that 
the protein can bind to an amylose column and runs on SDS PAGE at a mass of 97 
kDa if the sample is not boiled before loading onto the gel; whereas it has an apparent 
mass of 45 kDa if the sample is boiled.  All these observations agree with literature 
examples.99,111 
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CD was performed on the protein to establish whether it contained the high proportion 
of beta sheets consistent with a beta-barrel found in maltoporin.  This was found to be 
the case with CD showing a characteristic minimum at 217 nm that typifies -structures 
(Figure 2-14).112 
 
 
 
Figure 2-14 A CD spectrum of the purified protein showing a characteristic line in keeping with a 
beta-barrel protein. 
 
 
2.2.7 Investigations into the binding of maltoporin using microscale 
thermophoresis (MST) 
 
The binding of maltoporin has previously been tested with electrochemical 
conductance measurements in black lipid membranes.  In the Turnbull lab this 
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equipment was not readily available and so the implementation of a more commonly 
used biophysical technique was sought. 
 
One of these techniques is Microscale thermophoresis (MST). MST works by 
measuring the movement of molecules along a temperature gradient at different 
concentrations.  Any change in the hydration shell of a protein due to ligand binding will 
result in a relative change in movement along the temperature gradient and thus 
binding affinities can be determined.  MST has been shown to be an effective method 
to measure binding using nanomolar quantities of protein.113  
 
To allow maltoporin’s movement to be tracked by the instrument it was non-specifically 
labelled with FITC.  This was performed by adding FITC in DMSO to the protein in 
sodium carbonate buffer at pH 8.5.  Use of the nanodrop showed a labelling efficiency 
of 0.2 molecules of FITC per monomer.  Both maltoheptaose and maltose were tested 
against the FITC-labelled maltoporin.  Starting at 0.5 M a 15-fold serial dilution of the 
sugars was performed and the binding studied by MST. 
 
Figure 2-15 MST results for maltoheptaose (3 mM) against maltoporin (570 nM). 
 
No change in the thermophoretic motion of maltoporin was found when the 
concentration of ligand was varied.  It was thought that as changes in movement along 
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the temperature gradient were based on changes in the hydration shell of the protein 
this may be an inefficient method for the measurement of binding within the maltoporin 
channel (Figure Figure 2-15).  A different method was therefore sought to measure the 
binding of maltoporin. 
 
 
2.2.8 Investigations into the binding of maltoporin using Isothermal titration 
calorimetry (ITC) 
 
ITC was selected as a method to measure binding to maltoporin as it required no 
further derivatisation of the protein and it relied on the heat changes on binding as 
opposed to any change in the hydration shell of the protein.  As a method it also gives 
comprehensive thermodynamic data in addition to binding affinities.  There is no 
literature precedent for the use of ITC with maltoporin and the first challenge lay in 
accurately matching the buffers for the protein and ligand.  This matter was 
complicated by the need to also match the detergent concentration which cannot easily 
be achieved by dialysis because of micelle formation. 
 
Therefore, the detergent was initially removed from the maltoporin solution by 
precipitation of the protein with acetone.  The resulting pellet was redissolved in buffer 
containing a known amount of octyl-POE and dialysed against the same buffer-
detergent solution.  To test how well this method was at matching the detergent 
concentration, the maltoporin sample was subject to an ITC experiment which involved 
titrating the buffer against the protein solution.  This experiment showed only a small 
heat of dilution which indicated that the buffer was sufficiently matched to allow further 
titrations (Figure 2-16). 
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Figure 2-16 Buffer titrated into maltoporin in Octyl-POE 
 
Binding to maltoporin was subsequently tested using maltose, maltotetraose and 
maltoheptaose.  First maltoheptaose was tested although only very weak binding was 
seen by ITC (Figure 2-17).  As the theoretical binding affinity for maltoheptaose would 
be less than 60 M, at a ligand concentration of 7.5 mM, a large proportion of 
maltoporin should be bound within the first few injections.68  This was not seen in the 
data with the point at which binding started to level off at a molar ratio of over 30.  
There is also a small heat of dilution when with the large number of water molecules 
displaced and hydrogen bonds formed it would be thought that the heat of binding 
would be high.  This is not reflected in the data where only a small amount of heat is 
shown to be released. 
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Figure 2-17 Titration of maltoheptaose (7.5 mM) into maltoporin (14 M) in Octyl-POE 
 
It was thought possible that the octyl-POE may have been occupying the binding site of 
maltoporin leading to a much weaker apparent affinity in the ITC experiment.  If octyl-
POE was occupying the binding site then its replacement by a maltooligosaccharide 
would also create a much smaller change in heat than if the sugar was displacing water. 
 
To overcome this potential problem, it would be necessary to remove detergent from 
the buffer without maltoporin precipitating from solution.  ITC of membrane proteins has 
previously been achieved with the use of Amphipol A8-35 in place of detergent. This 
large amphiphilic polymer can wrap around membrane proteins keeping them in 
solution without the use of detergent.114 
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Figure 2-18 Comparison of Amphipol A8-35 solubilised protein and octyl-POE solubilised 
protein.  Lane 1 + 3 – protein marker, Lane 2 –maltoporin solubilised with octyl-POEmaltoporin; 
Lane 4 – maltoporin solubilised  with  amphipol A8-35 
 
The detergent in a 1 ml sample of maltoporin (27 M) was replaced with Amphipol A8-
35 by adding five equivalents of the polymer.  The solution was left for 15 minutes 
before pre-washed SM2 biobeads (Bio-Rad) were added to remove detergent.  The 
solution was agitated for 2 hours before the buffer containing maltoporin was decanted 
from the solution.  SDS PAGE showed maltoporin as the folded trimer suggesting the 
amphipol had successfully kept the protein in solution (Figure 2-18). 
 
ITC experiments were repeated to show that the buffers were again matched.  
Maltoheptaose was tested against the amphipol-solubilised protein as this was the 
sugar with the highest expected binding affinity.  These ITC experiments again showed 
a curve consistent with much weaker binding than was expected.  For maltoheptaose 
the baseline had shifted a large amount (Figure 2-19).  This is generally due to the 
system not having enough time to return to equilibrium between injections.  The 
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experiment was therefore repeated with a 5 minute interval between injections instead 
of 2 minutes, thus giving the system longer to equilibrate. 
 
 
Figure 2-19 ITC with amphipol solubilised maltoporin. A - Maltose (100 mM) into maltoporin (16 
M); B – Maltotetraose (7.5 mM) into maltoporin (21 M); C – Maltoheptaose (7.5 mM) into 
maltoporin (21 M). 
 
With the solution having longer to return to equilibrium it became clearer that the 
observed heat changes were unlikely to be due to maltoheptaose interacting with the 
pore of maltoporin.  The point at which the base line was reached was still at a molar 
ratio of over 20.  This value gives a binding affinity that is much larger and therefore 
incompatible with the previous binding affinities for MOSs.  This concluded that the 
peaks seen could not be due to the binding of MOSs in the pore of maltoporin. 
 
The peaks could either be due to heat of dilution, or to complexation at a much weaker 
binding site, perhaps in the loops of maltoporin.  There is also a much broader 
secondary peak seen in the ITC data which could be due to maltoheptaose binding in 
the pore (Figure 2-20).  If so, then it suggests that the threading into and binding of 
maltoheptaose in the pore of maltoporin has very slow kinetics. 
 
65 
 
 
Figure 2-20 ITC of maltoheptaose (7.5 mM) into maltoporin (14 M) with 4 min between 
injections. 
 
As accurate ITC data relies on a very fast binding event it appears that the binding of 
maltoporin to maltooligosaccharides occurs on too long a timescale for ITC to be an 
effective technique. 
 
 
2.2.9 The expression and modification of maltoporin mutant G382C 
 
As it had been concluded that binding between maltoporin and maltooligosaccharides 
occured too slowly to be measured by ITC, a different approach was needed.  Methods 
using fluorescently-labelled maltoporin could give information on binding and would not 
be adversely affected by the binding kinetics.  The solutions could be pre-mixed and 
allowed to equilibrate before being measured. 
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To fluorescently label maltoporin a cysteine residue would need to be added to the 
surface of the protein.  Maltoporin already contains two cysteine residues at positions 
22 and 38, but these are buried deep within the protein and are found not to be reactive 
to labelling when the protein is folded.111,115  Position 382 was picked to be mutated as 
this was in the loop region of the protein and therefore would have the greatest 
exposure to ligands binding in the pore of maltoporin (Figure 2-21). 22 
 
 
Figure 2-21 Maltoporin pictured from above its extracellular face with position 382 highlighted in 
blue. 
 
Site directed mutagenesis was employed to introduce the mutation G382C.  A PCR 
reaction was carried out with the pSAB2.2-M5 plasmid containing the gene for LamB 
and primers encoding for the G382C mutation.  After the reaction the plasmid was 
digested with Dpn1 which showed no loss of the plasmid at ~5700 bp.  Dpn1 only 
cleaves at methylated sites therefore it cleaves the parent plasmid but not the PCR 
product.  This is because bacteria methylate DNA but the PCR product has been 
produced synthetically so it will not have been methylated.  As an agarose gel of the 
reaction showed a strong band after Dpn1 digestion it suggests there is a large amount 
of the synthetic product produced (Figure 2-22). 
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As the mutatgenesis appeared to be successful, the plasmid was transformed into 
XL10 cells, grown on an agar plate and three colonies were extracted and sequenced 
which showed the correct mutant had been made. 
 
.  
Figure 2-22 A Dpn1 digest of the mutagenesis product showing no loss of plasmid.  Lane 1 – 
DNA ladder; Lane 2 – Undigested plasmid; Lane 3 – Dpn1 digested plasmid. 
 
The pSAB2.2-M5 plasmid containing the LamB G382C gene was transformed into 
omp8 cells for expression.  These were then expressed following the same procedure 
as the for wild type maltoporin except for the introduction of DTT into any buffers used.  
This was to ensure no intramolecular sulfide bridges were formed resulting in 
aggregation of the protein. 
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Figure 2-23 Gel demonstrating the successful expression of maltoporin G382C mutant.  Lane 1 
– Protein ladder; Lane 2 – Remaining cell pellet; Lane 3 – Triton X-100-solubilised protein 
 
SDS PAGE demonstrated a strong band at ~97 kDa in the Triton X-100-solubilised 
fraction (Figure 2-23) showing the mutant had successfully been expressed. 
 
 
2.2.10 Labelling of the G382C mutant 
 
As the mutant has been successfully expressed it could now be labelled with a 
fluorescent molecule containing a maleimide group.  Tetramethylrhodamine-5-
maleimide 2.1 (Santa Cruz Biotechnology) was chosen as the fluorescent molecule as 
it could act as a FRET pair with both fluorescein and dansyl groups that were being 
used in the ligands to be evaluated (Figure 2-24). 
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Figure 2-24 Tetramethylrhodamine-5-maleimide 
 
T. Ferenci and co-workers had reported a greater degree of labelling of a cysteine 
mutant at pH 8.4, while labelling still occurred at pH 7.4.111  Both of these methods 
were investigated with the use of TCEP to ensure that the cysteines were reduced 
before labelling.  The reaction at pH 8.4 was shown to be more effective but also 
labelled the wild-type maltoporin which suggested that at the higher pH either the 
internal cysteines could be labelled or, more likely, that non-specific labelling at free 
amines on the protein was also occurring.  Labelling at pH 7.4 was shown to be more 
selective with the wild-type maltoporin showing no labelling while the G382C mutant 
fluoresced under UV light (Figure 2-25) 
 
 
 
Figure 2-25 Labelling of maltoporin G382C with tetramethylrhodamine maleimide.  The image 
on the left is shown under UV light. Lane 2 + 6 – WT maltoporin pH 7.4; Lane 3 + 7 – G382C 
maltoporin pH 7.4; Lane 4 + 8 – WT maltoporin pH8.4; Lane 5 + 9 – G382C maltoporin pH 8.4 
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2.3 Expression and purification of MBP 
 
It was also necessary to express MBP for use in the project.  As it is commonly used as 
a fusion protein to aid solubility and purification, it is available in a variety of vectors.  
An empty pMal-c5X plasmid encoding MBP was transformed into E. coli C43 cells.  
The cells were then grown to the exponential phase before induction with IPTG.  
 
 
 
Figure 2-26 Amylose column purification of MBP with 20% glucose.  Lanes 2 + 3 flow through; 
Lanes 4 + 5 washes; Lanes 6 – 14 glucose elutions. 
 
MBP fusion proteins are usually purified by use of an amylose column and elution with 
maltose.  This strategy would not be ideal for the current project as MBP has a M 
binding affinity for maltose and so if eluted with this ligand, the MBP would be 
inactivated for further binding.  Therefore, it was decided to elute with a high 
concentration of glucose as it has a much lower binding affinity and could thus be 
easily removed by dialysis.  This method proved to be successful with a strong band at 
~45,000 Da in the elution fractions producing 40 mg / L of MBP (Figure 2-26). 
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Figure 2-27 Mass spectrometry trace of MBP 
 
Mass spectrometry gave a mass of 44670 Da compared to the expected mass of MBP 
being 44669 Da, confirming it was the correct product (Figure 2-27). 
 
ITC was performed on MBP to confirm it had not been inactivated during its purification.  
Titration with maltose gave a good binding curve with a dissociation constant of 9 M 
confirming its binding site was free and it could still interact with ligands (Figure 2-28). 
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Figure 2-28 ITC with maltose (1 mM) and MBP (40 M) 
 
 
2.4 Conclusion 
 
The two principal proteins required for this project were successfully expressed, 
purified and analysed.  Maltoporin was successfully expressed on a workable scale 
using E. coli BL21(DE3)omp8 cells and purified with the use of an amylose column.  
MBP was expressed from an empty pMal c5x plasmid in E. coli C43 cells and purified 
with an amylose column and eluted with glucose. 
 
Although literature procedures for the expression of maltoporin were available these 
did not prove reliable and a significant amount of optimisation was required.  During 
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this process information about maltoporin was discovered.  It was found that the leader 
sequence is integral to successful expression of the protein.  It was also demonstrated 
that an OD600 of 0.6 is optimum for maltoporin expression and above this value the 
amount of folded maltoporin expressed is significantly reduced.  A slower growth rate is 
also desirable for efficient removal of the leader sequence from maltoporin.  Refolding 
of maltoporin has previously been shown to be possible from purified maltoporin but 
after testing a wide range of conditions it was shown not to be possible directly from 
inclusion bodies. 
 
MST was found to be unsuitable for measuring binding of maltoporin to 
maltooligosaccarides, presumably as there was little change to the hydration shell of 
maltoporin on ligand binding.  ITC was also evaluated as a binding assay. However, 
the threading of maltooligosaccharides into the pore of maltoporin was found to occur 
on a much longer timescale than previously thought, thus making ITC unsuitable for 
use with this protein. 
 
A maltoporin mutant of G382C was successfully produced and this mutant was 
derivatised using a rhodamine maleimide compound. 
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3 Chapter III: Preliminary studies into the 
synthesis of the maltose fragment 
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3.1 Central maltose fragment design 
 
Central to the design of the switch is maltose, a known substrate for maltoporin.  This 
maltose moiety will need to be derivatised at both the reducing and non-reducing end 
to allow its insertion into the centre of the axle. This central maltose fragment was the 
crux of the synthesis and its design was based on the known permeability of maltoporin 
as well as the ease of its integration into the rest of the switch. 
  
To assure the ability of the maltose fragment to pass through maltoporin, its design 
was kept as close to the natural ligand as possible.  An -maltoside was selected for 
the initial design as this is the type of linkage found within maltooligosaccharides.  The 
fragment would also be derivatised at the 4'-position and the anomeric centre, again 
mimicking the natural construct (Figure 3-1).  These design criteria provide challenges 
for synthesis of the compounds as -glycosides are notoriously more difficult to 
synthesise than their -linked cousins and the 4'-position would need to be derivatised 
regioselectively. 
  
 
Figure 3-1 Maltose fragment 3.1 derivatised at either end with an amine at the non-reducing end 
and a carboxylic acid at the reducing end. 
 
To allow the efficient synthesis of the switch a maltose fragment 3.1 derivatised at one 
end with an amine and a carboxylic acid at the other, for its use in solid phase peptide 
synthesis (SPPS) (Figure 3-1).  This synthetic strategy would allow the length and type 
of linker to be varied at will. 
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Two parallel synthetic routes were pursued towards production of the maltose mimic.  
One route involved the introduction of a carboxylic acid at the reducing end of the 
disaccharide while the other aimed to introduce an amine at the non-reducing end.  It 
was envisaged that once both syntheses had been optimised they could be combined 
into a single procedure leading to a maltose fragment with both the carboxylic acid and 
amine attached. 
 
 
3.2 Introduction of a carboxylic acid at the reducing terminus of maltose 
 
As previously discussed maltoporin is only permeable to (14)linked sugars 
therefore in the production of the switch the linkages between maltosyl groups should 
ideally also be configured.  -Anomers are often formed using glycosyl donors with a 
non-participating protecting group in the 2-position.  However, other work previously 
performed by members of the group had shown that acetylated sugars perform better 
in SPPS.  Therefore, an acetylated -linked maltose would be the ideal substrate.  
However, as acetates are participating groups and therefore glycosylation with them 
will selectively give the -product, a standard glycosylation procedure could not be 
followed without the need for extensive remodelling of the protecting groups. 
 
 
3.2.1  Preliminary studies into the formation of an -C-glycoside 
 
Giannis and Sandhoff have reported a procedure for making -configured C-glycosides 
from sugar peracetates.116  As C-glycosides are resistant to glycosidase degradation 
they are an attractive target for use in the synthesis of glycopolymers.  Therefore, initial 
work focussed around the formation of a C-glycoside.  This required the formation of 
acetylated maltose which would act as the donor for C-glycosylation.  
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Scheme 3-1 The C-glycosylation of per-acetylated maltose 3.2 which was found to give a 
mixture of isomers. 
 
With the peracetate 3.2 in hand the C-glycoside 3.3 was synthesised following the 
general procedure of Giannis and Sandhoff (Scheme 3-1). 116  Although they reported 
yields in excess of 50% for glucosides and cellubiosides, in my hands a yield of only 11% 
was achieved for the maltose substrate.  This result was attributed to an incomplete 
reaction as well as the formation of a hemiacetal byproduct.  Due to a lack of 
stereoselectivity and the poor yields this route was abandoned. 
 
Angelo Alberti and co-workers have demonstrated previously that glycosyl halides, 
including acetobromomaltose, can be converted into -C-glycosides117  when treated 
with acrylonitrile and tributyltin hydride under UV irradiation.  These reactions are 
reported to proceed in near quantitative yields and with complete stereoselectivity.  
Acetobromomaltose 3.5 was formed from acetylated maltose 3.2 using a standard 
procedure with the use of hydrogen bromide in acetic acid (Scheme 3-2).118 
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Scheme 3-2 Formation of C-glycosides 3.6 and 3.7 via acetobromomaltoside 3.5 using a UV 
catalysed reaction. 
 
The radical chemistry was performed under UV light but no product was seen with 
acrylonitrile or t-butyl acrylate.  Mass spectrometry showed evidence of polymerisation 
of t-butyl acrylate but even with the use of acrylonitrile, that was shown not to 
polymerise, no product was seen.  Due to the difficulties in the formation of a C-
glycoside it was decided to focus on the formation of an O-glycoside as a model 
system. 
 
 
3.2.2 Preliminary studies into the formation of an -O-glycoside 
 
O-Glycosides are much more common, would be simpler to make and could be used 
as models for studies with maltoporin and MBP in vitro.  The usual strategy for making 
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-glycosides involves using glycosyl donors with non-participating groups.  However, 
the glycosylation reactions rarely proceed with complete stereoselectivity.119,120 An 
alternative strategy for making O-glycosides is anomeric alkylation.  This approach can 
provide simple -glycosides in comparable selectivity to traditional methods,121 and is 
compatible with the ester protecting groups that are desirable for SPPS.  First, 
peracetate 3.2 was selectively deprotected at the anomeric position using hydrazine 
acetate in DMF. 
 
 
Scheme 3-3 Deprotection and alkylation of the anomeric hydroxyl group. 
 
Alkylation of hemiacetal 3.8 was achieved using tert-butyl bromoacetate and potassium 
carbonate (Scheme 3-3).  This reaction gave a 6:1 (mixture of anomers 3.9 which 
were not separable by column chromatography.  Some cleavage of the disaccharide 
glycosidic linkage also occurred which contributed to a decreased yield.  The reaction, 
although successful to a certain extent, had taken 11 days to reach completion. 
 
 
Scheme 3-4 Alkylation of the anomeric hydroxyl group with the addition of Bu4N.I. 
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As the alkylation step was slow it was repeated in the presence of tetrabutylammonium 
iodide (TBAI) to replace the bromine with the more reactive iodide leaving group which 
should reduce the reaction time (Scheme 3-4).  It was found that this additive allowed 
the reaction to proceed to completion in 24 h with no effect on yield or stereoselectivity. 
 
 
Figure 3-2 Proposed origins of the stereoselectivity shown in the alkylation reaction. 
 
The speed of the reaction had been increased so now the carbonate base was varied 
to attempt to improve the stereoselectivity and/or yield of the reaction (Scheme 3-4).  
This was done as research by Y. Queneau and co-workers from which the original 
reaction was taken suggested that the stereoselectivity arose from the metal of the 
carbonate chelating to the acetate in position 2 and the anomeric hydroxyl group, thus 
holding it in the -configuration (Figure 3-1).121  It was thought that a metal with a 
higher charge may give higher selectivity.   
 
Alkylation did not occur with the use of BaCO3 while Cs2CO3 gave a 10% increase in 
yield (Scheme 3-5).  No change in the stereoselectivity of the reactions was found.  No 
reaction was seen with BaCO3 as it is very insoluble and so likely could not participate 
in the reaction.  Why Cs2CO3 would increase the yield over K2CO3 is unclear. 
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Scheme 3-5 Anomeric alkylation as carried out with a variety of carbonates 
 
Although the yields and rate of reaction had been improved it was still impossible to 
separate the anomers.  So the reaction was repeated using benzylidene acetal 
derivative 3.10 as it was thought that the added rigidity may allow selective 
crystallisation of a single anomer.   
 
Removal of the anomeric acetate forming 1-hydroxy product 3.11 was successful 
(Scheme 3-6).  Benzyl bromoacetate was chosen for the alkylation step instead of a 
tert-butyl bromoacetate as the benzyl group would be stable under the acidic conditions 
needed for removal of the benzylidene acetal. 
 
The reaction gave a better yield than had previously been obtained for the anomeric 
alkylation reaction; however the stereoselectivity was poorer with a ratio of 2:1 for the 
 anomers (Scheme 3-6).  The bulk of a benzyl group compared to a tert-butyl group 
is less so this may account for the loss in stereoselectivity.  Although this would 
suggest a smaller role for the metal ion in the stereoselectivity of the reaction.  
Crystallisation of the product 3.12 was not possible and the anomers were still found to 
be inseparable by column chromatography.  Partial deprotection of the product 3.12 
(either removal of the benzylidene acetal, acetate groups or benzyl group) was 
attempted but no separation could be achieved.   
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Scheme 3-6 Removal of the anomeric acetate with hydrazine acetate and alkylation with benzyl 
bromoacetate. 
 
The selective formation of an -glycoside had proved difficult although the use of 
acetate protecting groups was still desired due to their proven success in SPPS.  The 
conventional methods for -glycoside formation were not investigated due to the added 
steps involved in changing protecting groups early on in the synthesis of the switch.  It 
was therefore decided to investigate the potential use of -glycosides. 
 
 
3.2.3 Is maltoporin permeable to -maltosides? 
 
The work so far has illustrated the difficulty in achieving formation of the -glycoside 
selectively.  This led to research into whether maltoporin could be permeable to the 
much more easily synthesised -glycoside.  Crystal structures have shown two maltose 
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molecules end on in the binding site arranged in a configuration analogous to a β-
glycosidic linkage (Figure 3-3).  This observation does not necessitate that a β-linked 
molecule could pass through the pore, but it does suggest that it could bind to 
maltoporin. 
 
 
Figure 3-3 Binding site of maltoporin demonstrating the orientation of sugars into a β-linkage 
like arrangement. 
 
To investigate the permeability of maltoporin, a -glycoside was synthesised with a 
PEG group as the aglycone as this is similar to the linking groups in the final polymer.  
The -glycoside 3.13 was produced stereoselectively from acetobromomaltose 3.5 
(Scheme 3-7). 
 
 
Scheme 3-7 Synthesis of -glycoside 7 from acetobromomaltose 5. 
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A liposome swelling assay was used to measure permeability as it is a simple 
procedure which has been used previously for maltoporin.99,122  In a liposome swelling 
assay giant multilamellar vesicles are formed in the presence of dextran and 
punctuated with maltoporin.   This allows suitable ligands to pass into the vesicles and 
due to osmotic pressure causes them to swell (Figure 3-4).  The swelling of these 
vesicles can be followed by light scattering and these values can then be compared to 
a negative control in the absence of maltoporin.  As maltose and sucrose have 
previously been studied using this method, they can be used as positive and negative 
controls, respectively. 
 
 
Figure 3-4 The liposome swelling assay 
 
Following the liposome swelling assay procedure,123 20 l of 20 mM sugar solutions 
were added to 600 l of liposomes containing 0.2 M maltoporin.  The absorption was 
measured every 5 seconds for 1 minute after addition and the gradients of the sugars 
compared.  A bigger loss in absorption means a greater degree of swelling of the 
liposomes and therefore maltoporin has a greater permeability to that ligand. 
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Figure 3-5 Liposome swelling assay results showing loss in absorbtion of vesicles with 
maltoporin (blue), without maltoporin (red) and the difference between these two results (green).   
 
The liposome swelling assay results (Figure 3-5) show maltoporin to be permeable to 
maltose but not to sucrose.  This is in agreement with T. Schirmer and co-workers.124  
The -maltoside 3.13 is shown to have a higher degree of permeability than maltose.  
This could be explained by the -maltoside having a lower affinity for maltoporin.  It has 
previously been demonstrated that maltooligosaccharides with a higher affinity for 
maltoporin reside in the pore for longer.68  If the binding of the -maltoside is weaker 
than maltose it would spend less time in the binding site and so pass through the pore 
faster.  As only its ability to pass through the pore of maltoporin is desired the synthesis 
of a maltose mimic could be continued with a - instead of an -glycosidic linkage. 
 
 
3.3 Preliminary studies into the selective derivatisation of the 4'-position 
 
This section will outline investigations into derivatisation of the 4'-position and its 
optimisation.  The chemistry at the non-reducing end comprised two distinct challenges: 
the first being selective deprotection of the 4'-position; the second being attachment of 
a functional group to the unprotected hydroxyl group.  Sugar chemistry is notorious for 
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its dependence on protecting group chemistry and, as such, several methods exist for 
the selective deprotection of the 4-position of glycosides based on the regioselectivity 
of protecting group manipulations. 
 
 
3.3.1 Initial plan for introduction of an amine at the non-reducing terminus of 
maltose  
 
 
 
Scheme 3-8 The patented synthesis of amino sugar 15.
86
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A patented route exists for the selective deprotection of the 4'-position followed by 
formation of a 4'-amine starting from the benzylidene acetal protected sugar 3.10 
(Scheme 3-8).86  Benzylidene acetals have been shown to selectively protect the 4- 
and 6-positions of sugars as they are the only positions able to form a stable 6-
membered ring.  This molecule could be selectively synthesised from maltose. 
 
 
Scheme 3-9 Protection of the 4' and 6' positions on maltose with a benzylidene acetal. 
 
The 4' and 6' positions of maltose 1.19 were protected using dimethoxy toluene in the 
presence of acid (Scheme 3-9) to give benzylidene acetal 3.19.  After the reaction was 
complete, the product was stirred with TFA to remove any acyclic acetals that had 
formed with other hydroxyl groups.  Flash column chromatography gave the product in 
good yields allowing for the protection of the remaining hydroxyl groups.  This was 
done using a hot acetylation protocol as procedures in the presence of amine bases 
usually lead to a mixture of anomers.  The hot acetylation protocol is selective for the -
anomer (Scheme 3-9),125 removing the additional complication of needing to 
characterise a mixture of diastereoisomers.  The hot acetylation was stereoselective 
with ~9:1 formation of the : glycoside, giving exclusively the -product 11 following 
recrystallization.  As the reaction could be scaled up easily, the low yield could be 
accepted given its stereoselectivity.  With the regioselectively protected maltoside 3.10 
in hand, the 4'-position could be deprotected. 
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Scheme 3-10 Removal of the benzylidene acetal with fluoroboric acid before acetylation of the 
6' hydroxyl group using acetylated HOBt. 
 
Following the method of P. Deshong and co-workers the benzylidene acetal was 
removed with the use of fluoroboric acid in acetonitrile, to give the diol 3.14.  To 
selectively protect the 6'-hydroxyl group a weak acetylating agent was needed.  
Acetylated HOBt 3.15 had been reported to enable this reaction,86 however in my 
hands the reaction resulted in moderate yields (Scheme 3-10).  The acetylating agent 
was shown to not to be very selective, as the 4'-position was substantially acetylated 
before all the 6'-position had reacted.  As benzylidene acetal removal followed by 
acetylation gave an overall yield of 27%, a new more selective method was sought. 
 
 
3.3.2 The testing of acetic acid as an efficient reagent for the selective 
acetylation at the 6'-position 
 
A novel one step synthesis based on a personal communication with Stefan Oscarson 
was investigated as it combined deprotection and acetylation into a single step.  The 
Oscarson group had observed 6'-acetylation in near quantitive yields while attempting 
to hydrolyse a benzylidene acetal using aqueous acetic acid in acetonitrile.  In my 
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hands 4'-hydroxyl 3.16 was produced in ~10% yields (Scheme 3-11) with deacetylation 
shown to occur after 4 h.   
 
 
Scheme 3-11 First attempt at the combined benzylidene acetal removal and 6' acetylation. 
 
The reaction appeared to be promising as the product had been produced even though 
it was also consumed after a short period of time.  Which of the reagents were 
important in the reaction was unclear, but deacetylation would be unlikely to occur if 
H2O was excluded, so the reaction was repeated under dry conditions. 
 
 
Scheme 3-12 The various methods attempted for the combined benzylidene acetal removal and 
subsequent 6' acetylation. 
 
It was found that excluding water from the reaction increased the yield to 43% and this 
increased again to 59% if the acetic acid was dried via crystallisation prior to use.  It 
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was also discovered that MeCN was not essential for the reaction.  Now that the 
conditions to improve the yield of reaction were known, a possible reaction mechanism 
was proposed (Scheme 3-12). 
 
It was thought that the benzylidene acetal could be protonated allowing ring opening to 
produce an oxacarbenium ion 3.22.  Acetic acid may then act as a nucleophile 
attacking the benzylic position to produce acyclic acetal 3.23.  The benzylidene acetal 
could then be lost through an acid catalysed SN1 reaction with another molecule of 
acetic acid to give the benzylidene diacetate 3.26.  It is this molecule 3.26 that could 
then act as an acetylating agent, reacting with the more reactive 6'-position to give the 
target molecule 3.16.  This hypothesis seems plausible as the positive charge would be 
stabilised by delocalisation on carbocation 3.22 and acetic acid would seem to be the 
only species in the reaction mixture able to act as a nucleophile.  The final step yields 
the product plus acetic acid and benzaldehyde (Scheme 3-13). 
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Scheme 3-13 Reaction scheme for the putative mechanism of the removal of the benzylidene 
acetal and subsequent acetylation of the primary alcohol. 
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Although the yield had been increased significantly, the reaction had taken 8 days to 
reach completion. Therefore, with a hypothesis for the mechanism in hand, three 
different methods were investigated with the aim of increasing the reaction rate.  A 
higher temperature, stronger acid and drying agents were all tested (Scheme 3-14) 
with the reactions followed by TLC. 
  
 
Scheme 3-14 Deprotection/acetylation steps carried out at higher temperature, with p-
toluenesulfonic acid added and with acetic anhydride added.  These reactions were not purified 
but followed by TLC. 
 
Addition of acetic anhydride gave no product within 24 h.  This could mean that water is 
needed in some catalytic amount during the reaction for example during the initial 
removal of the benzylidene acetal.  From TLC anaylsis heating the reaction and the 
use of a stronger acid resulted in faster product formation but also caused cleavage of 
the glycosidic bond and formation of the per-acetylated products leading to a reduced 
yield.  As these changes in method had produced no increase in efficiency of the 
reaction and a successful method was now available for the deprotection of the 4’-
position the optimisation was stopped and derivatisation at the 4’-position pursued.  
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3.3.3 Alkylation at the 4'-position of an acetylated sugar 
 
Following the work of P. Deshong and co-workers (Scheme 3-8), the 4'-position would 
be converted to an amine allowing its use in SPPS.  The configuration at the 4'-position 
was inverted by conversion of the 4'-alcohol to a triflate followed by an SN2 reaction 
with tetrabutylammonium nitrite.  The intermediate nitrite ester hydrolysed on aqueous 
work-up to give galactoside 3.17 in 43% yield (Scheme 3-15).  However, NMR 
spectroscopy showed the product comprised of a 10:1 ratio of axial and equatorial 
isomers.   
 
 
Scheme 3-15 Inversion of the 4' position. 
 
As a mixture of diastereoisomers was formed in a low yield a different strategy was 
considered in which the 4'-hydroxyl group would be alkylated with bromoacetonitrile.  
The nitrile group could then be reduced to an amine (Scheme 3-16). 
 
 
Scheme 3-16 Alkylation strategy for introduction of an amine at the non-reducing terminus. 
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Alkylation at the 4'-position was tested with bromoacetonitrile (Scheme 3-17).  
Alkylation was found to occur but a mixture of products was produced due to the 
formed 4'-alkoxide also picking up acetate groups resulting in non-specific alkylation.  
Acetate groups are also known to migrate between adjacent hydroxyl groups especially 
under conditions where the alkoxide is formed.   Although alkylation was shown to be 
incompatible with acetate protecting groups, it did present itself as a promising route 
due to the reduced number of steps compared to inversion and the variety of functional 
groups that could be attached using this method.  It was therefore decided to pursue 
the alkylation reaction and search for a different protecting group strategy.   
 
 
Scheme 3-17 Attempted alkylation at the 4' position of the heptaacetate protected sugar. 
 
 
3.3.4 New protecting group strategies 
 
As acetate groups were found to be incompatible with alkylation new methods to 
replace these protecting groups were investigated.  First a new strategy for the 
protection of the 6'-position was investigated.  Aqueous AcOH was used to remove the 
benzylidene acetal and the 6'-position was protected with a silyl-protecting group 
(Scheme 3-18).  Three different conditions were used for silyl-protection with the use of 
pyridine as a solvent and DMAP as the catalyst found to give the best yields. 
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Scheme 3-18 Reaction schemes for the removal of the benzylidene acetal and protection of the 
6' position with a TBDMS group. 
 
The yields for protection with a silyl protecting group were not as high as would be 
desired so the reductive opening of the benzylidene acetal was investigated.  Sodium 
cyanoborohydride reductive opening of the benzylidene acetal gave yields similar to 
the use of a silyl protecting group.  Another method using triethylsilane, known to be an 
effective reducing reagent with benzylidene acetals126, and TFA in the presence of the 
trifluoroacetic acid anhydride was tested.  This method gave the product 3.31 in one 
step and in higher yield (Scheme 3-19). 
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Scheme 3-19 Ring opening and reduction of the benzylidene acetal. 
 
Now an effective method had been found for the deprotection and protection of the 4'- 
and 6'-positions respectively this method could be combined with a new protecting 
group strategy.  As reducing the benzylidene acetal results in the formation of a benzyl 
group it made sense to use benzyl groups to protect the rest of the molecule as they 
could all be removed in one step. 
 
To test the alkylation reaction with benzyl protecting groups a single anomer was 
desired to allow for ease of characterisation.  A -thioglycoside was chosen as it would 
be stable to all the conditions of the synthesis and could be orthogonally reacted to 
allow derivatisation of the reducing end of the sugar.  From acetobromomaltose 3.5 a 
thiophenolglycoside 3.32 was formed, this was then deprotected with sodium 
methoxide in methanol.  Once derivatised with a benzylidene acetal it was also 
protected with benzyl groups and the 4'-position deprotected using triethylsilane 
showing the reaction to be robust to different protecting groups.  The synthesis of the 
4'-deprotected maltoside 3.36 was a success producing 1 g of the product 3.36 over 8 
steps in a 8% overall yield (Scheme 3-20). 
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Scheme 3-20 The synthesis of 4'-deprotected thioglycoside 3.36 from per-acetylated maltose. 
 
With a benzyl-protected maltoside in hand alkylation of the 4'-position could be tested.  
This was carried out using TIPS-protected 2-(2-(2-chloroethoxy)ethoxy)ethanol 3.38.  
The PEG group was chosen as it gave the option of later derivatisation with a number 
of different functional groups as well as putting the position of connection distal from 
the sugar to hopefully avoid perturbing binding to the protein.  TIPS was selected as it 
is one of the most base stable silyl ethers which could be cleaved orthogonally to the 
benzyl ethers (Scheme 3-21). 
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Scheme 3-21 Protection of 2-(2-(2-chloroethoxy)ethoxy)ethanol 3.37 with TIPS ether and 
subsequent derivatisation of thioglycoside 3.36 
 
Alkylation at the 4'-position was successful but low yielding likely in part due to the 
reaction proceeding via an unfavourable SN2 reaction  to an oxygen (Scheme 3-21).  
The TIPS group was removed using TBAF in quantitative yield leaving a lone hydroxyl 
group to be derivatised as needed.  The preliminary studies on the non-reducing end of 
the sugar were now complete.  It has been shown that the 4'-position can be selectively 
deprotected and functionalised. 
 
 
3.4 Preliminary studies conclusion 
 
This chapter has covered the preliminary studies into forming the maltose fragment 
derivatised at the 4'-position and anomeric position needed for the synthesis of the 
switch.   
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Investigations into formation of the desired -glycoside showed this synthetic route to 
be problematic.  Therefore a -glycoside’s ability to pass through maltoporin was tested 
with a liposome swelling assay.  This test found that maltoporin is permeable to -
maltosides therefore the switch axle could contain -linked maltosides. 
 
The work at the non-reducing end showed the use of triethylsilane was the most 
convenient route to selective 4'-deprotection.  It also demonstrated that alkylation was 
the most promising method to derivatise the 4'-position and benzyl protecting groups 
were the best type of protecting group to achieve this.  A sugar was also successfully 
alkylated at the 4'-position allowing these methods to be taken through into the 
synthesis of the switch axle.  
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4 Chapter IV: The synthesis of molecules 
designed to probe the binding of maltoporin 
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4.1 Introduction 
 
During this project a variety of compounds have been synthesised alongside the 
development of the switch.  These compounds have all been designed to probe the 
working of maltoporin through binding studies. The first part of this chapter deals with 
the synthesis of three molecules which will help in understanding the binding of 
maltoporin in very different ways.  While the second part of this chapter investigates the 
methods to test the binding of these molecules. 
 
 
4.2 The synthesis of a pseudotetrasaccharide to probe the bind-and-slide 
mechanism of maltoporin 
 
Maltoporin operates a bind-and-slide mechanism and it is this functionality that is being 
used to enable the operation of the switch.  To understand this mechanism better and 
thus ensure the successful implementation of the switch, a pseudotetrasccharide was 
synthesised.  This compound had many of the functional groups that would be present 
in the switch and its binding would give insights into how the final switch would operate 
in conjunction with maltoporin. 
 
The pseudotetrasaccharide would consist of two maltose units connected by a PEG-
linker.  This would serve two purposes; it would demonstrate the permeability of 
maltoporin to this kind of structure and also deliver information on how a molecule like 
this would bind. 
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Figure 4-1 Maltooligosaccharides compared to the pseudomaltotetraose 
  
A pseudomaltotetraose 4.3 (Figure 4-1) would be interesting to study as it is not known 
how important the distance between the binding sites on maltooligosaccharides is for 
their binding to maltoporin.  A pseudomaltotetraose 4.3 could be thought to mimic two 
independent maltose units or it could bind with a similar affinity to maltotetraose 4.1 
with the PEG-linker being of little importance.  Maltoheptaose 4.2 will also be tested as 
the two molecules have a similar length and this could be a factor in binding. 
 
 
4.2.1 Synthesis of the pseudotetrasaccharide 
 
The thioglycoside 3.40 synthesised in the last chapter was reacted with 
propargylbromide to produce a maltoside 4.4 derivatised at the 4'-position with an 
alkyne (Scheme 4-1).  
 
 
Scheme 4-1 Derivatisation of the free hydroxyl in donor sugar 3.40 with propargyl bromide. 
Another sugar 4.5 was functionalised with an azide to complement the alkyne at the 4'-
position of the maltose fragment.  Sodium azide was used to displace the primary 
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chloride in maltoside 4.5. Disaccharide 4.6 was then deacetylated and protected with 
benzyl groups to complement those on the maltose fragment to which it would be 
connected (Scheme 4-2). 
 
 
Scheme 4-2 Functionalisation of a PEG-linked maltoside with sodium azide 
 
Now the two sides of the pseudotetrasaccharide 4.3 had been synthesised, they could 
be attached via a copper catalysed azide-alkyne cycloaddition (CuAAC) reaction.  This 
reaction proceeded well, however the product could not be separated by column 
chromatography from residual starting materials.  The products were therefore taken 
through the next two steps without purification (Scheme 4-3). 
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Scheme 4-3 Formation of the psuedotetrasaccharide. 
 
After removal of the thiophenyl group, the benzyl protecting groups were removed by 
hydrogenation.  Once deprotected, the product 4.3 could be purified by size exclusion 
chromatography giving 4.3 in a 27% yield over three steps. 
 
 
4.3 Trivalent ligand synthesis 
 
The synthesis of another, very different molecule to probe maltoporin’s binding was 
also pursued.  This followed an alternative method of adhering small molecules to the 
surface of bacteria via maltoporin.  Utilising multivalency, a compound which could bind 
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all three of maltoporin’s binding sites would be expected to have a very high affinity 
(Figure 4-2). 
 
Figure 4-2 A cartoon of a multivalent molecule binding to maltoporin (green) via three 
maltooligosaccharides (red). 
 
Previously in the lab, Dr Martin Fascione had developed a synthesis of multivalent 
ligands for maltoporin using SPPS (Figure 4-3).  This synthesis utilised Dde-lysine 1.17 
residues as they allow for introduction of the Boc-aminooxyacetic acid 4.17 groups at 
the final stage of the synthesis ensuring they do not interfere with any peptide coupling 
reactions.  It also included a triglycine motif at the N-terminal of the peptide which 
would allow subsequent sortase ligation.127  Once cleaved from the resin the Boc 
groups can be removed and the aminooxy groups reacted with maltoheptaose 4.2 to 
form mono-, di- and trivalent ligands 4.10 which should be able to bind one, two or all 
of maltoporin’s monomers respectively. As Dr Fascione had successfully completed the 
synthesis of the mono- and di-valent compounds although purification of the trivalent 
analogue was found to be problematic.  The aim of this project was to synthesise and 
purify the trivalent ligand. 
 
Figure 4-3 The mono-, di- and trivalent ligand before its connection to maltoheptaose via oxime 
ligation  
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4.3.1 Building block synthesis for SPPS 
 
Modified lysine residues were needed for the SPPS of the trivalent ligand, as this 
orthogonal protecting group could be removed in the presence of Boc-groups.  A 
fluorescently-tagged lysine was also desired to allow easy detection of the products 
both during the purification of the compound and in fluorescence-based binding studies. 
 
 
Scheme 4-4 Synthesis of Fmoc-lys(Dde)-OH 1.17 from lysine and dimedone. 
 
Dde-OH 4.13 was used as a protecting group as it could be orthogonally removed by 
hydrazine leaving the terminal Boc-glycine protected.  Dde-OH 4.13 was first 
synthesised from dimedone 4.11 before reaction with Fmoc-lys-OH 4.12 to produce 
Fmoc-lys(dde)-OH 1.17 (Scheme 4-4). 
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Scheme 4-5 Synthesis of Fmoc-lys(dansyl)-OH 4.15 from unprotected dansyl lysine 4.14. 
 
Previous attempts in the lab at synthesising Fmoc-lys(dansyl)-OH from dansyl chloride 
and Fmoc-lys-OH 4.14 had led to the formation of a side product that had proved 
difficult to remove; therefore a new route employing dansyl lysine and  Fmoc chloride 
was followed.  This produced Fmoc-lys(dansyl)-OH 4.15 in a 43% yield (Scheme 4-5). 
 
 
Scheme 4-6 Protection of (Boc-aminooxy)acetic acid 4.16 with succinimide. 
 
An aminooxy compound with an NHS ester to allowing for its use in SPPS was 
synthesised.  (Boc-aminooxy)acetic acid 4.16 was activated with N-hydroxy 
succinimide to give 4.17 and kept crude as its purification had previously been shown 
to be unnecessary for SPPS (Scheme 4-6). 
 
 
4.3.2 Assembly of the trivalent ligand 
 
2-chlorotrityl resin was used for the assembly of the trivalent ligand 4.10c as the 
product could be released without removing the Dde- and Boc-protecting groups.  The 
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resin was already preloaded with a glycine residue.  Dansyl lysine 4.15 was added 
followed by three Dde-lysines 1.17 and a further two glycines 4.19 (Scheme 4-7).  The 
main chain was capped with a Boc-protected glycine 4.20 allowing for the selective 
removal of the Dde-groups while leaving the terminal amino acid protected.  
 
Once the lysine residues were deprotected, the side chains could be attached; these 
consisted of PEG-groups 4.23 with an Fmoc-protected amine and carboxylic acid.  
Boc-aminooxyacetic acid NHS esters 4.17 were used to cap the PEG-groups to allow 
the attachment of sugars (Scheme 4-7). 
 
Once cleaved from the resin the ligand was isolated by size exclusion chromatography 
to give the main product 4.10c with some impurities.  Mass spectrometry showed these 
impurities to contain several products in which the aminooxy group, despite being Boc-
protected, had reacted with additional Boc-aminooxyacetic acid NHS esters.  The bis-
Boc-protected reagent could be used instead to prevent this problem in future reactions. 
The ligand was purified by HPLC to remove these side products.  At this point 
analytical HPLC showed only one product 4.10c which was confirmed to have the 
correct mass by HRMS. 
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Scheme 4-7 SPPS of trivalent maltoporin ligand 4.10c. 
 
The three ‘arms’ of the ligand 4.10c were derivatised with maltoheptaose 4.2 through 
an oxime ligation.  This involved removal of the Boc-groups with TFA before addition of 
maltoheptaose in an anilinium acetate buffer at pH 4.5 (Scheme 4-8).  After 48 h the 
reaction mixture was passed down a size exclusion column to separate unreacted 
oligosaccharide. 
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Scheme 4-8 Oxime ligation of the trivalent ligand with maltoheptaose 
 
NMR spectrometry showed a product containing signals for both the dansyl group and 
a sugar although analytical HPLC showed multiple products with similar retention times.  
It is likely that the oxime ligation did not go to completion and the multiple peaks were 
due to a mixture of mono-, di- and tri-valent ligands. 
 
The multiple peaks were separated by HPLC but it was found not to be possible to 
analyse these products by mass spectrometry or NMR due to the small amount of 
material. 
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4.4 Fluorescent ligand  
 
It had been demonstrated that ITC could not deliver the binding information needed for 
maltoporin, therefore other methods such as fluoresence anisotropy and FRET were 
investigated.  For these experiments a fluorescent ligand that could be out competed 
during binding is needed this is because the molecules already synthesised for binding 
experiments do not have a fluorescent label which would be essential for these 
methods.   
 
Maltoheptaose was selected as the molecule to be used as longer 
maltooligosaccharides are known to have higher affinities for maltoporin.68  Fluorescent 
experiments are very sensitive and a low affinity ligand would need to be used in such 
high concentrations to fill the binding sites that it could potentially saturate the detectors.  
Fluorescein 4.25 was chosen as the fluorescent part of the molecule.  This was 
because it can act as a FRET pair with tetramethylrhodamine 2.1, the fluorescent 
group already attached to maltoporin (Chapter II). 
 
A short linker was desired to attach the two molecules as this would hold the 
fluorescent group close to maltoporin on binding.  This closeness would allow for more 
effective FRET and more pronounced anistropic effects due to the lack of movement 
around the linker. 
 
 
4.5 Synthesis of the fluorescent ligand 
 
An aminooxy ligation was first selected as a method to attach fluorescein to 
maltoheptaose as this chemistry was already in use in other areas of the project and 
thus the reagents were already available.  It also used a short linker in a minimum 
number of steps. 
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Scheme 4-9 Reaction of 6-aminofluorescein with Boc-aminooxyacetic acid NHS ester. 
  
Reaction of 6-aminofluorescein 4.25 with Boc-aminooxyacetic acid NHS ester 4.17 
(Scheme 4-9) produced a product 4.26, which although having the correct mass, was 
found to hydrolyse in the presence of TFA.  As an amide would be resistant to 
hydrolysis under these conditions it was postulated that an ester had instead been 
formed.  This was supported by the amine in 6-aminofluorescein 4.10 being 
deactivated by the lactone, while the hydroxyl groups were both on activated rings. 
 
Reductive amination was attempted using maltoheptaose 4.2 and 6-aminofluorescein 
4.25 (Scheme 4-10).  Although the attachment of the two molecules was successful, 
the reaction also resulted in a loss of fluorescence.  As the mass of the product 4.27 
had also increased by two it was theorised that the fluorescein could also have been 
reduced during the reaction. 
 
 
Scheme 4-10 Unsuccessful reductive amination of maltoheptaose and 6-aminofluorescein 
 
6-Aminofluorescein 4.25 had proved to be a difficult reagent to work with so a new 
strategy for an oxime ligation was followed with the use of FITC.  N-Boc-1,6-
hexadiamine 4.28 was derivatised with Boc-aminooxyacetic acid 4.17 and 
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subsequently deprotected with TFA before an oxime ligation was performed with 
maltoheptaose 4.2 (Scheme 4-11).  This left a free amine to which FITC could be 
attached.  This method yielded the fluorescent ligand 4.31 in three steps. 
 
 
Scheme 4-11 Formation of the fluorescent ligand via an oxime ligation 
 
 
4.5.1 Fluorescent binding studies 
 
The ability of the fluorescent ligand 4.31 to bind maltoporin was tested by fluorescence 
anisotropy.  For this experiment a serial dilution of maltoporin from 110 - 0.2 M was 
set up with a constant concentration (200 nM) of the fluorescent ligand. 
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Figure 4-4 Fluorescence anisotropy experiment showing the fluorescent ligand 4.31 (200 nM) 
against a serial dilution of maltoporin. 
 
The fluorescence anisotropy experiment showed increasing anisotropy as the 
concentration of maltoporin increased.  This is to be expected as when bound the 
fluorescent ligand will tumble slower in solution and so the anisotropic effect will be 
greater.  This experiment therefore demonstrated binding of the fluorescent ligand. 
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Figure 4-5 Total fluorescence against maltoporin concentration showing quenching of the 
fluorescent ligand 
 
The fluorescence of the ligand 4.31 was also shown to be quenched on binding to 
maltoporin as a fall in total fluorescence was also measured (Figure 4-5).  Although this 
was not a problem in itself the quenching of fluorescence would need to be taken into 
account for all binding measurements.  To test the utility of the fluorescent ligand a 
competition assay was set up with maltoheptaose 4.2.  For this a concentration of 
maltoporin (15 M) from the midpoint of the anisotropy curve was chosen.  This 
concentration still had a large degree of anisotropy and would make best use of protein 
stocks.  A serial dilution of maltoheptaose 4.2 was set up from 10 mM to 20 M with 
each well also containing the fluorescent ligand 4.31 (200 nM) and maltoporin (15 M). 
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Figure 4-6 Fluorescence anisotropy experiment with a maltoheptaose concentration gradient 
with fluorescent ligand 4.31 (200 nM) and maltoporin (15 M) 
 
The competition assay showed no variation in anisotropy with maltoheptaose 
concentration which suggested the fluorescent ligand was not binding in the pore of 
maltoporin (Figure 4-6).  To confirm this hypothesis a FRET experiment was carried out.  
If the fluorescent ligand was binding in the pore of maltoporin it should show some 
FRET activity with the tetramethylrhodamine attached to G382C maltoporin. 
 
For the FRET assay both the fluorescent ligand 4.31 and TAMRA maltoporin were 
excited at 450 nm and their emissions measured.  450 nm was selected as fluorescein 
has the greatest absorption at this wavelength compared to TAMRA.  A second 
measurement was taken of the fluorescent ligand and TAMRA maltoporin after they 
had been combined and allowed to sit for 30 min.  A third measurement was also taken 
after the addition of maltoheptaose to the solution. 
 
This method was carried out three times at different concentration of the fluorescent 
ligand while the protein concentration was set at 1.2 M.  If FRET occurs a reduction in 
fluorescein fluorescence should be seen coupled with an increase in TAMRA 
fluorescence as the fluorescein is quenched by TAMRA.  The maximum emission for 
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the fluorescent ligand was seen to be 515 nm while it was 568 nm for TAMRA (Figure 
4-7). 
 
 
Figure 4-7 The emission spectra of the fluorescent ligand 4.31 (100 nm) and TAMRA maltoporin 
(1.2 M). 
 
At all three concentrations of the ligand 4.31 (100 nM, 2 M and 20 M) no change in 
fluorescence was seen (Figure 4-8).  This supports the hypothesis that the fluorescent 
ligand 4.31 is not binding in the pore of maltoporin.  As if the ligand was bound the 
distance between the two fluorophores should be within the 1 – 10 nm that FRET 
requires.128  It was thought that the ligand 4.31 could potentially be binding to the 
micelles in solution instead of to maltoporin.  This is because the ligand 4.31 has a 
hydrophobic head group consisting of fluorescein and an alkyl chain (Scheme 4-11).  
This binding would produce an anisotropic effect and could explain why no FRET 
occurred yet fluorescence anisotropy showed binding. 
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Figure 4-8 FRET assay. A – Fluorescent ligand 4.31 and TAMRA maltoporin (1.2 M) assay; B - 
Fluorescent ligand and TAMRA maltoporin theoretical combined fluorescence; C - Fluorescent 
ligand X and TAMRA maltoporin (1.2 M) and maltoheptaose (10 mM) assay 
 
To test whether the fluorescent ligand was binding to micelles another fluorescence 
anisotropy experiment was run with samples in both water and detergent.  6-
Aminofluorescein was also tested with fluorescent ligand 4.31.  The results of this test 
show a clear increase in anisotropy when the fluorescent ligand is in a 0.5% octyl-POE 
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solution (Figure 4-9).  6-Aminofluorescein is also shown to bind the micelles but to a 
lesser degree than the fluorescent ligand 4.31.  This could be due to the ligands 
structure being similar in nature to a detergent molecule with a hydrophobic head 
consisting of fluorescein and an alkyl chain with a hydrophilic tail of maltoheptaose 
(Scheme 4-11). 
 
Figure 4-9 Relative fluorescence anisotropy between 6-aminofluorescein and Fluorescent ligand 
4.31 in both water and detergent 
 
The ligand 4.31 binding to the micelles would also explain the initial fluorescence 
anisotropy results (Figure 4-4).  In concentrating the protein any micelles in solution 
would also be concentrated so their concentration would also be decreased when the 
protein was subjected to a serial dilution.  As it had been found that the fluorescent 
ligand binds to the micelles of Octyl-POE a new method to solubilise maltoporin would 
be needed.  The options include amphipol A8-35 which has been previously used in 
chapter II or alternatively lipids could be used in place of the detergent. 
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4.6 Conclusion 
 
A pseudotetrasaccharide 4.3 was synthesised successfully connecting two maltose 
residues via a CuAAC.  This novel molecule will allow for an investigation into the bind-
and-slide mechanism to take place. 
 
The synthesis of the trivalent ligand 4.10c was successful.  Its purification was also 
achieved by a combination of size exclusion chromatography and HPLC.  The 
attachment of maltoheptaose residues via an oxime ligation still requires optimisation 
but can now begin from a pure starting material. 
 
A fluorescent ligand 4.31 was successfully produced using oxime ligations.  The 
binding of this molecule to maltoporin was investigated with fluorescence anisotropy 
which showed a good correlation between protein concentration and anisotropy.  
Further investigations with FRET and fluorescence anisotropy showed this binding to in 
fact be to micelles in the solution. 
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5 Chapter V: The synthesis of the switch axle 
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5.1 Introduction 
 
In the initial plan the axle of the switch was to be constructed using SPPS.  However 
during the preliminary studies and synthesis of the multivalent ligand some challenges 
to this method became apparent.  For the multivalent ligand all of the reagents were 
synthesised in a single step from commercially available materials.  This meant they 
could be produced in quantities of over a gram.  While during the preliminary studies in 
chapter III it had become evident that the building block synthesis could not be scaled 
up to make SPPS practical.  CuAAC was instead chosen as it had proved a reliable 
method to connect the pseudotetrasaccharide 4.18 together. 
 
A retrosynthesis of the switch axle was performed with three main fragments 
connected via PEG-linkers 5.1 (Scheme 5-1).  The PEG-linkers 5.1 were derivatised at 
one end with a Boc-protected oxyamine and an azide at the other.  This allowed them 
to be attached via an oxime ligation to an unprotected sugar and via CuAAC to an 
alkyne.  This method allowed the same linker to be used throughout the axle 5.6. 
 
 
The fragment at the non-reducing end would be maltoheptaose 4.2 while a propargyl 
containing fluorescein group 5.2 would cap the axle at the reducing end.  The central 
Scheme 5-1 Retrosynthesis of the switch axle 
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fragment 5.5 consisted of unprotected maltose derivatised at the 4'-position with an 
alkyne.  The construction of the axle 5.6 from the non-reducing end would allow for 
alternating methods of attachment. 
 
The PEG-linkers 5.1 were chosen to have a chain length of 10 as this had been shown 
to be sufficient to allowing binding to both maltoporin and MBP (Scheme 5-2).  
Fluorescein was selected as it would be too large to fit through the pore of maltoporin 
and could be used in FRET experiments upon the switch’s completion. 
 
Scheme 5-2 A model of binding between the switch and maltoporin (green) and MBP (blue).  
The maltoheptaose fragment (red) can be seen binding to MBP while the smaller maltose 
fragment (red) can also be seen in the binding site of maltoporin.  Fluorescein (yellow)  
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5.2 Synthesis of the maltose fragment 
 
Here the complete synthesis of the maltose fragment is shown. The optimisation of the 
techniques used in this synthesis is shown in chapter III.  It had been shown that the 
use of benzyl ethers was crucial for the alkylation step at the 4'-position and that an 
aminooxy ligation with the unprotected sugar was the most efficient method of 
attachment at the reducing terminus. 
 
In the first step of the synthesis benzylidene acetal-protected maltoside 5.7 was 
benzylated before the benzylidene acetal was selectively opened using triethylsilane 
under acidic conditions.  This left the 4'-position unprotected and available for 
derivatisation (Scheme 5-3). 
 
 
Scheme 5-3 Benzylation of the benzylidene acetal protected maltose 10. 
 
With the maltose fragment 5.9 selectively deprotected at the 4'-position, a propargyl 
group could be attached.   It was decided to attach the propargyl group via a PEG-
linker as this allowed the propargyl group to be placed distal from the sugar.  This 
approach was considered to be advantageous as the triazole produced in the CuAAC 
reaction would not interrupt any binding between the sugar and maltoporin. 
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Scheme 5-4 The formation of the propargyl containing PEG and its attachment to the 4'-position 
of maltose. 
 
The product 5.11 was synthesised successfully in two successive base-promoted 
alkylations (Scheme 5-4).  Both reactions were found to be low yielding due to the 
PEG-group 5.10 polymerising in the first reaction and the beta-effect in the subsequent 
reaction.  Despite the low yield, the product 5.11 was formed on a large enough scale 
to avoid the need for optimisation.  Using this method also avoided additional 
protection and deprotection steps that would be required if the propargyl group were 
added later. 
 
Ideally the maltose fragment 5.11 could be deprotected at this stage as an oxime 
ligation requires a free hemiacetal at the reducing end.  However, this was not possible 
under the standard conditions of H2 with palladium on carbon as the alkyne would also 
be hydrogenated. 
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Scheme 5-5 The unsuccessful deprotection of benzylated maltoside 5.11 with boron trichloride-
dimethyl sulfide. 
 
Two milder methods were tested for the removal of benzyl ethers in the presence of a 
propargyl group.  It has been shown that boron trichloride-dimethyl sulfide is an 
effective way to remove benzyl ethers in the presence of other functional groups.129  A 
combination of sodium bromate and sodium dithionite has also been shown to remove 
benzyl groups from oligosaccharides in the presence of azides.130  It was found that the 
use of boron trichloride-dimethyl sulfide removed the propargyl group but also resulted 
in cleavage of the glycosidic linkage (Scheme 5-5). 
 
 
Scheme 5-6 The unsuccessful oxidative deprotection of benzylated maltoside 5.11 with sodium 
bromate and sodium dithionite. 
 
The use of sodium bromate and sodium dithionite was found to have successfully 
deprotected the sugar as the product 5.5 was no longer visible under UV.  Although an 
unknown addition to the molecule had occurred as the mass of the molecule was 
substantially higher than the desired product.  It was clear that the benzyl groups could 
not be removed easily in the presence of the alkyne.  There was a potential option to 
protect the alkyne before removal of the benzyl ethers but the additional steps and loss 
of yield was thought not to justify its use.  As it was not possible to deprotect the sugar 
5.11 without destruction of the propargyl group it was decided to remove the benzyl 
groups once the maltose fragment was integrated into the switch axle. 
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5.3 The synthesis of the linker 
 
A linker was needed to connect the different fragments of the switch.  A PEG-linker 
was selected due to its water solubility, suitable length and the commercial availability 
of heterobifunctional PEG-groups.  An azide-amine PEG was used as it already 
contained the desired azide and the amine allowed ease of attachment of a Boc-
protected aminooxy group. 
 
 
Scheme 5-7 Synthesis of the azide-aminooxy-functionalised PEG-linker. 
 
An N-methylaminooxy compound was desired as these had been shown to cyclise on 
attachment to sugars producing the -glycoside.131  To form this product N-
methylhydroxylamine 5.12 was protected with Boc-anhydride 5.13 before alkylation 
with ethyl bromoacetate 5.15.  The ester 5.16 was hydrolysed and an NHS ester 5.17 
formed which was used to attach the protected aminoxyacetic acid to the amine of the 
PEG-linker 5.18.  The linker 5.1 had thus been successfully synthesised in 4 steps 
(Scheme 5-7). 
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5.4 Synthesis of the fluorescein fragment 
  
A large fluorescent molecule would be needed at one end of the switch to stop the 
switch threading all the way through the pore of maltoporin and also to be used for 
fluorescent binding studies.  To attach fluorescein to the switch it would need to be 
functionalised with an alkyne as the end of the PEG-linker contained an azide.  
Fluorescein isothiocyanate 5.19 (FITC) was reacted with propargylamine in methanol 
(Scheme 5-8).  Mass spectrometry showed the presence of the correct product 5.2 
which was then attached to the PEG-linker 5.1 via a CuAAC reaction.  The CuAAC 
reaction was not successful as the alkyne-fluorescein was shown to be insoluble in the 
mixture of solvents used.  The reaction was also attempted in methanol but still no 
product was seen. 
 
 
Scheme 5-8 The unsuccessful synthesis of the fluorescent fragment. 
 
It had been shown that the propargyl-derivatised fluorescein 5.2 was insoluble in 
common solvents used for CuAAC reactions.  Therefore the PEG-linker 5.1 would be 
modified first to allow its attachment directly to FITC 5.19. 
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Scheme 5-9 The reduction and functionalisation of the PEG-linker with FITC. 
   
The PEG-linker 5.1 was hydrogenated to produce an amine 5.22 to which FITC 5.19 
was attached.  The product was found to be soluble in MeOH and could be purified by 
size exclusion chromatography.  This led to the successful synthesis of the fluorescent 
fragment 5.23 of the switch (Scheme 5-9).  
 
 
5.5 The maltoheptaose fragment 
 
To allow the switch to bind to maltoporin a high affinity ligand was needed at the non-
reducing end.  As longer maltooligosaccharides were shown to bind more tightly,68 the 
seven-mer maltoheptaose 4.2 was selected.   This also had the advantage that it could 
be readily synthesised from -cyclodextrin 5.24.81 
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Scheme 5-10 Synthesis of maltoheptaose from acetylated -cyclodextrin 
 
Acetylated -cyclodextrin 5.24 was ring opened in the presence of acetic anhydride 
and sulfuric acid.  Per-acetylated maltoheptaose 5.25 is the most abundant product as 
ring strain causes the bonds in the -cyclodextrin to be slightly more reactive than in 
the linear product (Scheme 5-10).  Removal of the acetate groups with sodium 
methoxide and purification by size exclusion gave maltoheptaose 4.2 as the pure 
product. 
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Scheme 5-11 Attachment of maltoheptaose to the linker 
 
The PEG-linker 5.1 was attached to maltoheptaose 4.2 via an oxime ligation (Scheme 
5-11).  The Boc-group was removed from the linker by stirring in TFA which was 
subsequently removed under a stream of nitrogen.  Maltoheptaose 4.2 was added in 
sodium acetate/acetic acid buffer at pH 4.0.  This reaction took 8 days after which the 
reaction mixture was separated by size exclusion chromatography.  It could be seen 
that a large amount of starting material 4.2 was still remaining and a low yield of 15% 
was achieved.  Despite the low yield the final fragment 5.3 of the switch had now been 
made and the synthesis could be moved on to assemble the final product. 
 
 
5.6 Assembly of the switch 
 
The individual parts of the switch had been synthesised which now left the final 
construction of the polymer.  This involved a copper catalysed click reaction to attach 
the maltoheptaose fragment to the maltose section followed by removal of the benzyl 
groups and a final oxime ligation to attach the fluorescein fragment. 
  
A CuAAC reaction enabled connection of maltoheptaose and maltose through a PEG-
linker.  The benzyl groups were then removed with palladium on carbon under an 
atmosphere of hydrogen (Scheme 5-12).  Unfortunately this reaction also led to 
132 
 
cleavage of the aminooxy bond. As the milder methods for removal of benzyl groups 
had already been shown to be ineffective with the kind of functional groups present, a 
different order was proposed to assemble the switch axle.  
 
 
Scheme 5-12 The attempted synthesis of the unprotected sugar containing section of the switch. 
 
In the new method of construction the PEG-linker 5.1 is attached to the maltose 
fragment 5.11 first and the benzyl groups removed.  In this order the hydroxylamine 
remains Boc-protected so the benzyl groups can be removed under hydrogen.  In this 
manner the central part of the switch is constructed first and can be connected to the 
fluorescein 5.23 and maltoheptaose 5.23 fragments through oxime ligations. 
 
This method was successful with the maltose fragment 5.11 connected with the linker 
5.1 via a CuAAC reaction.  The benzyl groups were then removed by hydrogenation 
without affecting the aminooxy functional group (Scheme 5-13).  Now all that remained 
were the oxime ligations to attach the terminal sections of the switch. 
 
133 
 
 
Scheme 5-13 The attachment of the linker to maltose and its subsequent deprotection. 
 
The fluorescent fragment was first deprotected with TFA which was shown to be 
successful by mass spectrometry.  The product 5.29 was then immediately reacted 
with the fluorescein fragment 5.23 in anilinium acetate buffer at pH 4.5 (Scheme 5-14).  
Although after five days no reaction was seen. 
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Scheme 5-14 An oxime ligation between the fluorescein and central maltose fragments. 
 
The reaction was repeated with p-phenylenediamine as this had been shown to be 
more effective than aniline due to its increased solubility allowing a higher 
concentration to be used.132  Again LCMS showed no product formation after 48 hours 
and both starting materials remained.  The reaction relies on sugars been in their 
acyclic form which they have been shown to only occupy for a tiny fraction of their 
time.133,134  This is thought to be the reason behind the slow reaction times in the 
synthesis of the switch axle as oxime ligations are fast reactions in the presence of 
aniline.135 
 
Although carbohydrates are slower to react with N-methyloxyamine compounds than 
aldehydes, in the presence of aniline, they have been found to react within 24 hours.136  
This has also been observed within this project where maltose has been derivatised in 
24 h.  The difference between these reactions and the connection of the central and 
fluorescent fragments is the complexity of the molecules.  
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As the compounds have grown larger the speed at which they react has decreased this 
can be prescribed to the large number of orientations the molecules can assume and 
the subsequent reduction in the probability of a collision occurring in the correct 
orientation for a reaction to occur.137  This problem is compounded by the precious 
nature of the reagents involved which does not allow for a large excess of the 
carbohydrate to be used. 
 
Based on these assertions a new method was needed for the connection of the 
fragments. 
 
 
5.7 Conclusion 
 
The synthesis of the building blocks was completed successfully.  The synthesis of the 
most complex central fragment 5.11 was optimised from chapter IV by derivatising the 
PEG-chain at the 4'-position before attachment.  As well as using a mixture of O-benzyl 
anomers thus simplifying the molecules protection.  A variety of methods were 
attempted to remove the benzyl groups before its incorporation into the switch axel but 
this was not possible. 
 
The use of a single PEG-linker 5.1 that could be used for both connections proved to 
be useful, reducing the total number of steps needed in the synthesis.  The PEG-linker 
5.1 was successfully connected to both maltoheptaose 4.2 and FITC 5.19 
demonstrating its effectiveness. 
 
CuAAC was found to be an effective method to connect fragments together although 
the synthesis was halted when it was found that an unprotected oxyamine could not 
survive hydrogenation.  This resulted in a new order of assembly being followed.  The 
PEG-linker was successfully attached to the 4'-position of the central fragment 5.11 via 
CuAAC and hydrogenated. 
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The limitation to this synthesis was the utility of the oxime ligation reaction when used 
with the compounds formed in this synthesis.  It was thought that the short time 
carbohydrates reside in the open chain formation combined with the size and flexibility 
of the fragments resulted in the molecules not reacting.  This obstacle ultimately 
requires a redesign of the current synthesis. 
 
 
5.8 Future work 
 
In the future to overcome the limitations of the oxime ligation a small alkyne containing 
oxyamine 5.31 could be reacted with the central fragment 5.29.  Used in a large excess 
it could push the reaction to completion and would not suffer the same problems as a 
large PEG-containing compound. 
 
 
Scheme 5-15 Proposed reaction of the central fragment with a small alkyne containig oxyamine 
 
Once formed the new central fragment 5.32 could be reacted with an excess of 
maltoheptaose 4.2.  Although the reaction of maltoheptaose 4.2 with the PEG-linker 5.1 
was found to be slow it was also successful and an excess of maltoheptaose 5.1 could 
be used to push the reaction to completion. 
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Scheme 5-16 Proposed synthesis of an azide derivatised fluorescein 
 
The final fluorescent fragment 5.33 could be attached through CuAAC chemistry which 
had proved to be reliable.  This new synthesis requires the least amount of subsequent 
chemistry and makes use of the already synthesised central fragment.  
  
138 
 
6 Chapter VI: Conclusions and future work  
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6.1 Summary 
 
The two principal proteins required for this project, maltoporin and MBP, were 
successfully expressed, purified and analysed.  A variety of methods were tested and 
optimised for the expression of maltoporin and its purification from the membrane 
fraction of BL21(DE3)omp8 cells was found to be the most effective.  A G382C mutant 
of maltoporin was also expressed and modified with tetramethylrhodamine-5-maleimide.  
The ligand binding of maltoporin was found to occur on a timescale too long to 
measure by ITC.   
 
 
Figure 6-1 The maltose fragment 
 
The synthesis of a maltose fragment with which to build the switch axle was optimised 
(Figure 6-1).  During this procedure it was found that maltoporin was permeable to -
maltosides with the use of a liposome swelling assay. 
 
Figure 6-2 The pseudotetrasaccharide 
140 
 
A pseudotetrasaccharide 4.3 was synthesised with a long linker between the maltose 
stations to probe the functioning of the bind-and-slide mechanism (Figure 6-2).  The 
synthesis of the trivalent ligand precursor 4.10c was also optimised with a view to 
further binding studies comparing the affinities of the mono-,di- and trivalent ligands 
(Figure 6-3). 
 
 
Figure 6-3 The fluorescent ligand 
 
To test the binding of these molecules a fluorescent ligand 4.31 was synthesised and 
its binding investigated (Figure 6-3).  Through fluorescence anisotropy and FRET 
assays its binding to micelles was discovered.  Its use will be further investigated with 
the use of different strategies to solubilise maltoporin. 
 
 
Figure 6-4 The synthesised molecular switch axle precursors 
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The building blocks required for the construction of the switch axle were successfully 
synthesised (Figure 6-4).  The use of oxime ligations was found to need optimisation 
although the use of CuAAC proved efficient at connecting the molecules together.   
Significant progress has been  made in the formation of the switch all that remains is 
the successful connection of the precursors before binding experiments can be 
performed. 
 
6.2 Future Work 
 
Several avenues of research are still available following this project.  The use of 
biophysical techniques can now be used to investigate the binding of maltoporin as well 
as measuring the efficiency of the maltose responsive switch. 
 
 
6.2.1 Binding studies on the bind-and-slide mechanism of maltoporin 
 
Micelles have proven to interfere with fluorescence anisotropy and FRET so the 
experiments can be repeated with either Amphipol A8-35 or lipid vesicles.  When these 
experiments have been optimised comparisons of the pseudotetrasaccharide 4.3 with 
maltotetraose and maltose can begin.  This experiment could give insight into how the 
bind-and-slide mechanism functions.  Will replacement of maltose units in the centre of 
a MOSs with PEG units result in a loss in binding or can maltoporin ‘slide’ past them to 
the next maltose unit it can bind?  Other molecules with longer linkers between the 
maltose moieties could also be synthesised with more than two maltose stations and 
longer linkers between them. 
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6.2.2 Multivalent ligand 
 
The oxime ligation reaction using the trivalent ligand will be re-attempted although with 
a much higher equivalence of maltoheptaose.  Once synthesised the binding of the 
mono-, di- and trivalent ligands could be tested via fluorescence anisotropy.  As the 
multivalent ligands already have a fluorescent dansyl group attached they should not 
require the use of the fluorescent ligand.  This method should demonstrate the 
increase in binding affinity along with multivalency.  If the binding affinity for the 
multivalent ligands was found to be in the nM range as could be expected their ability 
to bind live cells would be tested. 
 
Flow cytometry is a technique that can sort cells and measure their fluorescence 
individually.  Omp8 cells expressing WT maltoporin could be stained with 4′,6-
diamidino-2-phenylindole (DAPI) which, on binding DNA, emits blue fluorescence.  
After incubating the stained cells with the multivalent ligand their co-fluorescence can 
be measured.  Any instances of fluorescence from both the DAPI and dansyl group on 
the multivalent ligand would demonstrate binding to live cells. 
 
 
6.2.3 Proto-cells 
 
Once the switch has been synthesised following the protocols in the future works of 
Chapter V its binding can be investigated with a range of techniques.   
 
To test the effectiveness of a maltose responsive switch FRET assays would be 
performed.  These would be developed through the formation of unilamellar vesicles 
punctuated with G382C maltoporin and containing the switch axle.  These would be 
formed by re-suspending a thin layer of dried 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) in a solution containing G382C maltoporin and the switch axle.  This should 
capture the switch axle in multilamellar vesicles punctuated by maltoporin.  To 
transform these into unilamellar vesicles they would be subject to extrusion and could 
then be purified by gel filtration chromatography to remove any free axle. 
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The first FRET experiment to take place would be comparing the fluorescence of the 
free axle compared to the encapsulated axle.  As the axle is so long and maltoporin 
should bind the highest affinity ligand on the axle (i.e. maltoheptaose) it is not thought 
that any FRET should occur in this experiment. 
 
The second experiment would add MBP to the outside of the vesicles.  If MBP can bind 
to the protruding axle it should pull the ligand through pushing fluorescein close to the 
pore of maltoporin and also the tetramethylrhodamine.  This experiment would 
demonstrate the ability of the switch to form a rotaxane as if formed the proximity of the 
fluorescent groups should allow quenching and a FRET signal. 
 
To demonstrate that the formation of the rotaxane was reversible and the system can 
act as a switch, maltose would be added to the system.  At this point the MBP should 
preferentially bind the maltose releasing the axle and a loss of FRET should be seen. 
 
 
6.2.4 Live cells 
 
For the switch to act as a fully reversible system it needs to be on the surface of a living 
cell as the cells own maltose transport system will relieve MBP of the maltose it binds 
allowing it to rebind the axle. 
 
For these experiments a small amount of G382C maltoporin would be expressed in 
BL21(DE3)omp8 cells using a low concentration of IPTG.  The smaller amount of 
protein would ensure the cells viability.  Maltoporin could then be labelled with 
tetramethylrhodamine-5-maleimide on the surface of the cells. 
 
The same experiments as on a plate could then be repeated on live cells.  Although in 
this case the experiment could be repeated more than once to test the ability of the 
system to return to equilibrium after addition of maltose. 
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7 Chapter VII: Experimental  
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7.1 Biology Experimental 
 
 
7.1.1 Instrumentation 
 
Analytical grade reagents were obtained from Sigma Aldrich, Fisher Scientific, Alfa 
Aesar and VWR International. Water was purified using the ELGA PURLAB Classic. 
Ampicillin sodium salt was obtained from Fisher Biotech. Protein moleclar weight 
markers used during SDS-PAGE were obtained from Fermentas. Amylose resin was 
obtained from Sigma Aldrich.  MBPTrap columns were obtained from GE Healthcare 
Life Sciences. Bacterial cltures were grown using an ISF1-X shaker incubator 
(Kuhner). Centrifugation was performed using the Avanti J30-I (Beckman Coulter), Pico 
17 and Fresco 21 centrifuges (Thermo Scientific). Gels were imaged and analysed 
using a Universal Hood II gel documentation system (BioRad). 
Analytical grade reagents were supplied by Sigma-Aldrich, Fisher Scientific, Melford 
laboratories and VWR International. Pwo enzyme (DNA polymerase) (from Pyrococcus 
woesei) was made in the Turnbll lab. Restriction enzymes, T4 DNA ligase, DpnI and 
CIP were purchased from NEB. Competent cells were purchased from Stratagene or 
made in the Turnbull Lab. Primers and DNA parts for gene synthesis were purchased 
from IDT. 
 
 
7.1.2 Cell lines 
 
BL21(DE3)omp8 
Genotype: BL21(DE3), ΔlamB ompF::Tn5ΔompAΔompC107 
This cell line was provided by the laboratory of Ralf Koebnik and does not 
produce any of the major outer membrane pore proteins which consist of OmpC, 
OmpA, OmpF, LamB. 
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7.1.3 The pMal-c5X plasmid 
 
 
Figure 7-1 The pMal-c5X plasmid from New England Biolabs.  This plasmid is 
used for the gene fusion of MBP to a protein of choice.  Expression is controlled 
by the lac operon. 
 
7.1.4 Primers 
 
Forward Primers 
Minus leader Mfe1 Forward (51 bases): CAC GAG CAA TTG AAC AAG GAC CAT 
AGA TT ATG GTT GAT TTC CAC GGC TAT G 
Minus leader + 6His/TEV cleavage site Mfe1 Forward (90 bases): CAC GAG CAA TTG 
AAC AAG GAC CAT AGA TT ATG CAT CAC CAC CAT CAT CAC GAA AAC CTG 
TAC TTT CAG GGC GTT GAT TTC CAC GGC TAT G 
G382C mutation forward (38 bases):  GG GGT  TAC GAC TAC ACC TGC AAC GCT 
GAT AAC AAC GCG 
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Mfe1 restriction site, ribosome binding site, start codon, overlap region, His Tag, 
TEV cleavage, G382C mutation 
 
Reverse Primers 
HindIII Reverse (37 bases): GAT GGA AAT CTG GTG GTA ATA AAT AAG CTT CAA 
ATA A 
G382C mutation reverse (38 bases):  CGC GTT GTT ATC AGC GTT GCA GGT GTA 
GTC GTA ACC CC 
Overlap Region, HindIII restriction site, G382C mutation 
 
 
7.1.5 Expressed sequences 
 
Maltoporin 
MMITLRKLPLAVAVAAGVMSAQAMAVDFHGYARSGIGWTGSGGEQQCFQTTGAQSK
YRLGNECETYAELKLGQEVWKEGDKSFYFDTNVAYSVAQQNDWEATDPAFREANVQ
GKNLIEWLPGSTIWAGKRFYQRHDVHMIDFYYWDISGPGAGLENIDVGFGKLSLAATR
SSEAGGSSSFASNNIYDYTNETANDVFDVRLAQMEINPGGTLELGVDYGRANLRDNY
RLVDGASKDGWLFTAEHTQSVLKGFNKFVVQYATDSMTSQGKGLSQGSGVAFDNEK
FAYNINNNGHMLRILDHGAISMGDNWDMMYVGMYQDINWDNDNGTKWWTVGIRPM
YKWTPIMSTVMEIGYDNVESQRTGDKNNQYKITLAQQWQAGDSIWSRPAIRVFATYA
KWDEKWGYDYTGNADNNANFGKAVPADFNGGSFGRGDSDEWTFGAQMEIWW 
Leader sequence 
 
Maltoporin without leader sequence 
VDFHGYARSGIGWTGSGGEQQCFQTTGAQSKYRLGNECETYAELKLGQEVWKEGD
KSFYFDTNVAYSVAQQNDWEATDPAFREANVQGKNLIEWLPGSTIWAGKRFYQRHD
VHMIDFYYWDISGPGAGLENIDVGFGKLSLAATRSSEAGGSSSFASNNIYDYTNETAN
DVFDVRLAQMEINPGGTLELGVDYGRANLRDNYRLVDGASKDGWLFTAEHTQSVLK
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GFNKFVVQYATDSMTSQGKGLSQGSGVAFDNEKFAYNINNNGHMLRILDHGAISMGD
NWDMMYVGMYQDINWDNDNGTKWWTVGIRPMYKWTPIMSTVMEIGYDNVESQRT
GDKNNQYKITLAQQWQAGDSIWSRPAIRVFATYAKWDEKWGYDYTGNADNNANFGK
AVPADFNGGSFGRGDSDEWTFGAQMEIWW 
 
Maltoporin G382C mutant 
VDFHGYARSGIGWTGSGGEQQCFQTTGAQSKYRLGNECETYAELKLGQEVWKEGD
KSFYFDTNVAYSVAQQNDWEATDPAFREANVQGKNLIEWLPGSTIWAGKRFYQRHD
VHMIDFYYWDISGPGAGLENIDVGFGKLSLAATRSSEAGGSSSFASNNIYDYTNETAN
DVFDVRLAQMEINPGGTLELGVDYGRANLRDNYRLVDGASKDGWLFTAEHTQSVLK
GFNKFVVQYATDSMTSQGKGLSQGSGVAFDNEKFAYNINNNGHMLRILDHGAISMGD
NWDMMYVGMYQDINWDNDNGTKWWTVGIRPMYKWTPIMSTVMEIGYDNVESQRT
GDKNNQYKITLAQQWQAGDSIWSRPAIRVFATYAKWDEKWGYDYTCNADNNANFGK
AVPADFNGGSFGRGDSDEWTFGAQMEIWW 
Mutated residue 
 
MBP 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGP
DIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIY
NKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGK
YDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWS
NIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEA
VNKDKPLGAVALKSYEEELVKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINA
ASGRQTVDEALKDAQTNSSSNNNNNNNNNNLGIEGRISHMSMGGRDIVDGSEFPAG
N 
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7.1.6 Buffer solutions 
 
Standard buffers 
Elution buffer: HEPES (pH 7.0, 20 mM): 1% (v/v) Octyl-POE, 20% (w/v) maltose, 0.1 M 
NaCl. 
Elution buffer (+DTT): HEPES (pH 7.0, 20 mM): 1% (v/v) Octyl-POE, 20% (w/v) 
maltose, 0.1 M NaCl, 10 mM DTT. 
Labelling buffer (pH 7.4): Phosphate (pH 7.4, 100 mM): 0.5% (v/v) Octyl-POE, 0.1 M 
NaCl. 
Labelling buffer (pH 8.4): Phosphate (pH 8.4, 100 mM): 0.5% (v/v) Octyl-POE, 0.1 M 
NaCl. 
Lysis buffer (+DTT): Tris-HCl (pH 8.0, 50 mM): 10 mM MgSO4, 0.1 M NaCl, 10 mM 
DTT. 
MBP elution buffer: Tris-HCl (pH 7.4, 50 mM): 0.1 M NaCl, 20% (w/v) glucose. 
Tris buffer: Tris-HCl (pH 7.4, 50 mM): 0.1 M NaCl. 
Triton buffer: Tris-HCl (pH 8.0, 50 mM): 2% (v/v) Triton X-100, 10 mM EDTA, 0.1 M 
NaCl. 
Triton buffer (+DTT): Tris-HCl (pH 8.0, 50 mM): 2% (v/v) Triton X-100, 10 mM EDTA, 
0.1 M NaCl, 10 mM DTT. 
Urea buffer: Tris-HCl (pH 8.0, 50 mM): 1 mM EDTA, 8 M Urea, 0.1 M NaCl. 
Wash buffer: HEPES (pH 7.0, 20 mM): 1% (v/v) Octyl-POE, 0.1 M NaCl. 
Wash buffer (+DTT): HEPES (pH 7.0, 20 mM): 1% (v/v) Octyl-POE, 0.1 M NaCl, 10 
mM DTT. 
Buffer N3 – 4.2 M Guanidine HCl, 0.9 M KAc 
Buffer QG – Tris-HCl (pH 6.6, 20 mM), 5.5 M GuSCN 
Buffer P1 – Tris-HCl (pH 8.0, 50 mM), 10 mM EDTA, 100 μg.mL-1 RNase A 
Buffer P2 – 200 mM NaOH, 1% (w/v) SDS 
Buffer PB – 5.0 M Guanidine HCl, 30% (v/v) isopropanol 
Buffer PE – Tris-HCl (pH 7.5, 10 mM), 80% (v/v) ethanol 
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Bacterial growth buffers 
LB growth media (LB): LB Broth (25 g premixed; 10 g Tryptone, 5 g Yeast extract, 10 g 
NaCl), Ampicillin (100 mg). 
SOC growth media (SOC): LB Broth (20 g Tryptone, 5 g Yeast extract, 0.58 g NaCl, 
0.19 g KCl, MgCl2 (0.95 g), MgSO4 (1.20 g), glucose (3.60 g), Ampicillin (100 mg). 
Anaerobic minimal media: LB Broth (5 g premixed; 2 g Tryptone, 1 g Yeast extract, 2 g 
NaCl), Cysteine HCl (500 mg), Maltose (4 g), Ampicillin (100 mg). 
Agar gels: agar (1.5 g) added to 100 ml of LB. 
 
Buffers for DNA analysis and manipulations  
50 × TAE Buffer: 2 M Tris-HCl (314 g), concentrated acetic acid (57.1 mL) and EDTA 
(0.5 M at pH 8.0, 100 mL). 
6 × Agarose electrophoresis loading buffer (10 ml, pH 7.6): 15% (w/v) Ficoll 400, 66 
mM EDTA (193 mg), 19.8 mM Tris-HCl (31 mg), 0.12% (w/v) SDS and 0.9% (w/v) 
Orange G.  
10 × EcoRI buffer (10 mL, pH 7.5): 1 M Tris-HCl (1.57 g), 500 mM NaCl (292 mg), 
100 mM MgCl2 (95 mg) and 0.25% (v/v) Triton X-100. 
10 × Ligase Buffer (10 mL pH 7.5): 500 mM Tris-HCl (7.85 g), 100 mM MgCl2 (95 mg) 
10 mM adenosine triphosphate  (ATP, 55 mg) and 100 mM dithiothreitol (DTT, 
154 mg). 
 
Protein analysis buffer 
5 x SDS running buffer: 125 mM Tris (15.15 g), 960 mM glycine (72.1 g), 0.5% w/v 
SDS (5 g). 
SDS loading buffer: Tris (0.5M, pH 6.8, 1.25 ml), SDS (0.3 g), DTT (0.47 g), glycerol (1 
ml), bromophenol blue (~5 crystals), water (7.2 ml). 
SDS loading buffer without DTT: Tris (0.5M, pH 6.8, 1.25 ml), SDS (0.3 g), glycerol (1 
ml), bromophenol blue (~5 crystals), water (7.2 ml). 
Coomassie stain: coomassie G250, methanol (400 ml), acetic acid (100 ml). 
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7.1.7 Molecular Biology 
 
7.1.7.1 PCR 
PCR was carried out using the pSAB2.2-M5 vector containing the Maltoporin gene and 
primers listed in the primers section of the standard protocols.  The concentrations are 
shown in Table 7-1. 
 
Table 7-1 Materials used in PCR experiments. 
 Amount (µl) 
H2O 43.2 
PCR Buffer 5 
DNTPs 0.4 
PWO 0.2 
F primer 0.5 
R primer 0.5 
Template 0.2 
 
 
The sample was initially heated for 5 min at 95 °C before 25 cycles of 30s at 95 °C, 30s 
at 50 °C and 2m at 70 °C.  The sample was held for an additional 5 min at 70 °C before 
being stored at 4 °C. 
 
 
7.1.7.2 Site directed mutagenesis 
Site directed mutagenesis was carried out using the pSAB2.2-M5 vector and primers 
listed in the primers section of the standard protocols.  The concentrations are shown 
in Table 7-2. 
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Table 7-2 Materials for site directed mutatgenesis 
 Volume (l) Concentration 
pMaltp Plasmid 0.48 0.105 mM 
Forward Primer 0.7 10 mM 
Reverse Primer 0.7 10 mM 
PFU buffer (with MgSO4) 5.0 10x stock 
dNTPs 0.39 25 mM 
PFU DNA polymerase 1.0 3 U / l 
H2O 41.7  
 
The sample was initially heated for 1.5 min at 95 °C before 20 cycles of 20s at 95 °C, 
20s at 55 °C and 12m at 70 °C.  The sample was held for an additional 24 min at 72 °C 
before being stored at 4 °C. 
 
 
7.1.7.3 Gel Extraction 
This was conducted using a QIAquick gel extraction kit, following the manufacturer-
recommended protocol. All centrifugation steps took place at 17,900 × g at room 
temperature. The gel generated from an agarose gel electrophoresis experiment was 
viewed under UV light, and the target band excised from the gel (with minimal gel) 
using a scalpel. Buffer QG (3 gel volumes) was added at 50 °C to dissolve the agarose. 
Isopropanol (1 gel volume) was added to increase the DNA yield, and the solution 
passed through a silica membrane by centrifugation for 1 min, to which DNA is 
adsorbed but RNA, protein and metabolites may pass through. The membrane was 
washed by centrifugation for 1 min with buffer PE (750 μL) to remove salts, before a 
further 1 min centrifugation to remove residual ethanol. The DNA was then eluted in 
water (30 μL) by centrifugation for 1 min. 
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7.1.7.4 PCR Clean-up 
This was conducted using a QIAquick PCR purification kit, following the manufacturer-
recommended protocol. All centrifugation steps took place at 17,900 × g at room 
temperature. Buffer PB (5 volumes) was added to the PCR reaction mix, and the 
solution passed through a silica membrane by centrifugation for 1 min, to which DNA is 
adsorbed. The membrane was washed by centrifugation for 1 min with buffer PE (750 
μL) to remove salts, subjected to a further 1 min centrifugation to remove residual 
ethanol, and the DNA eluted by centrifugation for 1 min in water (30 μL). 
 
 
7.1.7.5 Plasmid preparation 
This was conducted using a QIAprep spin Miniprep kit, following the manufacturer-
recommended protocol. All centrifugation steps took place at 17,900 × g at room 
temperature. Bacterial cells were pelleted from cltures by centrifugation for 5 min, 
then resuspended in buffer P1 (250 μL). Buffer P2 (250 μL) was added in order to lyse 
the bacterial cells by alkaline lysis5, followed by buffer N3 (350 μL) to neutralise the 
suspension and adjust to high salt binding conditions, whilst precipitating SDS. The 
precipitate (SDS, genomic DNA, and cell debris) was pelleted by centrifugation for 10 
min, and the supernatant passed through a silica membrane by centrifugation for 1 min, 
to which the DNA was adsorbed. The membrane was washed by centrifugation for 1 
min with buffer PB (500 μL) to remove endonucleases, and PE (750 μL) to remove 
salts, before the DNA was eluted in water (50 μL) by centrifugation for 1 min. 
 
 
7.1.7.6 Agarose Gel 
DNA purity was analysed by agarose gel using Bio-Rad Subcell agarose gel 
electrophoresis systems.  A 1% gel using agarose (443 mg) in TAE buffer (40 ml) was 
prepared by heating the solution in a microwave until all the agarose had dissolved.  
Ethidium bromide (1.2 µL, 0.3 g / ml) was added and mixed. The solution was then 
immediately poured into a mold and a comb added before the gel was left to set.  
Samples for analysis were prepared by mixing 5 µL of DNA sample with 1 µL DNA 
loading buffer and 5 µL aliquots were loaded into the sample wells. Electrophoresis 
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was performed at 100 V in TAE running buffer for 20 min. Gels were then visualised 
under UV light using the Gel Doc system. 
 
 
7.1.7.7 DNA concentration 
All DNA concentrations (ng μL-1) were determined by spectrophotometry at 260 nm and 
calclated using the equation;  DNA    50   (A260- A320). 
 
 
7.1.7.8 Restriction digest 
Insert preparation - A restriction digest was used to give the Maltoporin PCR product 
sticky ends. The DNA (30 L) was added to a solution of MfeI (2 L, 20 U), Hind III (2 
L, 20 U), 10 × buffer 4 (4 L) and sterile water (2 L). The reaction mixture was 
incubated at 37 °C for 1.5 h before the digested DNA was isolated by agarose gel 
electrophoresis and purified using a QIAquick Gel Extraction Kit.  
Vector preparation - The pMal vector was prepared for DNA ligation using a slightly 
modified restriction digest procedure. The plasmid DNA (20 L) was added to a 
solution of MfeI (3 L, 20 U), Hind III (3 L, 20 U), 10 × buffer 4 (4 L) and sterile water 
(2.5 L). The reaction mixture was incubated at 37 °C for 1 h before calf-intestinal 
phosphatase (3 L, 10 U) was added. The incubation was continued at 37 °C for an 
additional hour before the linearised plasmid was isolated and purified as previously 
described.  
 
 
7.1.7.9 Ligation 
The Maltoporin gene insert and linear pMal vector were ligated together using the 
following procedure. A ligation mixture was prepared over ice using the linear plasmid 
vector (50 ng), gene insert (3:1 molar ratio of insert to vector), 10 × ligase buffer (1 µL), 
T4 ligase (1 µL, 20 U) and H2O to make a total volume of 10 mL. The reaction mixture 
was incubated at 4 °C overnight before being transformed into chemically competent E. 
coli XL10 cells. 
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7.1.7.10 Transformation 
The plasmid (1 l) was added to chemically competent freshly thawed cells (10 l) on 
ice and left for 10 min.  The solution was then heat shocked at 42 °C for 45 s before 
being placed back on ice for 10 min.  900 l LB was added and the solution incubated 
at 37 °C for 1 h before centrifugation at 18,000 x g for 4 min.  800 l of the supernatant 
was discarded and the pellet re-suspended in the remaining 100 l.  The culture was 
spread onto an agar plate and incubated for 16 h.  A colony was selected from the 
plate and used to inoculate a falcon tube of LB growth media (5 mL) with ampicillin (0.5 
mg) to be incubated at 37 °C for 20 h.  Aliquots (500 l) of the culture were then mixed 
with 80% (v/v) glycerol (500 l) and stored in the -80 °C freezer. 
 
 
7.1.7.11 Heat competent procedure 
Cells were grown up in 5 ml LB with 5 µl kanamycin.  100 ml of LB was then inoculated 
with 300 µl of the cells grow up.  The 100 ml grow up was allowed to grow to OD600 = 
0.4 at which point 50 ml of the solution was transferred to a 50 ml falcon tube which 
was cooled in ice for 10 min.  The falcon tubes were then pelleted at 4,000 x g for 10 
min at 4 °C and the supernatant poured off.  The pellets were re-suspended in 10 ml 
ice-cold 0.1 M CaCl2 and pelleted again at 4,000 x g for 10 min.  The supernatant was 
poured off and the cells were re-suspended in 2 ml ice-cold 0.1 M CaCl2.  The solution 
was then split into 75 µl aliquots combined with 25µl 40% glycerol and stored in the -
80 °C fridge. 
 
 
7.1.7.12 DNA extraction and sequencing procedure 
The DNA was extracted from the bacterial cell pellet using a QIAprep Spin Mini Prep 
Kit and sequenced by GATC Biotech. 
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7.1.7.13 Agar plate procedure 
To make the plates agar mix (50 ml) and antibiotic (5 mg) were mixed in a falcon tube 
and poured onto a petri dish where the plate was allowed to cool. 
 
 
7.1.8 Protein expression 
 
LB Media 
Maltoporin was expressed in the following way. A stab was taken from a stock of E.coli 
BL21(DE3)omp8 cells containing the plasmid encoding the protein to be expressed, 
and a falcon tube of LB growth media (5 mL) was inoculated. This starter culture was 
incubated at 37 °C for 20 h. This starter clture (3 mL) was added to 1 L LB growth 
media plus antibiotic (ampicillin or kanamycin as stated) (100 mg) and was then 
incubated at 37 °C for a further 3 h when the OD600 had reached ~0.8 and IPTG (120 
mg) was added to each flask to induce protein over-expression. The incubation was 
continued for 4 h before isolating the bacterial cells by centrifugation at 10,000 x g for 
15 min. The supernatant was discarded and the bacterial pellet was frozen at -80 °C 
until being purified. 
 
SOC Media 
Maltoporin was expressed in the following way. A stab was taken from a stock of E.coli 
BL21(DE3)omp8 cells containing the plasmid encoding the protein to be expressed, 
and a falcon tube of LB growth media (5 mL) was inoculated. This starter clture was 
incubated at 37 °C for 20 h. This starter culture (3 mL) was added to 1 L SOC growth 
media plus ampicillin (100 mg) and was then incubated at 16 °C for a further 14 h when 
the OD600 had reached ~0.6 and IPTG (24 mg) was added to each flask to induce 
protein over-expression. The incubation was continued at 16 °C for 12 h before 
isolating the bacterial cells by centrifugation at 10,000 x g for 15 min. The supernatant 
was discarded and the bacterial pellet was frozen at -80 °C until being purified. 
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Anaerobic maltoporin expression 
Maltoporin was expressed in the following way. A stab was taken from a stock of E.coli 
BL21(DE3)omp8 cells containing the plasmid encoding the protein to be expressed, 
and a falcon tube of LB growth media (5 mL) was inoculated. This starter culture was 
incubated at 37 °C for 20 h. This starter clture (3 mL) was added to 1 L anaerobic 
minimal media plus ampicillin (100 mg); which had been sealed and purged with 
nitrogen.  This was then incubated at 37 °C for a further 26 h when the OD600 had 
reached ~0.6 and IPTG (120 mg) was added to each flask to induce protein over-
expression. The incubation was continued for 20 h before isolating the bacterial cells 
by centrifugation at 10,000 x g for 15 min. The supernatant was discarded and the 
bacterial pellet was frozen at -80 °C until being purified. 
 
MBP Expression 
MBP was expressed in the following way. A stab was taken from a stock of E.coli C43 
cells containing an empty pMal-c5X plasmid encoding the protein to be expressed, and 
a falcon tube of LB growth media (5 mL) was inoculated. This starter culture was 
incubated at 37 °C for 20 h. This starter clture (3 mL) was added to 1 L LB growth 
media plus ampicillin (100 mg) and was then incubated at 37 °C for a further 3 h when 
the OD600 had reached ~0.6 and IPTG (120 mg) was added to each flask to induce 
protein over-expression. The incubation was continued for 20 h before isolating the 
bacterial cells by centrifugation at 10,000 x g for 15 min. The supernatant was 
discarded and the bacterial pellet was frozen at -80 °C until being purified. 
 
 
7.1.9 Protein purification 
 
Maltoporin purification 
The frozen bacterial pellet was resuspended on ice in 10 mM MgCl2 (30 mL). Cells 
were lysed using the sonicator for 2 x 4 min, the resulting lysate was cleared by 
centrifugation at 48,000 x g for 30 min and the supernatant discarded.  The cell pellet 
was re-suspended in 2% (v/v) Triton X-100 in TEN buffer and the insoluble fraction 
separated by centrifugation at 48,000 x g for 30 min. 
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Maltoporin G382C mutant purification 
The frozen bacterial pellet was resuspended on ice in Lysis buffer (+DTT) (30 mL). 
Cells were lysed using the sonicator for 2 x 4 min, the resulting lysate was cleared by 
centrifugation at 48,000 x g for 30 min and the supernatant discarded.  The cell pellet 
was re-suspended in Triton buffer (+DTT) (30 ml) and the insoluble fraction separated 
by centrifugation at 48,000 x g for 30 min. 
 
MBP Purification 
The frozen bacterial pellet was resuspended on ice in Tris Buffer (30 mL). Cells were 
lysed using the sonicator for 3 x 2 min.  The resulting lysate was cleared by 
centrifugation at 48,000 x g for 30 min and the pellet discarded. 
 
7.1.10 Amylose column purification 
 
Maltoporin amylose column 
For the amylose column, the protein solution was loaded and non-binding proteins 
were removed by washing with wash buffer (40 mL). Maltoporin was eluted with elution 
buffer (40 mL) and fractions were collected (5 mL). The fractions containing protein 
were concentrated and purified by dialysis to remove maltose. 
 
Maltoporin G382C mutant amylose column 
For the amylose column, the protein solution was loaded and non-binding proteins 
were removed by washing with wash buffer (+DTT) (50 mL). Maltoporin was eluted with 
elution buffer (+DTT) (40 mL) and fractions were collected (5 mL). The fractions 
containing protein were concentrated and purified by dialysis to remove maltose. 
 
MBP amylose column 
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For the amylose column, the protein solution was loaded and non-binding proteins 
were removed by washing with Tris buffer (40 mL). MBP was eluted with MBP elution 
buffer (40 mL) and fractions were collected (5 mL). The fractions containing protein 
were concentrated and purified by dialysis to remove glucose. 
 
MBPTrap AKTA FPLC Purification 
The Triton X-100 solubilised protein was passed through a 5 ml MBPTrap column with 
the use of an AKTA FPLC machine.  The column was equilibrated in wash buffer, 100 
ml of sample was passed through the column, washed with 15 ml wash buffer and the 
protein step eluted with 50 ml elution buffer.  All flow through was kept and the process 
repeated. 
 
 
7.1.11 Protein Modification 
 
Solubilising maltoporin into amphipol A8-35 
Maltoporin (27 uM) in wash buffer (670 l) had 5:1 (w/w) amphipol A8-35 (4.3 mg) 
added.  The solution was vortexed and allowed to stand for 15 min.  10:1 (w/w) SM2 
biobeads (39 mg) were added and the solution was mixed for 2 h before the beads 
were removed by centrifugation at 3500 x g for 10 min. 
 
 
Labelling of cysteine mutant 
G382C maltoporin (72 uM) in wash buffer (400 l) had its buffer exchanged for labeling 
buffer (500 l) using a PD-10 column.  To this solution was added TCEP (50 mM) in 
labeling buffer (4 l) and tetramethylrhodamine maleimide (20 mM) in DMSO (1.7 l).  
The mixture was left in the dark o.n. 
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7.1.12 Liposome swelling assay 
To make the mltilamellar liposomes 6.2 l of dipalmitoyl phosphorycholine and 0.2 l 
of dicetyl phosphate were dissolved in chloroform and dried under a stream of N2.  The 
lipids were then re-suspended by sonication with 0.2 M Maltoporin (0 M Maltoporin 
for the negative control) in 5 mM Tris, pH 8 and 0.1% Octyl-POE.  The water was 
removed by heating to 45 °C under a stream of N2 before re-suspension in 17% 
Dextran T9.9, 5 mM Tris, pH 7.5 and 5 mM MgCl2 by vortexing for 2 h. 
The sugar solutions were made up to 20 mM sugar, 5 mM MgCl2 and 5 mM Tris, pH 
7.5. 
For the assay 600 l of the sugar solution was placed in a curvette in a UV 
spectrometer and 20 l of the liposome solution was added.  The absorption of the 
liposomes was plotted every 5 seconds for 1 min and the gradient of the line recorded. 
 
 
7.1.13 SDS-PAGE 
Protein purity was assessed by sodium dodecyl slfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using BioRad tetragel apparatus. A resolving gel (10%) 
was prepared using before pouring the gel into the plates. Tert-butanol was poured on 
top of the resolving gel to produce a flat surface and the gel was left to set. 
 
The stacking gel (5%) was prepared using the materials in Table 7-3, with the TEMED 
left until last. The tert-butanol was decanted off of the set resolving gel, the stacking gel 
poured on top and the plastic comb inserted to create sample wells. The gel was again 
left to set at room temperature. Samples for analysis were prepared by mixing 10 µL of 
protein sample with 10 µL SDS loading buffer and 10 µL aliquots were loaded into the 
sample wells. Electrophoresis was performed at 180 V in SDS running buffer. 
 
After 45 minutes the gels were removed and stained with instant blue for at least 1 h 
before being stored in water until the gel was imaged. 
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Table 7-3 Materials for preparing SDS-PAGEs. 
 Resolving Gel / mL Stacking Gel / mL 
H2O 4.93 3.24 
3 M TRIS-HCl pH 8.8 1.25 - 
0.5 M TRIS-HCl pH 6.8 - 1.25 
10% w/v SDS 0.1 0.05 
40% Acrylamide 2.5 0.5 
TEMED 0.013 0.01 
20% w/v APS 0.083 0.04 
 
 
7.1.14 Protein concentration analysis 
Protein concentrations were measured using UV absorption at 280 nm. The 
concentration was determined using the following equation: 
      
Where A is the absorbance, ε is the extinction coefficient, c is the concentration in mol 
L-1 and l is the pathlength in cm. 
The theoretical extinction coefficient for maltoporin was obtained from ExPASy 
ProtParam. For the maltoporin monomer this was 137,280 mol-1 L cm-1.  
The theoretical extinction coefficient for MBP was obtained from ExPASy ProtParam. 
For the maltoporin monomer this was 66,350 mol-1 L cm-1. 
 
 
7.1.15 Biophysical experiments 
 
7.1.15.1 Fluorescence anisotropy 
 
Appropriate dilution series (110 µM to 0.2 µM, 25 µl) were set up in triplicate before 
addition of fluorescent ligand (1.2 µM stock, 5 µl) Total volume 30 µl, 200 nM probe. 
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Fluorescence Anisotropy measurements were taken in 96-well plate format using an 
Envision 2103 Mltilabel Reader. 
G-factor was calclated by the average of the readings on a blank probe sample where 
G=S/P 
Anisotropy (r) of individual wells was then calclated using: 
 
  
       
        
 
 
The total fluorescence (S+2G*P) was plotted vs protein concentration to confirm there 
was no observable quenching. 
The anisotropy values for the triplicate wells were averaged and standard errors 
calclated. These values were used to produce a plot of anisotropy vs protein 
concentration. This plot was fitted with a logistic method (fixed power of 1) and this 
used to convert the anisotropy values to fraction bound. 
 
 
7.1.15.2 FRET assay 
 
Solutions of TAMRA labelled maltoporin (1.2 M), fluorescent ligand (100 nM, 2 M, 20 
M), in HEPES (20 mM, pH 7.0), NaCl (0.1 M) and Octyl-POE (0.5% v/v) had their 
emissions from 500 – 650 nm measured separately in a 600 l quartz curvette with a 
HORIBA scientific Fluoromax-3 fluorimeter.  The emission spectra of these combined 
provided a negative control. 
A 500 l solution of TAMRA labelled maltoporin (1.2 M) and fluorescent ligand (100 
nM, 2 M, 20 M) in HEPES (20 mM, pH 7.0), NaCl (0.1 M) and Octyl-POE (0.5% v/v) 
as well as a 500 l solution of TAMRA labelled maltoporin (1.2 M), fluorescent ligand 
(100 nM, 2 M, 20 M) and maltohetpaose (10 mM) in HEPES (20 mM, pH 7.0), NaCl 
(0.1 M) and Octyl-POE (0.5% v/v) where then also measured. 
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A decrease in fluorescence at 515 nm and an increase in fluorescence at 568 nm 
wold be indicative of FRET occurring. 
 
 
7.1.15.3 Isothermal titration calorimetry (ITC) 
 
ITC titrations were performed using a Microcal ITC200 calorimeter (GE healthcare) with 
a cell volume of 0.2028 mL and data processed and fitted using Origin with the one site 
model.138 Protein samples were dialysed into phosphate buffer (SnakeSkin® pleated 
dialysis tubing, Thermo Scientific, with 7000 MWCO) prior to analysis. The ligands 
were then dissolved in the dialysis buffer to ensure an exact match for the buffers 
during the titration. The reference cell was filled with water and the analysis cell was 
filled with the protein solution and both were allowed to reach thermal equilibrium at 
25 °C before titrations were performed. Titrations typically comprised 20 injections of 
2 µL at 2 minute intervals. Separate titrations of the ligand into buffer were used to 
subtract the heat of dilution from the integrated data prior to curve fitting. 
 
 
7.2 Chemistry Experimental 
 
7.2.1 General Methods 
 
All solvents were dried prior to use, according to standard methods.  Boron trifluoride 
diethyl etherate (BF3.OEt2) was distilled over calcium hydride, and all other 
commercially available reagents were used as received. Where appropriate anhydrous 
quality material was purchased. All solvents used for flash chromatography were GPR 
grade, except hexane and ethyl acetate, when HPLC grade was used. All 
concentrations were performed in vacuo, unless otherwise stated. All reactions were 
performed in oven dried glassware under a N2(g) atmosphere, unless otherwise stated. 
 
1H NMR spectra were recorded at 500 MHz on a Bruker Avance 500 instrument or at 
300 MHz on a Bruker Avance 300 instrument. 13C NMR spectra were recorded at 75 
MHz on a Bruker Avance 300 instrument. Chemical shifts are given in parts per million 
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downfield from tetramethylsilane. The following abbreviations are used in 1H NMR 
analysis: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = double 
doublet, dt = double triplet, td = triple doublet, ddd = double double doublet. 
 
Electrospray (ES+) ionisation mass spectra were obtained on a Bruker HCTUltra mass 
spectrometer, and high resolution ES+ were performed on a Bruker Daltonics 
MicroTOF mass spectrometer. Isotopic ratios were calculated by comparison of the 13C 
peak area of the most abundant ion, using Bruker Compass Data Analysis 4.0 software. 
Infra-red spectra were recorded on a Bruker ALPHA FT-IR spectrometer with platinum 
ATR. Melting points were obtained on a Reichert hot-stage apparatus and are 
uncorrected. Optical rotations were measured at the sodium D-line with a Schmidt and 
Haensch Polartronic H 532. []D values are given in units of 10
-1 deg cm2 g-1 
 
Analytical TLC was performed on silica gel 60-F254 (Merck) with detection by 
fluorescence and/or charring following immersion in a 5% H2SO4/methanol solution, 
unless otherwise stated. 
 
 
7.2.2 Experimental 
(1.17) Fmoc-lys(dde)-OH 
 
2-(1-Hydroxyethylidene)-5,5-dimethyl-1,3-cyclohexanedione (1 g, 5.47 mmol), Fmoc-
lys-OH (1.01 g, 2.73 mmol) and trifluoroacetic acid (21 µl, 0.27 mmol) in EtOH (22 ml) 
were stirred at 85 °C under reflux for 74 h.  The solvent was removed under reduced 
pressure and the residue taken into EtOAc (25 ml), washed with 1 M KHSO4 (20 ml), 
water (20 ml), sat. aq. NaCl (20 ml), dried (MgSO4) and the solvent removed under 
reduced pressure.  The solid was purified by flash column chromatography (silica, 
50:50:2 EtOAc-Hex-AcOH) to afford a colourless solid (1.37 g, 95%).  [lit.139 []d +3.1 
165 
 
(c 1.0, MeOH)]; []d +8.7 (c 1.0, CHCl3); IR (cm
-1): 3303 (O-H), 1711 (C=O, 
ketone/carboxylic acid), 1625 (C=O, amide); HRMS: Found ([M+H]+) 533.2646, 
C31H36N2O6 requires 533.2661;  HRMS  
1H NMR (500 ΜΗz, CDCl3); Η Dde: 2.53 (s, 
3H, C=CCH3), 2.36 (s, 2H, C(O)CH2), 2.35 (s, 2H, C(O)CH2), 1.00 (s, 6H, C(CH3)2), 
Fmoc: 7.74 (d, J 7.6, 2H, Ar-H), , 7.58 (dd, J 7.4 Hz, J 10.7, 2H, Ar-H), 7.37 (t, J 7.4 Hz, 
2H, Ar-H), 7.30-7.23 (m, 2H, Ar-H), 4.44 (d, J 6.9 Hz, 2H, CH2-CH), 4.21 (t, J 6.9 Hz, 
1H, CH2-CH) Lys: 5.83 (d, J 8.1 Hz, 1H, C(O)NH), 4.44-4.40 (m, 1H, H), 3.39-3.35 
(m, 2H, 2 x H), 2.00-1.93 (m, 1H, H'), 1.75-1.70 (m, 1H, H''), 1.74-1.68 (m, 2H, 2 x 
H), 1.61-1.44 (m, 2H, 2 x H).   13C NMR (75 MHz, CDCl3):  C =  Dde: 198.4 (C=O), 
141.3 (NHC=C), 108.3 ((O=C)2C=C), 52.4 (O=CCH2), 30.9 (C(CHx)4), 28.2 (C(CH3)2), 
18.2 (C=CCH3), Fmoc: 174.4 (NHC=O), 143.9 (Ar-C), 143.8 (Ar-C), 128.2, 127.7, 
125.1, 120.0 (Ar-CH), 67.1 (CH2-CH), 47.1 (CH2-CH), Lys: 174.8 (COOH), 53.7 (C), 
43.3 (C), 32.0 (C), 28.4 (C), 22.6 (C).  
 
 
(3.2) β-D-Glucopyranose, 4-O-(2,3,4,6-tetra-O-acetyl--D-glucopyranosyl)-, 
1,2,3,6-tetraacetate 
 
Sodium acetate (50 g, 0.61 mol) in acetic anhydride (541 mL, 4.86 mol) was heated 
under reflux.  The solution was removed from the heat and maltose (100 g, 0.29 mol) 
was added in portions to keep the solution boiling.  The solution was allowed to cool to 
75°C, poured into ice (2 L) and stirred for 19 hrs.  The water was decanted off and 
extracted with DCM (200 mL), the remaining solid was dissolved in DCM (200 mL) and 
the extracts combined.  The extracts were washed with water (2 x 100 mL), sat. aq. 
NaHCO3 (3 x 100 mL), water (100 mL), dried (MgSO4) and the solvent removed under 
reduced pressure.  The solid was recrystallised from EtOH to give colourless crystals 
(139 g, 70%).  Mp 125 – 134 °C; []D +65.3 (C 0.94, CHCl3);  [lit.
140 []D +63 (C 1, 
CHCl3)]; MS: m/z ([M+Na]
+) = 701.1; IR (cm-1): 1752 (C=O); 1H NMR (500 ΜΗz, CDCl3); 
δΗ = 5.76 (d, 1H, J1-2 8.1 Hz, H-1), 5.42 (m, 1H, H-1'), 5.39 (m, 1H, H-3'), 5.33 (m, 1H, 
H-3), 5.06 (dd, 1H, J4'-3' 9.9 Hz, J4'-5' 9.9 Hz, H-4'), 4.99 (dd, 1H, J2-1 8.1 Hz, J2-3 9 Hz, H-
2), 4.89 (dd, 1H, J2'-1' 4 Hz, J2'-3' 10.5 Hz, H-2'), 4.47 (dd, 1H, J6a-5 2.6 Hz, J6a-6b 12.3 Hz, 
H-6a), 4.25 (m, 2H, H-6b, H-6'a), 4.05 (m, 2H, H-4, H-6'b), 3.96 (ddd, 1H, J5'-4' 9.9 Hz, 
J5'-6'a 6 Hz, J5'-6'b 3 Hz, H-5'), 3.85 (ddd, 1H, J5-4 9.6 Hz, J5-6a 4.4 Hz, J5-6b 2.6 Hz, H-5), 
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1.9-2.1 (m, 24H, C(O)CH3).  
13C NMR (75 MHz, CDCl3): δC = 170.6, 170.5, 170.4, 
170.1, 169.9, 169.5, 168.9 (8 x COCH3), 95.7 (CH-1'), 91.2 (CH-1), 75.2, 72.9, 72.3, 
70.9, 69.9, 69.3, 68.5, 67.9, 68.6, 67.8 (8 x CH), 61.8, 61.3 (2 x CH2), 20.9, 20.8, 20.7, 
20.6, 20.5, 18.4 (6 x COCH3). 
 
 
(3.5) 2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-O-acetyl-1-bromo-
1-deoxy--D-glucopyranose 
 
HBr-HOAc (33% w/v) (21.6 mL, 124 mmol), was added to a solution of maltose (20.0 g, 
29.6 mmol) in DCM (200 ml) at 0°C, the reaction mixture was then stirred for 3 hrs.  
The mixture was poured into DCM (1.2 L) and washed with water (2 x 200 ml), sat. aq. 
NaHCO3 (300 ml), sat. aq. NaCl (300 ml), dried (MgSO4) and the solvent removed 
under reduced pressure.  The solid was purified by flash column chromatography 
(silica, 3:2 (v/v) ethyl acetate-hexane) to afford a white solid (7.9g, 38%).  Rf (EtOAc–
Hex, 2:1) 0.43;  []D +146.3 (C 1.1, CHCl3) [lit.
141 []D +172 (C 1, CHCl3)]; MS: m/z 
([M+Na]+) = 722.4; IR (cm-1): 1749 (C=O); 1H NMR (500 ΜΗz, CDCl3); Η = 6.50 (d, 1H, 
J1-2 4 Hz, H-1), 5.61 (dd, 1H, J3-2 9.5 Hz, J3-4 9.5 Hz, H-3), 5.43 (d, 1H, J1'-2' 4 Hz, H-1'), 
5.38 (dd, 1H, J3'-2' 10 Hz, J3'-4' 10Hz, H-3'), 5.08 (dd, 1H, J4'-3' 10 Hz, J4'-5' 10 Hz, H-4'), 
4.88 (dd, 1H, J2'-1' 4 Hz, J2'-3' 11 Hz, H-2'), 4.71 (dd, 1H, J2-1 4 Hz, J2-3 10 Hz, H-2), 4.53 
(dd, 1H, J6a-5 4 Hz, J6a-6b 14 Hz, H-6a), 4.23-4.28 (m, 3H, H-5, H-6b, H-6'a), 4.05-4.13 
(m, 2H, H-4, H-6'b), 3.94-4.05 (m, 1H, H-5'), 2.01-2.15 (m, 21H, C(O)CH3). 
13C NMR 
(75 MHz, CDCl3):  C = 170.6, 170.5, 170.4, 170.1, 169.9, 169.5, 168.9 (8 x COCH3), 
95.7 (C-1'), 86.6 (C-1), 72.5 (C-5), 72.3 (C-3), 71.5 (C-4), 71.0 (C-2), 70.0 (C-2'), 69.2 
(C-3'), 68.6 (C-5'), 67.8 (C-4'), 61.8 (C-6), 61.3 (C-6'), 21.0, 20.8, 20.7, 20.6, 20.6, 20.5, 
20.5 (7 x COCH3). 
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(3.8) 2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-O-acetyl-,-D-
glucopyranose 
 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-
glucopyranose (5 g, 7.36 mmol) and hydrazine acetate (0.75 g, 8.1 mmol) in DMF (70 
ml) were heated to 50°C for 1 hr 10 min and then allowed to stir at r.t. for 23.5 hrs.  The 
solvent was removed under reduced pressure and the solid recrystallised from EtOH to 
give an inseperable mixture of anomers (dr: 59:41) as a white solid (3.56 g, 76%).  Mp 
174 – 176 °C; []D +78.8 (C 1.00, CHCl3); [Lit.
142 []D +86 (C 1.04, CHCl3)]; MS: m/z 
([M+Na]+) = 659.1; IR (cm-1): 1748 (C=O), 3473 (O-H); 
 - Major diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 5.59 (t, 1H, J3,2 9 Hz, J3,4 
9 Hz, H-3), 5.45 (d, 1H, J1',2' 4 Hz, H-1'), 5.38 (t, 1H, J3',2' 10 Hz, J3',4' 10 Hz, H-3'), 5.34 
(d, 1H, J1,2 3.5 Hz, H-1), 5.08 (t, 1H, J4',3' 9 Hz, J4',5' 9 Hz, H-4'), 4.88 – 4.85 (m, 1H, H-
2'), 4.80 – 4.76 (m, 1H, H-2), 4.52 – 4.48 (m, 1H, H-6a), 4.28 – 4.21 (m, 3H, H-5, H-6b, 
H-6a'), 4.07 – 3.96 (m, 5.1H, H-4, H-5', H-6b'), 2.15 – 1.84 (m, 21H, 7 x COCH3).  
13C 
NMR (75 MHz, CDCl3):  C = 170.8, 170.8, 170.7, 170.4, 170.2, 170.1, 169.6 (7 x 
COCH3), 95.5 (C-1'), 89.9 (C-1), 72.6 (C-2, C-4), 72.4 (C-3), 70.0 (C-2'), 69.4 (C-3'), 
68.5 (C-5'), 68.4 (C-4'), 67.5 (C-5), 62.9 (C-6), 61.4 (C-6'), 21.0, 20.9, 20.9, 20.7, 20.6, 
20.6 (7 x COCH3). 
- Minor diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 5.41 (d, 1H, J1',2' 4 Hz, H-
1'), 5.40 – 5.35 (m, 1H, H-3'), 5.29 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 5.06 (t, 1H, J4',3' 9.5 
Hz, J4',5' 9.5 Hz, H-4'), 4.88 – 4.85 (m, 1H, H-2'), 4.80 – 4.76 (m, 2H, H-1, H-2), 4.52 – 
4.48 (m, 1H, H-6a), 4.28 – 4.21 (m, 2H, H-6b, H-6a'), 4.07 – 3.96 (m, 3H, H-4, H-5', H-
6b'), 3.76 – 3.70 (m, 1H, H-5), 2.15 – 1.84 (m, 21H, 7 x COCH3,).  
13C NMR (75 MHz, 
CDCl3):  C = 170.8, 170.8, 170.7, 170.4, 170.2, 170.1, 169.6 (7 x COCH3), 95.5 (C-1'), 
94.8 (C-1), 75.0 (C-3), 72.6 (C-4), 72.3 (C-5), 70.2 (C-2), 70.0 (C-2'), 69.3 (C-3'), 68.5 
(C-5'), 67.9 (C-4'), 62.9 (C-6), 61.4 (C-6'), 21.0, 20.9, 20.9, 20.7, 20.6, 20.6 (7 x 
COCH3). 
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(3.9) 2-(tert-Butyl acetyl) 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-
O-acetyl-O-,-D-glucopyranoside143 
 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-O-acetyl-,-D-
glucopyranose (2.4 g, 3.77 mmol), K2CO3 (1.56 g, 3.77 mmol) and tert-butyl 
bromoacetate (1.11 ml, 7.54 ml) in DMF (40 ml) were stirred for 19 hr 15 min.  The 
mixture was then filtered, the solid washed with DCM and the filtrate concentrated 
under reduced pressure.  The solid was taken into DCM (50 ml), washed with H2O (2 x 
50 ml), dried (Na2SO4) and the solvent removed under reduced pressure.  The solid 
was purified by flash column chromatography (silica, 1:1 (v/v) EtOAc–Hex) to give an 
inseparable mixture of diastereoisomers (dr: 80:20) as a white solid (1.56 g, 55%).  MS: 
m/z ([M+Na]+) = 773.3; IR (cm-1): 1747 (C=O). 
- Major diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 5.59 (t, 1H, J3,2 10 Hz, 
J3,4 10 Hz, H-3), 5.44 (d, 1H, J1’,2’  4 Hz, H-1'), 5.37 (t, 1H, J3’,2’ 10 Hz, J3’,4’ 10 Hz, H-3'), 
5.10 (d, 1H, J1,2 3.5 Hz, H-1), 5.07 (t, 1H, J4',3’ 10 Hz, J4',5’ 10 Hz, H-4'), 4.86 (dd, 1H, 
J2’,1’ 4 Hz, J2’,3’ 9.5 Hz, H-2'), 4.78 (dd, 1H, J 2,1 3.5 Hz, J2,3 10, H-2), 4.46 (dd, 1H, J6a,5 
2.5 Hz, J6a,6b 12.5, H-6a), 4.28 – 4.23 (m, 2H, H-6b, H-6a'), 4.18 – 4.13 (m, 1H, H-5), 
4.08 (s, 2H, OCH2C(O)), 4.06 – 4.02 (m, 1H, H-6b'), 4.00 (t, 1H, J4,3 9.5 Hz, J4,5 9.5 Hz, 
H-4), 3.99 – 3.95 (m, 1H, H-5'), 2.08 – 1.94 (m, 21H, 7 x C(O)CH3), 1.40 (s, 9H, 
OC(CH3)3).  
13C NMR (75 MHz, CDCl3):  C = 171.0, 170.6, 170.4, 170.4, 170.4, 170.3, 
170.0, 169.8, 169.8, 169.6, 169.4, 169.3, (7 x COCH3) 168.1 (C(O)OtBu), 95.4, 95.4 
(C-1', C-1), 82.0 (OC(CH3)3), 72.5 (C-4), 72.2 (C-3), 70.8 (C-2), 69.9 (C-2'), 69.3 (C-3'), 
68.4 (C-5'), 68.2 (C-5), 68.0 (C-4'), 64.5 (OCH2C(O)), 62.6 (C-6), 61.5 (C-6'), 28.0 
(OC(CH3)3), 20.9, 20.9, 20.8, 20.7, 20.6, 20.6, 20.5, 20.5 (7 x C(O)CH3). 
 - Minor diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 5.41 (d, 1H, J1’,2’ 4 Hz, H-
1'), 5.36 (t, 1H, J3’,2’ 9.5 Hz, J3’,4’ 9.5 Hz, H-3'), 5.28 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 5.05 
(t, 1H, J4’,3’ 9.5 Hz, J4’,5’ 9.5 Hz, H-4'), 4.88 (t, 1H, J2,1 9 Hz, J2,3 9 Hz, H-2), 4.90 – 4.84 
(m, 1H, H-2'), 4.69 (d, 1H, J1,2 9 Hz, H-1), 4.49 (dd, 1H, J6a.5 2.5 Hz, J6a,6b 12.5, H-6a), 
4.28 – 4.23 (m, 2H, H-6b, H-6a'), 4.08 (s, 2H, OCH2C(O)), 4.06 – 4.02 (m, 2H, H-4, H-
6b'), 3.99 – 3.95 (m, 1H, H-5'), 3.70 (ddd, 1H, J5,4 9.5 Hz, J5,6a 3.5, J5,6b 9.5 Hz, H-5).  
2.08 – 1.94 (m, 26.25H, 7 x C(O)CH3,), 1.41 (s, 9H, OC(CH3)3).  
13C NMR (75 MHz, 
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CDCl3):  C = 171.0, 170.6, 170.4, 170.4, 170.4, 170.3, 170.0, 169.8, 169.8, 169.6, 
169.4, 169.3, (7 x C(O)CH3) 168.0 (C(O)OtBu), 99.5 (C-1), 95.5 (C-1'), 82.0 (OC(CH3)3), 
75.1 (C-3), 72.5 (C-4), 72.2 (C-5), 70.8 (C-2), 69.9 (C-2'), 69.3 (C-3'), 68.4 (C-5'), 68.0 
(C-4'), 64.5 (OCH2CO), 62.7 (C-6), 61.4 (C-6'), 27.9 (OC(CH3)3), 20.9, 20.9, 20.8, 20.7, 
20.6, 20.6, 20.5, 20.5 (7 x COCH3). 
 
 
(3.10) 2,3-Di-O-acetyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)-1,2,3,6-
tetra-O-acetyl--D-glucopyranose86 
 
Maltose (10.0 g, 29.2 mmol), ,-dimethoxy toluene (10.9 ml, 73 mmol) and p-
toluenesulfonic acid (0.64g, 5.84 mmol) were dissolved in DMF (72 ml) and rotated on 
a rotary evaporator at 48°C and at 30 Torr for 6.5 h.  The solution was neutralised with 
triethylamine and the solvent removed under reduced pressure.  The concentrate was 
taken up into DMF (70 ml) and TFA (1 ml) was stirred for 6 h 10 min.  The solution was 
neutralised with triethylamine and the solvent removed under reduced pressure.  The 
solid was purified by flash column chromatography (silica, 4:1 (v/v) CHCl3 –MeOH) to 
afford a white solid.  The solid, (R)-4,6-O-benzylidene-D-glucopyranosyl-(14)-D-
glucose (9.30 g, 21.6 mmol), was added in portions to a solution of sodium acetate 
(8.87 g, 108 mmol) in acetic anhydride (88 ml) which had been heated at reflux.  The 
solution was heated to boiling for an additional 15 min.  The solution was allowed to 
cool and then poured into crushed ice (300 ml).  The mixture was stirred for 3 hr 20 min, 
extracted into DCM (100 ml), washed with sat. aq. NaHCO3 (30 ml), H2O (30 ml), sat. 
aq. NaHCO3 (30 ml), sat. aq. NaCl (30 ml), dried (MgSO4) and concentrated under 
reduced pressure.  The solid was recrystallised from ethanol to give a white solid (1.31 
g, 26%).  Mp 206 – 207 °C [lit.144 Mp 209 – 210];  []D +36.5 (C 1.0, CHCl3) [lit.
145 []D 
+35 (C 1.1, CHCl3)]; MS: m/z ([M+Na]
+) = 705.2; IR (cm-1): 1751 (C=O);  1H NMR (500 
ΜΗz, CDCl3); Η = 7.43-7.42 (m, 2H, Ar-o), 7.37-7.34 (m, 3H, Ar-m, Ar-p), 5.74 (d, 1H, 
J1,2 = 8 Hz, H-1), 5.48 (s, 1H, Bz-H), 5.46 (t, 1H, J3',2' 10 Hz, J3',4' 10 Hz, H-3'), 5.36 (d, 
1H, J1',2' 4 Hz, H-1'), 5.31 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 4.98 (t, 1H, J2,1 8 Hz, J2,3 8 Hz, 
H-2), 4.88 (dd, 1H, J2’,3' 10, J2',1' 4 Hz, H-2'), 4.50 (dd, 1H, J6a,6b 12.5, J6a,5 2 Hz, H-6a), 
4.28 – 4.23 (m, 2H, H-6b, H-6a'), 4.05 (t, 1H, J4,3 9 Hz, J4,2 9 Hz, H-4), 3.86 – 3.81 (m, 
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2H, H-5, H-5'), 3.72 (t, 1H, J6b',6a' 10.5 Hz, J6b',5' 10.5 Hz, H-6b'), 3.63 (t, 1H, J4',3' 10 Hz, 
J4',5' 10 Hz, H-4'), 2.15 – 2.00 (m, 18H, 6 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 
170.8, 170.3, 170.1, 169.7, 169.7, 168.8 (6 x COCH3), 136.7 (Ar-iC), 129.2 (Ar-pC), 
128.3 (Ar-oC), 126.2 (Ar-mC), 101.6 (Bz-C), 96.6 (C-1'), 91.2 (C-1), 78.7 (C-4'), 75.3 
(C-3), 73.0 (C-4), 72.5 (C-5), 71.0 (C-2), 70.8 (C-2'), 68.4 (C-3', C-6'), 63.8 (C-5'), 62.3 
(C-6), 20.9, 20.8, 20.8, 20.7, 20.6 (6 x COCH3). 
 
 
(3.12) 2-(tert-Butyl acetyl) 2,3-di-O-acetyl-(R)-4,6-O-benzylidene--D-
glucopyranosyl-(14)-2,3,6-tri-O-acetyl-O-,-D-glucopyranoside 
 
2,3-Di-O-acetyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-
acetyl--D-glucopyranose (500 mg, 0.74 mmol) and hydrazine acetate (75 mg, 0.81 
mmol) in DMF (7 ml) were stirred at 58 °C for 1 h.  The solvent was removed under 
reduced pressure and the solid recrystallised from ethanol to give a white solid.  The 
solid, 2,3-Di-O-acetyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)-2,3,6-tri-O-
acetyl-,-D-glucopyranose (150 mg, 0.23 mmol), caesium carbonate (228 mg, 0.70 
mmol), 2-bromo  benzylacetate (60 l, 0.47 mmol) and tetrabutylammonium iodide (26 
mg, 0.07 mmol) in DMF (2 ml) were stirred at r.t. for 24 h.  The reaction mixture was 
filtered under reduced pressure, taken into DCM (20 ml), washed with H2O (3 x 10 ml), 
the aqueous washes were then extracted with DCM (10 ml) and the organic extracts 
combined and dried (MgSO4) and the solvent removed under reduced pressure.  The 
solid was purified by flash column chromatography (silica, 2:3 (v/v) EtOAc–Hex) to give 
a white solid (135 mg, 74%).   
 - Major diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 7.45-7.28 (m, 5H, Ar-H), 
5.58 (t, 1H, J3-2 10 Hz, J3-4 10 Hz, H-3), 5.48 (s, 2H, 2 x Bz-H'), 5.47 (t, 1H, J3'-2' 10 Hz, 
J3'-4' 10 Hz, H-3'), 5.38 (d, 1H, J1'-2' 4 Hz, H-1'), 5.16 (s, 2H, 2 x Bz-H), 5.12 (d, 1H, J1-2 4 
Hz, H-1), 4.90-4.87 (m, 1H, H-2'), 4.78 (dd, 1H, J2,1 4 Hz, J2,3 10 Hz, H-2), 4.47 (dd, 1H, 
J6a-5 2 Hz, J6a,6b 12 Hz, H-6a), 4.30 (s, 2H, OCH2C(O)), 4.22-4.19 (m, 2H, H-5, H-6a'), 
4.11 (m, 1H, H-6b), 3.99 (t, 1H, J4,3 10 Hz, J4,5 10 Hz, H-4), 3.84 (m, 1H, H-5'), 3.73 (t, 
1H, J6b'-5' 10 Hz, J6a'-6b' 10 Hz, H-6b'), 3.63 (t, 1H, J4'-3' 10 Hz, J4'-5' 10 Hz, H-4'), 2.20-
1.85 (m, 15H, 5 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 170.9, 170.5, 170.3, 
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169.7, 169.1 (5 x COCH3, 1 x COCH2), 136.8, 135.1, (2 x Ar-C), 129.1, 135.1, 129.1, 
128.7, 128.6, 128.5, 128.4, 128.2, 126.2 (10 x Ar-CH), 101.6 (Bz-C'), 96.4 (C-1'), 95.6 
(C-1), 78.2 (C-4'), 72.4 (C-4), 71.9 (C-3), 70.9 (C-2), 70.8 (C-2'), 66.9 (Bz-H, C-3', C-5, 
C-6'), 64.2 (OCH2C(O)), 63.7 (C-5'), 62.4 (C-6), 20.9, 20.8, 20.7, 20.6 (5 x COCH3). 
 - Minor diastereoisomer: 1H NMR (500 ΜΗz, CDCl3); Η = 5.48 (s, 2H, 2 x Bz-H'), 
5.45 (t, 1H, J3'-2' 10 Hz, J3'-4' 10 Hz, H-3'), 5.36 (d, 1H, J1'-2' 4 Hz, H-1'), 5.28 (t, 1H, J3-2 9 
Hz, J3,4 9 Hz, H-3), 5.17 (s, 2H, 2 x Bz-H), 4.90-4.87 (m, 2H, H-2, H-2'), 4.68 (d, 1H, J1,2 
8 Hz, H-1), 4.53 (dd, 1H, J6a-5 2 Hz, J6a-6b 12 Hz, H-6a), 4.32 (s, 2H, OCH2C(O)), 4.22-
4.19 (m, 2H, H-6b, H-6a'), 4.02 (t, 1H, J4,3 9 Hz, J4,5 9 Hz, H-4), 3.84 (m, 1H, H-5'), 3.73 
(t, 1H, J6b'-5' 10 Hz, J6b'-6a' 10 Hz, H-6b'), 3.66 (m, 1H, H-5), 3.63 (t, 1H, J4'-3' 10 Hz, J4'-5' 
10 Hz, H-4'), 2.20-1.85 (m, 15H, 5 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 170.9, 
170.5, 170.3, 169.7, 169.1 (5 x COCH3, 1 x COCH2), 136.8, 135.1, (2 x Ar-C), 129.1, 
135.1, 129.1, 128.7, 128.6, 128.5, 128.4, 128.2, 126.2 (10 x Ar-CH), 101.6 (Bz-C'), 
99.5 (C-1), 96.4 (C-1'), 78.8 (C-4'), 75.1 (C-3), 72.2 (C-4), 71.9 (C-5), 70.8 (C-2, C-2'), 
66.9 (C-3', C-6'), 65.2 (Bz-H), 64.2 (OCH2C(O)), 63.7 (C-5', C-6), , 20.9, 20.8, 20.7, 
20.6 (5 x5 x COCH3). 
 
 
(3.13) 2-(2-(2-chloroethoxy)ethoxy)ethoxy -D-glucopyranosyl-(14)--D-
glucopyranoside (7) 
 
Iodine (crystal) and silver carbonate (3.9 g, 14.4 mmol) in DCM (25 ml) were added to 
acetobromomaltose 5 (5 g, 7.2 mmol) and 2-(2-(2-chloroethoxy)ethoxy)ethanol 17 
(5.15 ml, 36 mmol) in DCM (25 ml).  The solution was stirred at r.t. for 19.5 h before 
being filtered and concentrated under reduced pressure.  The resulting syrup was 
taken up into acetic acid (10 ml) and pyridine (10 ml) and stirred for 25 h before being 
concentrated under reduced pressure.  The solid was purified by flash column 
chromatography (silica, 1:1 → 2:1 EtOAc-Hex).    The resulting solid was taken up into 
methanol (10 ml) with sodium methoxide (150 mg) and stirred at r.t for 18.5 h.  The 
solution was neutralised with IRC-120 H+ resin, filtered and concentrated under 
reduced pressure.  The resulting syrup was purified by size exclusion chromatography 
(MeOH, Sephadex LH-20) to give a clear oil (1.11 g, 32%).    []D +113.3 (C 1.0, 
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MeOH); HRMS: Found ([M+Na]+) 515.1503, C18H33ClO13 requires 515.1502; IR (cm
-1): 
3350 (OH); 1H NMR (500 ΜΗz, CDCl3); Η = 5.15 (d, J1',2' = 3.8 Hz, 1H, H-1'), 4.27 (d, 
J1,2 = 8.0 Hz, 1H, H-1), 3.83 (dt, J 11.4 Hz, J 4.1 Hz, 1H, PEG-H), 3.70 (dd, J6a,5 = 2.0 
Hz, J6a,6b = 12.2 Hz, 1H, H-6a), 3.66-3.58 (m, 4H, H-6a', 3 x PEG-H), 3.58-3.46 (m, 12H, 
H-3, H-5', H-6b, H-6b', 8 x PEG-H), 3.45 (t, J3',2' = 9.5 Hz, J3',2' = 9.5 Hz, 1H, H-3'), 3.39 
(t, J4,3 = 9.5 Hz, J4,5 = 9.5 Hz, 1H, H-4), 3.37-3.33 (m, 1H, H-5), 3.35 (dd, J2',1' = 3.8 Hz, 
J2',3' = 9.5 Hz, 1H, H-2'), 3.18 (t, J4',3' = 9.5 Hz, J4',5' = 9.5 Hz, 1H, H-4'), 3.10 (dd, J2,1 = 
8.0 Hz, J2,3 = 9.5 Hz, 1H, H-2); 
13C NMR (75 MHz, CDCl3):  C =75.2 (C-1), 72.8 (C-1'), 
50.2 (C-4), 49.3 (C-3), 47.7 (C-5), 46.1 (C-3'), 46.0 (C-2), 45.9 (C-5'), 44.9 (C-2'), 44.0 
(PEG-C), 42.9, 42.7, 42.6 (PEG-C), 42.5 (C-4'), 41.8 (PEG-C), 33.9 (PEG-C), 33.6 (C-
6), 16.3 (C-6'). 
 
 
(3.14) 2,3-Di-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-
glucopyranose86 
 
To a solution of 2,3-Di-O-acetal-(R)-4,6-O-Benzylidene-D-glucopyranosyl-(14)-
1,2,3,6-tetra-O-acetyl--D-glucopyranose (1.2 g, 1.76 mmol) in MeCN (34 ml), HBF4–
H2O (1:1 v/v) (0.34 ml, 2.72 mmol) was added.  The mixture was stirred for 10 min 
before being neutralised with triethylamine.  The solvent was removed under reduced 
pressure and the solid was purified by flash column chromatography (silica, EtOAc) to 
afford an amorphous solid (0.75 g, 72%).  []D +50.4 (C 1.00, CHCl3), [lit.
145 []D +53.1 
(C 2.1, CHCl3)]; MS: m/z ([M+Na]
+) = 617.1; IR (cm-1): 1747 (C=O), 3445 (O-H); 1H 
NMR (500 ΜΗz, CDCl3); Η = 5.75 (d, 1H, J1,2 8 Hz, H-1), 5.35 (d, 1H, J1',2' 4 Hz, H-1'), 
5.31 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 5.23 - 5.19 (m, 1H, H-3'), 4.98 (t, 1H, J2,1 9 Hz, J2,3 
9 Hz, H-2), 4.77 (dd, 1H, J2',3' 10.5, J2',1' 4 Hz, H-2'), 4.49 (dd, 1H, J6a,6b 10.5, J6a,5 2 Hz, 
H-6a), 4.21 (dd, 1H, J6a',6b' 12.5, J6a',6b' 4 Hz, H-6a'), 4.03 (t, 1H, J4,3 9.5 Hz, J4,5 9.5 Hz,  
H-4), 3.85 – 3.81 (m, 3H, H-5, H-6b, H-6b'), 3.69 – 3.67 (m, 2H, H-4', H-5'), 3.21 (bs, 
1H, OH-4'), 3.21 (bs, 1H, OH-6'), 2.23 – 1.97 (m, 18H, 6 x COCH3).  
13C NMR (75 MHz, 
CDCl3):  C = 171.3, 171.3, 170.8, 170.2, 169.7, 168.9 (6 x COCH3), 95.8 (C-1'), 91.3 
(C-1), 75.3 (C-3), 73.1 (C-5'), 72.8 (C-5), 72.0 (C-3'), 71.9 (C-4), 70.9 (C-2), 70.3 (C-2'), 
69.5 (C-4'), 62.7 (C-6), 62.0 (C-6'), 20.9, 20.9, 20.8, 20.7, 20.6 (6 x COCH3). 
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(3.16) 2,3,6-Tri-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-
glucopyranose86 
 
EDC (1.08 g, 5.65 mmol) and HOBt (0.7 g, 5.18 mmol) were added successively to a 
stirred solution of acetic acid (0.27 ml, 4.71 mmol) in DCM (10 ml).  After 23 hrs the 
solution was washed with aq. HCl (10%, 5 ml), sat. aq. NaHCO3 (5 ml), dried (MgSO4) 
and concentrated under reduced pressure to give 7 as an amorphous solid.  2,3-Di-O-
acetal--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-glucopyranose (0.67 g, 
1.13 mmol) and the solid (0.24 g, 1.35 mmol) were dissolved in DCM (6 ml).  
Triethylamine (0.25 ml, 1.66 mmol) was added and the solution was stirred for 19 hr 40 
min.  The solvent was removed under reduced pressure and the solid purified by flash 
column chromatography (silica, 3:2 (v/v) EtOAc–Hex) to afford a white solid (269 mg, 
37%).  []D +35.5 (C 1.0, CHCl3), [lit.
146 []D +46.5 (C 1.0, CHCl3)]; IR (cm
-1): 1747 (C=O), 
3479 (O-H); 1H NMR (500 ΜΗz, CDCl3); Η = 5.72 (d, 1H, J1,2 8 Hz, H-1), 5.35 (d, 1H, 
J1',2' 4 Hz, H-1'), 5.30 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 5.22 (t, 1H, J3',2' 9.5 Hz, J3',4' 9.5 
Hz, H-3'), 4.97 (t, 1H, J2,1 9 Hz, J2,3 9 Hz, H-2), 4.78 (dd, 1H, J2',1' 10.5, J2',1' 4 Hz, H-2'), 
4.49 – 4.53 (m, 2H, H-6a, H-6a'), 4.23 – 4.19 (m, 2H, H-6b, H-6b'), 4.04 (t, 1H, J4,3 9.5 
Hz, J4,5 9.5 Hz, H-4), 3.84 (ddd, 1H, J5,6a 2, J5,6b 4.5, J5,4 9.5 Hz, H-5), 3.81 – 3.79 (m, 
1H, H-5'), 3.53 (dt, 1H, J4',3' 9.5, J4',5' 9.5, J4',OH-4' 6 Hz, H-4'), 3.28 (bd, 1H, JOH-4',4' 6 Hz, 
OH-4'), 2.23 – 1.96 (m, 21H, 7 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 171.5, 
171.1, 170.8, 170.6, 170.1, 169.7, 168.8 (7 x COCH3), 95.9 (C-1'), 91.2 (C-1), 75.3 (C-
3), 73.1 (C-5), 72.3 (C-4), 71.6 (C-3'), 71.2 (C-2), 70.9 (C-5'), 70.0 (C-2'), 68.7 (C-4'), 
62.6 (C-6'), 62.5 (C-6), 20.9, 20.8, 20.7, 20.6 (7 x COCH3). 
 
 
 
(3.17) 2,3,6-Tri-O-acetyl--D-galactopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-
glucopyranose86 
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2,3,6-Tri-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-glucopyranose 
(109 mg, 0.17 mmol) in DCM (4 ml) was stirred and cooled to 0 °C.  Pyridine (30 l, 
0.24 mmol) and trifluoromethanesulfonic anhydride (40 l, 0.29 mmol) were added and 
the mixture stirred for 1 h 20 min.  The mixture was diluted with DCM (8 ml), washed 
with H2O (4 ml), sat. aq. NaHCO3 (4 ml), 5% aq. KHSO4 (4 ml), dried (MgSO4) and the 
solvent removed under reduced pressure.  The solid was taken up into DMF (6 ml) and 
tetrabutylammonium nitrite (1.00 g, 3.4 mmol) added.  The mixture was stirred for 18 h 
45 min.  The mixture was diluted with EtOAc (10 ml), washed with sat. aq. NaCl (2 x 8 
ml), H2O (8 ml), dried (MgSO4) and the solvent removed under reduced pressure.  The 
solid was purified by flash column chromatography (silica, 1:1 (v/v) EtOAc–Hex) to give 
a white solid (47 mg, 43%).  10:1 ax-eq.  []D +62.0 (C 0.7, CHCl3); MS: m/z ([M+Na]
+) 
= 659.2; IR (cm-1): 1747 (C=O), 3483 (O-H). 
ax - Major diastereoisomer -  1H NMR (500 ΜΗz, CDCl3); Η = 5.73 (d, 1H, J1,2 8 Hz, 
H-1), 5.42 (d, 1H, J1',2' 4 Hz, H-1'), 5.28 (t, 1H, J3,2 8 Hz, J3,4 8 Hz, H-3), 5.25 (dd, 1H, 
J2',1' 4 Hz, J2',3' 10.5 Hz, H-2'), 5.17 (dd, 1H, J3',2' 10.5 Hz, J3',4' 3 Hz, H-3'), 4.98 (t, 1H, 
J2,1 8 Hz, J2,3 8 Hz, H-2), 4.48 (dd, 1H, J6a,5 2 Hz, J6a,6b 12 Hz, H-6a), 4.33 (dd, 1H, J6a',5' 
6.5 Hz, J6a',6b' 11.5 Hz, H-6a'), 4.19 (dd, 1H, J6b,5 5 Hz, J6b,6a 12 Hz, H-6b), 4.16-4.10 (m, 
2H, H-4', H-6b'), 4.04-3.99 (m, 2H, H-4, H-5'), 3.83-3.81 (m, 1H, H-5), 2.75 (d, 1H, JOH-
4',4' 3.5 Hz, OH-4'), 2.17-1.99 (m, 21H, 7 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 
170.9, 170.8, 170.5, 170.1, 169.9, 169.6, 168.8 (7 x COCH3), 96.3 (C-1), 91.3 (C-1'), 
75.3 (C-3), 73.2 (C-5), 72.1 (C-4), 71.0 (C-2), 69.1 (C-3'), 68.7 (C-5'), 67.4 (C-4'), 67.2 
(C-2'), 62.7 (C-6), 62.3 (62.3), 21.0, 20.9, 20.8, 20.7, 20.7, 20.5 (7 x COCH3). 
 
(3.30) 2,3-Di-O-acetyl-6-O-tert-butyldimethylsilyl--D-glucopyranosyl-(14)-
1,2,3,6-tetra-O-acetyl--D-glucopyranose 
 
2,3-Di-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-glucopyranose 
(435 mg, 0.84 mmol), tert-butyldimethylsilyl chloride (515 mg, 4.2 mmol) and 4-
dimethylaminopyridine (35 mg, 0.29 mmol) were stirred in pyridine (8 ml) at r.t. for 17 h 
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45 min.  The solvent was removed under reduced pressure and the residue taken up 
into DCM (20 ml), washed with H2O (3 x 10 ml) and the aqueous washes were 
extracted with DCM (10 ml).  The combined organic extracts were dried (MgSO4) and 
the solvent removed under reduced pressure.  The solid was purified by flash column 
chromatography (silica, 3:2 (v/v) EtOAc–Hex) to give a white solid (270 mg, 45%).  []D 
+32.1 (C 0.7, CHCl3); MS: m/z ([M+Na]
+) = 659.2; IR (cm-1): 1751 (C=O), 3475 (O-H).  
1H NMR (500 ΜΗz, CDCl3); Η = 5.64 (d, 1H, J1,2 8.5 Hz, H-1), 5.22 (d, 1H, J1',2' 3.5 Hz, 
H-1'), 5.20 (t, 1H, J3,2 9 Hz, J3,4 9 Hz, H-3), 5.14 (t, 1H, J3',2' 10 Hz, J3',4' 10 Hz, H-3'), 
4.87 (t, 1H, J2,1 8.5 Hz, J2,3 8.5 Hz, H-2), 4.67 (dd, 1H, J2',1' 3.5 Hz, J2',3' 10.5 Hz, H-2'), 
4.37 (dd, 1H, J6a,5 2 Hz, J6a,6b 12.5 Hz, H-6a), 4.11 (dd, 1H, J6b,5 4.5 Hz, J6b,6a 12.5 Hz), 
3.92 (t, 1H, J4,3 9 Hz, J4,5 9 Hz, H-4), 3.83 (dd, 1H, J6a',5 4.5 Hz, J6a',6b' 10.5 Hz, H-6a'), 
3.73 (ddd, 1H, J5,4 9Hz, J5,6a 2 Hz, J5,6b 4.5 Hz, H-5), 3.65 (dd, 1H, J6b',5' 4 Hz, J6b',6a' 
10.5 Hz, H-6b'), 3.62 (t, 1H, J4',3' 10 Hz, J4',5' 10 Hz, H-4'), 3.56-3.54 (m, 1H, H-5'), 3.12 
(s, 1H, OH-4'), 2.08-2.19 (m, 18H, 6 x COCH3), 0.79 (s, 9H, C(CH3)3), 0.00 (s, 6H, 2 x 
Si(CH3)).  
13C NMR (75 MHz, CDCl3):  C = 171.0, 170.8, 170.4, 170.1, 169.7, 168.8 (6 
x COCH3), 95.9 (C-1'), 91.3 (C-1), 75.3 (C-3), 73.2 (C-5), 72.2 (C-4), 72.1 (C-5'), 71.9 
(C-3'), 71.0 (C-2), 70.2 (C-2'), 70.0 (C-5'), 63.0 (C-6), 62.6 (C-6'), 20.9, 20.7, 20.7, 20.6, 
20.5 (6 x COCH3). 
 
 
(3.31) 2,3-Di-O-acetyl-6-O-benzyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl-
-D-glucopyranose 
 
2,3-Di-O-acetyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-
acetyl--D-glucopyranose (270 mg, 0.40 mmol) and sodium cyanoborohydride (216 mg, 
3.48 mmol) were stirred in THF (2.7 ml) at r.t. in the presence of methyl orange.  HCl in 
ether was added in portions until TLC showed the reaction had gone to completion.  
The solvent was removed under reduced pressure, taken into DCM (5 ml) and washed 
with sat. aq. NaHCO3 (10 ml).  The aqueous layer was extracted with DCM (3 x 5 ml) 
before the organic extracts were combined and washed with sat. aq. NaCl (10 ml), 
dried (MgSO4) and the solvent removed under reduced pressure.  The solid was 
purified by flash column chromatography (silica, 1:1 (v/v) EtOAc–Hex) to give a white 
solid (137 mg, 50%). []D +38.5 (C 1.1, CHCl3); MS: m/z ([M+Na]
+) = 707.2; IR (cm-1): 
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1747 (C=O). 1H NMR (500 ΜΗz, CDCl3); Η = 7.37-7.28 (m, 5H, Ar), 5.73 (d, 1H, J1,2 8 
Hz, H-1), 5.36 (d, 1H, J1',2', H-1'), 5.28 (t, 1H, J3,2 8 Hz, J3,4 8 Hz, H-3), 5.22 (t, 1H, J3',2' 8 
Hz, J3',4' 3 Hz, H-3'), 4.96 (t, 1H, J2,1 8 Hz, J2,3 8 Hz, H-2), 4.80 (dd, 1H, J2',1' 3 Hz, J2',3' 8 
Hz, H-2'), 4.58 (s, 2H, Bn-H), 4.46 (d, 1H, J6a,6b 12 Hz, H-6a), 4.18 (dd, 1H, J6b,6a 12.5 
Hz, J6b,5 3.5 Hz, H-6b), 4.03 (t, 1H, J4,3 8 Hz, J4,5 8 Hz, H-4), 3.80-3.70 (m, 1H, H-5, H-4', 
H-6a', H-5'), 3.62 (d, 1H, J6b',6a' 10 Hz, H-6b'), 3.19 (s, 1H, OH-4'), 2.21-1.93 (m, 18H, 6 
x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 171.1, 170.7, 170.6, 170.1, 169.6, 168.8 
(6 x COCH3), 137.6 (Ar-iC), 128.5 (2 x Ar-mC), 127.8 (Ar-pC), 127.7 (2 x Ar-oC), 95.8 
(C-1'), 91.3 (C-1), 75.4 (C-3), 73.8 (Bz-C), 73.2 (C-5), 72.0 (C-3'), 71.8 (C-4), 71.0 (C-2, 
C-4'), 70.2 (C-2'), 68.7 (C-6'), 62.6 (C-6), 58.3 (C-5'), 20.8, 20.8, 20.7, 20.6, 20.5 (6 x 
COCH3). 
 
 
(3.32) Phenyl 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-O-acetyl-1-
thio-1-deoxy--D-glucopyranoside 
 
2,3,4,6-Tetra-O-acetyl--D-glucopyranosyl-(14)-1,2,3,6-tetra-O-acetyl--D-
glucopyranose 10 (19 g, 27.17 mmol) in DCM (100 ml) had 33% hydrogen bromide in 
acetic acid (35 ml, 118 mmol) added over 30 min.  The solution was stirred at r.t. for 5 
h and poured into a brine/ice slurry (100 ml).  The DCM layer was extracted, washed 
with sat. aq. NaHCO3 (100 ml), sat. aq. NaCl (100 ml), dried (MgSO4) and concentrated 
under reduced pressure.  The solid was taken into ethyl acetate (237.5 ml) with 
thiophenol (8.37 ml, 81.5 mmol), tetrabutylammonium sulphate (10.15 g, 29.9 mmol) 
and 1 M sodium carbonate solution (380 ml).  The solution was stirred at r.t for 30 min, 
the organic layer was extracted and washed with 1 M NaOH (100 ml), H2O (100 ml x 3), 
sat. aq. NaCl (100 ml), dried (MgSO4) and concentrated under reduced pressure.  The 
solid was purified by flash column chromatography (silica, 95:5→9:1 DCM-MeOH) to 
give a white solid (10.9 g, 55%). [lit.147 []D -19.6 (C 1.0, CHCl3)]; []D -20.5 (C 1.0, 
CHCl3); HRMS: Found ([M+Na]
+) 751.1900, C32H40O17SNa requires 751.1878; IR (cm
-1): 
1740 (C=O); 1H NMR (500 ΜΗz, CDCl3); Η = 7.47-7.45 (m, 2H, ArH), 7.33-7.29 (m, 3H, 
ArH), 5.37 (d, J1',2' 4.0 Hz, 1H, H-1'), 5.32 (t, J3',2' 9.0 Hz, J3',4' 9.0 Hz, 1H, H-3'), 5.28 (t, 
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J3,2 9.0 Hz, J3,4 9.0 Hz, 1H, H-3), 5.02 (t, J4',3' 9.0 Hz, J4',5' 9.0 Hz, 1H, H-4'), 4.83 (dd, 
J2',1' 4.0 Hz, J2',3' 9.0 Hz, 1H, H-2'), 4.78 (t, J2,1 9.0 Hz, J2,3 9.0 Hz, 1H, H-2), 4.74 (d, J1,2 
9.0 Hz, 1H, H-1), 4.53 (dd, J6a,5 2.6 Hz, J6a,6b 12.0 Hz, 1H, H-6a), 4.24-4.19 (m, 2H, H-
6a', H-6b), 4.04 (dd, J6b',5' 2.3 Hz, J6b',6a' 12.4 Hz, 1H, H-6b'), 3.96-3.92 (m, 1H, H-5'), 
3.92 (t, J4,3 9.0 Hz, J4,5 9.0 Hz, 1H, H-4), 3.71 (ddd, J 9.0, 4.9, 2.6 Hz, 1H, H-5), 2.20-
1.97 (m, 21H, 7 x COCH3).  
13C NMR (75 MHz, CDCl3):  C = 170.5, 170.4, 170.3, 
170.1, 169.8, 169.5, 169.4 (7 x COCH3), 133.4 (Ar-mC), 131.2 (Ar-iC), 128.9, 128.4 
(Ar-oC, Ar-pC), 95.6 (C-1'), 84.9 (C-1), 76.4 (C-3), 76.1 (C-5), 72.6 (C-4), 70.7 (C-2), 
70.0 (C-2'), 69.3 (C-3'), 68.5 (C-5'), 68.1 (C-4'), 62.8 (C-6), 61.5 (C-6'). 21.0, 20.9, 20.8, 
20.7, 20.6, 20.6, 20.6, 20.5 (7 x COCH3).
  
 
 
(3.35) Phenyl 2,3-di-O-benzyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)- 
2,3,6-tri-O-benzyl-1-thio-1-deoxy--D-glucopyranoside 
 
Phenyl 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(14)-2,3,6-tri-O-acetyl-1-thio-1-
deoxy--D-glucopyranoside 12 (11 g, 15.09 mmol) and sodium methoxide (1.1 g) were 
stirred at r.t. for 20 h.  The solution was neutralised with Amberlite IRC-120 H+ resin, 
filtered and the solvent removed under reduced pressure.  The resulting syrup, ,-
dimethoxy toluene (5.66 ml, 37.7 mmol) and p-toluenesulfonic acid (0.33 g, 3.00 mmol) 
were dissolved in DMF (80 ml) and rotated on a rotary evaporator at 48°C and at 30 
Torr for 6.5 h.  The solution was neutralised with triethylamine and the solvent removed 
under reduced pressure.  The concentrate was taken up into DMF (70 ml) and TFA (1 
ml) was stirred for 6 h 10 min.  The solution was neutralised with triethylamine and the 
solvent removed under reduced pressure.  The solid was purified by flash column 
chromatography (silica, 95:5→9:1 DCM-MeOH) to afford a white solid.  The solid in 
DMF (20 ml) was added to sodium hydride (60% in mineral oil) (1.73 g, 43.2 mmol) in 
DMF (23 ml).  Benzyl bromide (5.14 ml, 43.2 mmol) was added dropwise to the solution.  
Excess sodium hydride was quenched with methanol and diluted with Et2O (100 ml), 
washed with sat. aq. NaCl (100 ml), dried (MgSO4) and the solvent removed under 
reduced pressure.  The solidf was purified by flash column chromatography (silica, 
4:1→3:1 Hex-EtOAc) to afford a colourless oil (2.15 g, 13%). [lit.148 []d +6.4 (c 1.0, 
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CHCl3)]; []d +3.7 (c 1.0, CHCl3); HRMS: Found ([M+Na]
+) 993.4195, C61H62NaO11 
requires 993.4184; IR (cm-1): 1739 (C=O); 1H NMR (500 ΜΗz, CDCl3); Η = 7.66-7.64 
(m, 2H, ArH), 7.56-7.54 (m, 2H, ArH), 7.45-7.29 (m, 26H, ArH), 7.22-7.19 (m, 7H, ArH), 
5.73 (d, J1',2' 4.0 Hz, 1H, H-1'), 5.58 (s, 1H, Benzylidene acetal-H), 4.96 (d, J 10.5 Hz, 
1H, Bn-H), 4.94 (d, J 10.5 Hz, 1H, Bn-H), 4.87 (d, J 10.5 Hz, 1H, Bn-H), 4.89 (d, J 10.5 
Hz, 1H, Bn-H), 4.78 (d, J 10.5 Hz, 1H, Bn-H), 4.75-4.72 (m, 3H, H-1, 2 x Bn-H), 4.65 (d, 
J 10.5 Hz, 1H, Bn-H), 4.61 (d, J 10.5 Hz, 1H, Bn-H), 4.58 (d, J 10.5 Hz, 1H, Bn-H), 
4.23-4.19 (m, 2H, H-4, H-6a), 4.05 (t, J3',2' 9.0  Hz, J3',4' 9.0  Hz, 1H, H-3'), 3.96-3.85 (m, 
4H, H-3, H-6a', H-6b, H-6b'), 3.70-3.60 (m, 4H, H-2, H-4', H-5, H-5'), 3.55 (dd, J3',2' 9.0  
Hz, J3',4' 9.0  Hz, 1H, H-2').  
13C NMR (75 MHz, CDCl3):  C = 138.7, 138.6, 138.4, 138.3, 
137.9,137.8, 137.6, 134.5, 133.5, 132.2, 132.1, 129.8, 129.0, 128.4, 128.4, 128.4, 
128.3, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 126.2, 
126.1 (42 x Ar-C), 101.2 (C-1'), 97.6 (Benzylidene acetal-H), 87.2 (C-1), 86.9 (C-3), 
82.4 (C-5'), 81.0 (C-2), 78.8 (C-5'), 78.8 (C-2), 78.5 (C-5), 75.3 (Bn-C), 74.2 (Bn-C), 
74.0 (Bn-C), 73.5 (Bn-C), 72.2 (Bn-C), 71.9 (C-4), 69.0 (C-4', C-6), 63.4 (C-6'). 
 
 
(3.36) Phenyl 2,3,6-tri-O-benzyl--D-glucopyranosyl-(14)- 2,3,6-tri-O-benzyl-1-
thio-1-deoxy--D-glucopyranoside 
 
Phenyl 2,3-di-O-benzyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(14)- 2,3,6-tri-O-
benzyl-1-thio-1-deoxy--D-glucopyranoside (2.05 g, 2.10 mmol), trifluoroacetic 
anhydride (0.89 ml, 6.31 mmol), triethylsilane (1.67 ml, 10.51 mmol) in DCM (20 ml) 
were stirred at 0 °C.  Trifluoroacetic acid (0.80 ml, 10.51 mmol) was added dropwise to 
the solution over 15 min.  The solution was diluted with EtOAc (100 ml), washed with 
sat. aq. NaHCO3 (100 ml), sat. aq. NaCl (100 ml), dried (MgSO4) and the solvent 
removed under reduced pressure.  The syrup was purified by flash column 
chromatography (silica, 4:1→2:1 Hex-EtOAc) to afford a colourless oil (1.11 g, 54%).  
[lit.149 []d -11.0 (c 1.0, CHCl3)]; []d -9.80 (c 1.0, CHCl3); IR (cm
-1): 1740 (C=O); HRMS: 
Found ([M+Na]+) 997.3956, C32H40O17SNa requires 997.3966; 
1H NMR (500 ΜΗz, 
CDCl3); Η =  7.65-7.63 (m, 2H, Ar-H), 7.38-7.27 (m, 26H, Ar-H), 7.24-7.18 (m, 7H, Ar-
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H), 5.68 (d, J 3.6 Hz, 1H, H-1'), 4.97 (d, J 12.0 Hz, 1H, Bn-H), 4.93-4.88 (m, 3H, Bn-H), 
4.76 (d, J 12.0 Hz, 1H, Bn-H), 4.74 (d, J1,2 = 9.0 Hz, 1H, H-1), 4.64-4.60 (m, 4H, Bn-H), 
4.55 (d, J 11.8 Hz, 1H, Bn-H), 4.52 (d, J 11.8 Hz, 1H, Bn-H), 4.44 (d, J 12.1 Hz, 1H, 
Bn-H), 4.15 (t, J4,3 = 9.2 Hz, J4,5 = 9.2 Hz, 1H, H-4), 3.94 (dd, J6a,5 = 4.2 Hz, J6a,6b = 11.1 
Hz, 1H, H-6a), 3.90-3.78 (m, 4H, H-3, H-3', H-5', H-6b), 3.73-3.59 (m, 4H, H-2, H-4', H-
5, H-6a'), 3.54 (dd, J6b,5 = 3.8 Hz, J6b,6a = 10.2 Hz, 1H, H-6b'), 3.50 (dd, J2',1' = 3.6 Hz, 
J2',3' = 9.7 Hz, 1H, H-2').   
13C NMR (75 MHz, CDCl3):  C = 138.7, 138.6, 138.4, 137.9, 
137.8, 137.8, 133.6, 132.0, 128.9, 128.4, 128.3, 128.3, 128.2, 127.8, 127.7, 127.6, 
127.6, 127.4, 127.4, 127.2, 126.4 (Ar-C), 96.9 (C-1'), 87.2 (C-1), 86.7 (C-3), 81.2 (C-3'), 
80.9 (C-2), 78.9 (C-5), 78.7 (C-2'), 75.2 (Bn-C), 75.2 (Bn-C), 74.2 (Bn-C), 73.5 (Bn-C), 
73.2 (Bn-C), 73.2 (Bn-C), 72.6 (C-4), 71.4 (C-4'), 70.7 (C-5'), 69.7 (C-6'), 69.1 (C-6). 
 
 
(3.38) 2-(2-(2-chloroethoxy)ethoxy)ethoxytriisopropylsilyl ether 
 
2-(2-(2-chloroethoxy)ethoxy)ethanol 17 (0.86 ml, 5.9 mmol), imidazole (0.80 g, 11.8 
mmol) and triisopropylsilyl chloride (2.53 ml, 11.8 mmol) in DCM (6 ml) were stirred at 
r.t. for 21 h.  The solvent was removed under reduced pressure and the remaining oil 
taken into Et2O (30 ml), washed with sat. aq. NaHCO3 (30 ml) and extracted with Et2O 
(30 ml).  The combined organic fractions were washed with sat. aq. NaCl (30 ml), dried 
(MgSO4) and the solvent removed under reduced pressure.  The oil was purified by 
flash column chromatography (silica, 4:1→3:1 Hex-EtOAc) to afford a colourless oil 
(2.01 g, 98%).  IR (cm-1): 2941, 2891, 2865 (C-H); HRMS: Found ([M+Na]+) 347.1791, 
C32H40O17SNa requires 347.1780; 
1H NMR (500 ΜΗz, CDCl3); Η =  3.83 (t, J 5.5 Hz, 
2H, ClCH2), 3.74 (t, J 5.5 Hz, 2H, SiOCH2), 3.69-3.64 (m, 4H, CH2OCH2CH2OCH2), 
3.61 (t, J 5.5 Hz, 1H, SiOCH2CH2), 3.58 (t, J 5.5 Hz, 1H, ClCH2CH2), 1.09-1.03 (m, 21H, 
(CH3)2CHSi).   
13C NMR (75 MHz, CDCl3):  C = 72.9 (ClCH2CH2), 71.5 (SiOCH2), 70.9, 
70.8 (CH2OCH2CH2OCH2), 63.1 (ClCH2), 42.7 (SiOCH2CH2), 18.2, 18.1, 18.0, 17.9, 
17.8, 12.4, 12.3, 12.1, 12.0 ((CH3)2CHSi). 
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(3.39) Phenyl 2,3,6-tri-O-benzyl-4-2-(2-(2-
(chloroethoxy)ethoxy)ethoxytriisopropylsilyl ether)--D-glucopyranosyl-(14)- 
2,3,6-tri-O-benzyl-1-thio-1-deoxy--D-glucopyranoside 
 
Phenyl 2,3,6-tri-O-benzyl--D-glucopyranosyl-(14)- 2,3,6-tri-O-benzyl-1-thio-1-deoxy-
-D-glucopyranoside 16 (50 mg, 0.05 mmol) in DMF (2.5 ml) had sodium hydride (60% 
in mineral oil) in DMF (2.5 ml) added at 0 °C.  Tetrabutylammonium iodide (3.7 mg, 
0.01 mmol) and 2-(2-(2-chloroethoxy)ethoxy)ethoxytriisopropylsilyl ether (65 mg, 0.20 
mmol) were added dropwise to the stirred solution.  An additional aliquot of sodium 
hydride (60% in mineral oil) (25 mg) and tetrabutylammonium iodide (4 mg) were 
added to the solution.  The reaction was then quenched with MeOH (4 ml) and the 
solvent removed under reduced pressure.  The resulting oil was purified by flash 
column chromatography (silica, 5:1→3:1 Hex-EtOAc) to afford a colourless oil.  The oil 
and tetrabutylammonium fluoride (22 µl, 0.05 mmol) were taken into THF (1.5 ml) and 
stirred at r.t. for 18 h.  The oil was purified by flash column chromatography (silica, 
5:1→3:1 Hex-EtOAc) to afford a colourless oil (20 mg, 20%).  IR (cm-1): 3468 (O-H); 
HRMS: Found ([M+Na]+) 1129.4751, C32H40O17SNa requires 1129.4742; 
1H NMR (500 
ΜΗz, CDCl3); Η = 7.60-7.57 (m, 2H, Ar-H), 7.35-7.22 (m, 26H, Ar-H), 7.18-7.10 (m, 7H, 
Ar-H), 5.58 (d, J 3.7 Hz, 1H, H-1'), 4.93-4.78 (m, 5H, Bn-H), 4.69 (d, J 9.8 Hz, 1H, H-1'), 
4.63-5.53 (m, 5H, Bn-H), 4.46 (d, J 12.0 Hz, 1H, Bn-H), 4.37 (d, J 12.0 Hz, 1H, Bn-H), 
4.08 (t, J 9.0 Hz, 1H, H-4), 3.95-3.71 (m, 6H, H-3, H-3', H-5', H-6a, 2 x PEG-H), 3.70-
3.40 (m, 17 H, H-2, H-2', H-4', H-5, H-6a', H-6b, H-6b', 10 x PEG-H). 
 
 
(4.3) Psuedotetrasaccharide 
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Copper sulfate (0.92 mg, 6 mol) in H2O (2 ml) followed by sodium D-ascorbate in H2O 
(2 ml) were added to SUGAR X (35 mg, 30 mol) and SUGAR X (20 mg, 17 mol) in 
DCM (4 ml) and tBuOH (4 ml) and stirred for 24 h.  DMF (2 ml) was added and the 
solution stirred for another 24  h before Copper sulfate (0.92 mg, 6 mol) in H2O (2 ml) 
followed by sodium D-ascorbate in H2O (2 ml) were added again.  The solution was 
stirred for a final 4 days before being diluted with DCM (15 ml) and washed with H2O 
(15 ml), brine (15 ml) and dried (MgSO4) before being concentrated under reduced 
pressure.  The resulting oil was taken into acetone (0.7 ml) and H2O (30 l) before NBS 
(4.7 mg, 18 mol) was added.  The solution was quenched with EtOAc (10 ml) after 20 
min and the solvent removed under reduced pressure.  The resulting oil was taken into 
methanol (10 ml) with palladium on carbon (10 wt. %, 30 mg) was added and the 
solution put under an atmosphere of hydrogen before stirring for 48 h.  The solution 
was then filtered and concentrated under reduced pressure before purification by size 
exclusion chromatography (LH-20) to give the product as a clear oil (5 mg, 27%). 
HRMS: Found ([M+H]+) 1012.4203, C39H70N3O27
+ requires 1012.4192; 1H NMR (500 
MHz, D2O) δ 8.12 (s, 1H, triazole-H), 5.41 (d, J1,2 = 4.9 Hz, 1H, H-1y'), 5.40 (d, J1,2 = 
4.9 Hz, 1H, H-1x'), 5.24 (d, J 3.8 Hz, 1H, H-1y), 4.66 (m, 1H, H-1y), 4.49 (d, J1,2 = 
7.9 Hz, 1H, H-1x), 3.98 – 3.46 (m, 17H), 3.36 (t, J 9.5 Hz, 1H), 3.26 (dd, J 9.6, 8.2 Hz, 
2H), 3.21 (dd, J 9.5, 8.0 Hz, 1H). 
 
 
(4.4) Phenyl 2,3,6-tri-O-benzyl-4-2-(2-(2-(ethoxy)ethoxy)ethoxypropargyl ether)--
D-glucopyranosyl-(14)- 2,3,6-tri-O-benzyl-1-thio-1-deoxy--D-glucopyranoside 
 
Sodium hydride in oil (30 mg, 76.5 mmol) was added to Phenyl 2,3,6-tri-O-benzyl-4-2-
(2-(2-(chloroethoxy)ethoxy)ethoxytriisopropylsilyl ether)--D-glucopyranosyl-(14)- 
2,3,6-tri-O-benzyl-1-thio-1-deoxy--D-glucopyranoside (500 mg, 0.45 mmol) in DMF (5 
ml) at 0 °C.  Propargyl bromide (334 mg, 2.25 mmol) was then added dropwise and the 
solution allowed to stir for 1 h.  The reaction was then quenched with methanol and the 
solution concentrated under reduced pressure. The oil was taken into EtOAc (200 ml), 
washed with H2O (200 ml), sat. aq. NaCl (200 ml), dried (MgSO4) and concentrated 
under reduced pressure.  The oil was purified by flash column chromatography (silica, 
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3:1→2:1  Hex-EtOAc) to afford a colourless oil (141 mg, 27%); HRMS: Found 
([M+NH4]
+) 1162.5363, C69H80NO13S
+ requires 1162.5345; 1H NMR (500 ΜΗz, CDCl3); 
Η = 7.60-7.57 (m, 2H, Ar-H), 7.35-7.22 (m, 26H, Ar-H), 7.18-7.10 (m, 7H, Ar-H), 5.54 
(d, J 3.7 Hz, 1H, H-1'), 4.93-4.78 (m, 5H, Bn-H), 4.66 (d, J 9.8 Hz, 1H, H-1'), 4.63-5.53 
(m, 5H, Bn-H), 4.46 (d, J 12.0 Hz, 1H, Bn-H), 4.37 (d, J 12.0 Hz, 1H, Bn-H), 4.11 (d, J 
2.4 Hz, 2H, H-9), 4.08 (t, J 9.0 Hz, 1H, H-4), 3.95-3.71 (m, 6H, H-3, H-3', H-5', H-6a, 2 
x PEG-H), 3.70-3.40 (m, 17 H, H-2, H-2', H-4', H-5, H-6a', H-6b, H-6b', 10 x PEG-H), 
2.37 (t, J 2.4 Hz, 1H, H-7); 13C NMR (126 MHz, CDCl3) Η = 138.7, 138.6, 138.4, 138.0, 
137.9, 137.7 (6 x Ar-C), 133.6 (Ph-C), 131.9 (Ph-CH), 128.8, 128.2, 128.2, 128.1, 
128.1, 128.1, 127.8, 127.7, 127.7, 127.5, 127.4, 127.4, 127.3, 127.0, 126.4 (30 x Ar-CH, 
4 x Ph-CH), 97.2 (C-1'), 87.1 (C-1), 86.5 (C-3), 81.6 (C-3'), 80.8 (C-2), 79.5 (C-7), 79.1 
(C-2'), 78.7, 78.2 (C-4'), 75.3, 75.1, 74.4, 74.3, 73.3, 73.3, 73.2 (6 x Bn-CH2, C-4), 72.0 
(C-5), 71.0, 70.6, 70.5, 70.3, 70.3, 69.1 (6 x PEG-CH2), 69.0 (C-6), 58.2 (C-9). 
 
 
(4.6) 2-(2-(2-azidoethoxy)ethoxy)ethoxy 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-
(14)-2,3,6-tri-O-acetyl--D-glucopyranoside 
 
2-(2-(2-chloroethoxy)ethoxy)ethoxy 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(14)-
2,3,6-tri-O-acetyl--D-glucopyranoside (1 g, 2.03 mmol), sodium azide (1.32 g, 20.3 
mmol) and tetrabutylammonium iodide (74 mg, 0.20 mmol) were stirred in DMF (30 ml) 
at 80 °C for 26 h.  The solution was then diluted with Et2O (200 ml), washed with H2O 
(100 ml x 3), dried (MgSO4) and concentrated under reduced pressure.  The resulting 
solid was purified by flash column chromatography (silica, 2:1 EtOAc‒Hex) to afford a 
colourless oil (0.57 g, 55%).  HRMS: Found ([M+NH4]
+) 811.3092, C32H47N3NaO20+ 
requires 811.3112; 1H NMR (500 MHz, Chloroform-d) Η 5.42 (d, J1',2' = 4.0 Hz, 1H, H-
1'), 5.37 (dd, J3',2' = 10.6, J3',4' = 9.5 Hz, 1H, H-3'), 5.26 (t, J3,2 = 9.1 Hz, J3,4 = 9.1 Hz, 1H, 
H-3), 5.06 (t, J4',3' = 9.9 Hz, J4',5' = 9.9 Hz, 1H, H-4'), 4.87 (dd, J2',1' = 4.0 Hz, J2',3' = 10.6 
Hz, 1H, H-2'), 4.82 (dd, J2,1 = 7.8 Hz, J2,3 = 9.1 Hz, 1H, H-2), 4.64 (d, J1,2 = 7.8 Hz, 1H, 
H-1), 4.49 (dd, J6a,5 = 2.8 Hz, J6a,6b = 12.1 Hz, 1H, H-6a), 4.26 (dd, J6a',5' = 4.2 Hz, J6a',6b' 
= 12.3 Hz, 1H, H-6a'), 4.23 (dd, J6b,5 = 4.2 Hz, J6b,6a = 12.1 Hz, 1H, H-6b),  4.05 (dd, 
J6b',5' = 2.3 Hz, J6b',6a' = 12.3 Hz, 1H, H-6b'), 4.01 (dd, J4,3 = 9.1 Hz, J4,5 = 8.8 Hz, 1H, H-
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4), 3.98 – 3.90 (m, 2H, H-5', H-8a), 3.79 – 3.62 (m, 10H, H-5, H-8b, H-9, H-10, H-11, H-
12), 3.42 (t, J13,12 = 5 Hz, 2H, H-13), 2.20 – 1.97 (m, 21H, 7 x COCH3).  
13C NMR (126 
MHz, CDCl3) C 170.5, 170.5, 170.2, 169.9, 169.6, 169.4, (7 x COCH3), 100.3 (C-1), 
95.54 (C-1'), 75.4 (C-3), 72.8 (C-4), 72.16 (C-2), 72.1, 70.7, 70.4, 70.0,  (C-8, C-9, C-10, 
C-11, C-12), 70.00 (C-2'), 69.3 (C-5), 69.1 (C-3'), 68.5 (C-5'), 68.0 (C-4'), 62.9 (C-6), 
61.5 (C-6'), 50.7 (C-12), 20.90, 20.83, 20.67, 20.64, 20.56 (7 x COCH3). 
 
 
(4.7) 2-(2-(2-azidoethoxy)ethoxy)ethoxy 2,3,4,6-tetra-O-benzyl--D-
glucopyranosyl-(14)-2,3,6-tri-O-benzyl--D-glucopyranoside 
 
2-(2-(2-azidoethoxy)ethoxy)ethoxy -D-glucopyranosyl-(14)--D-glucopyranoside 
(0.56 g, 1.13 mmol) in DMF (10 ml) had sodium hydride (60% in oil) (0.63 g, 15.82 
mmol) added at 0 °C.  The solution was stirred for 40 min before the dropwise addition 
of benzyl bromide (1.88 ml, 15.82 mmol).  The solution was stirred for a subsequent 4 
h before being quenched with MeOH (10 ml).  The solvent was removed under reduced 
pressure and the resulting oil taken into EtOAc (50 ml) and washed with H2O (50 ml), 
brine (50 ml) and dried (MgSO4) before concentration under reduced pressure.  The 
resulting oil was purified by flash column chromatography (silica, 4:1 Hex‒EtOAc) to 
afford a colourless oil (0.33 g, 27%); HRMS: Found ([M+NH4]
+) 1147.5673, 
C67H79N4O13
+ requires 1147.5639; 1H NMR (500 MHz, Chloroform-d) H 7.37 – 7.05 (m, 
35H, Ar-H), 5.68 (d, J1',2' = 3.7 Hz, 1H, H-1'), 4.95 (d, J 11.2 Hz, 1H, Bn-H), 4.93 (d, J 
11.2 Hz, 1H, Bn-H), 4.88 (d, J 10.8 Hz, 1H, Bn-H), 4.81 – 4.73 (m, 3H, Bn-H), 4.64 – 
4.43 (m, 9H, 8 x Bn-H, H-1), 4.32 (d, J 12.2 Hz, 1H, Bn-H), 4.09 – 4.02 (m, 2H, H-3, H-
8a), 3.90 (t, J3',2' = 9.4 Hz, J3',4' = 9.4 Hz, 1H, H-3'), 3.84 – 3.69 (m, 7H, H-2, H-6a', H-8b, 
H-9, H-12), 3.67 – 3.61 (m, 3H, H-4', H-5, H-6a), 3.60 – 3.51 (m, 7H, H-4, H-5', H-6b, 
H-10, H-11), 3.49 (dd, J2',1' = 3.7 Hz, J2',3' = 9.9 Hz, 1H, H-2'), 3.44 (dd, J6b,5 = 2.0 
Hz,J6b,6a = 10.7 Hz1H, H-6b'), 3.26 (dd, J 5.8, 4.4 Hz, 2H, H-13). 
 
(4.13) 2-(1-Hydroxyethylidene)-5,5-dimethyl-1,3-cyclohexanedione 
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Dimedone (5 g, 35.7 mmol), acetic acid (2.04 ml, 35.7 mmol), dimethylamino pyridine 
(4.36 g, 35.7 mmol) and N,N'-Dicyclohexylcarbodiimide (7.35 g, 35.7 mmol) in DMF 
were stirred at r.t. for 21.5 h.  The solution was filtered and the solvent removed under 
reduced pressure, the residue taken into EtOAc (100 ml), dried (MgSO4) and the 
solvent removed under reduced pressure.  The residue was again taken into EtOAc 
(100 ml), washed with sat. aq. NaCl, dried (MgSO4) and the solvent removed under 
reduced pressure.  The solid was purified by flash column chromatography (silica, 
EtOAc) to afford a colourless solid (1.01 g, 20%).  IR (cm-1): 3458 (O-H), 1710 (C=O); 
HRMS: Found ([M+Na]+) 183.1015, C10H15O3 requires 183.1016; 
1H NMR (500 ΜΗz, 
CDCl3); Η = 2.59 (s, 3H, C=CCH3), 2.55 (s, 2H, CH2), 2.37 (s, 2H, CH2), 1.09 (s, 6H, 
C(CH3)); 
13C NMR (75 MHz, CDCl3):  C = 202.2 (C=O), 197.7 (C=O), 194.8 (C=COH), 
112.2 (C=COH), 52.3 (CH2), 46.7 (CH2), 30.5 (C(CH3)2), 28.4 (C=CCH3), 28.0 
(C(CH3)2). 
 
 
(4.15) Fmoc-lys(dansyl)-OH 
 
Lys(dansyl)-OH (0.5 g, 2.45 mmol) in 10% aq. Na2CO3 (6.5 ml) had 
Fluorenylmethyloxycarbonyl chloride (0.64 g, 2.45 mmol) in dioxane (4.5 ml) added at 
0 °C, the solution was allowed to warm to r.t. and stirred for 21 h.  The solution was 
diluted with EtOAc (25 ml), washed with 5% aq. KHSO4 (50 ml), dried (MgSO4) and the 
solvent removed under reduced pressure.  The solid was purified by flash column 
chromatography (silica, 1:0→9:1 DCM-MeOH then 50:50:2 EtOAc-Hex-AcOH) to give 
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a fluorescent green solid (630 mg, 43%). [lit.150 []d +1.7 (c 1.0, CH2Cl2)]; []d +5.0 (c 
1.0, CHCl3); IR (cm
-1): 3276 (O-H), 1698 (C=O);  HRMS: Found ([M+H]+) 602.2333, 
C33H36N3O6S requires 602.2319;  
1H NMR (500 ΜΗz, CDCl3); Η Dansyl: 8.52 (d, J 8.5 
Hz, 1H, Ar-H), 8.37 (d, J 8.5 Hz, 1H Ar-H), 8.21 (d, J 6.8 Hz, 1H Ar-H), 7.58-7.54 (m, 
1H, Ar-H), 7.33-7.21 (m, 1H, Ar-H), 7.13 (d, J 7.6 Hz, 1H, Ar-H), 2.86 (6H, s, N(CH3)2) 
Fmoc: 7.76 (d, J 7.7 Hz, 2H, Ar-H), 7.60 (d, J 7.7 Hz, 2H, Ar-H), 7.38-7.36 (m, 2H, Ar-
H), 7.33-7.21 (m, 2H, Ar-H), 4.44 (d, J 6.9 Hz, 2H, CH2-CH), 4.21 (t, J 6.9 Hz, 1H, 
CH2-CH) Lys: 5.30 (d, J 8.1 Hz, 1H, C(O)NH), 5.05 (t, J 6.1 Hz, 1H, SO2NH), 4.30-4.22 
(m, 1H, H), 2.92-3.83 (m, 2H, 2 x H), 1.74-1.66 (m, 1H, H'), 1.55-1.44 (m, 1H, H''), 
1.44-1.33 (m, 2H, 2 x H), 1.33-1.13 (m, 2H, 2 x H).  13C NMR (75 MHz, CDCl3):  C = 
Dansyl: 151.3, 129.9, 129.6 (Ar-C), 130.1, 129.6, 126.9, 123.3, 119.0, 115.3 (Ar-CH), 
30.9 (NCH3), Fmoc: 176.5 (NHC=O), 143.7 (Ar-C), 143.6 (Ar-C), 128.2, 127.7, 125.1, 
119.8 (Ar-CH), 67.0 (CH2-CH), 47.0 (CH2-CH), Lys: 176.1 (COOH), 53.3 (C), 42.6 
(C), 31.5 (C), 28.8 (C), 22.0 (C). 
 
 
(4.17) N'-Boc-aminooxyacetyl N-hydroxysuccinimide ester151 
 
A solution of Boc-aminooxyacetic acid (953 mg, 4.98 mmol), N-hydroxysuccinimide 
(631 mg, 5.48 mmol) and dicyclohexylcarbodiimide (1.13 g, 5.48 mmol) in 1:1 (v/v) 
ethyl acetate-hexane (20 mL) was stirred for 3 h at r.t. and then filtered through a celite 
pad. The filtrate was re-dissolved in ethyl acetate (25 mL), washed with 1% aq. 
NaHCO3 (2 x 25 mL), water (2 x 25 mL) and aq. NaCl (2 x 25 mL), and azeotroped 
three times with toluene to afford the product (1.178 g, 78%) as a crude colourless 
foam, which was used in SPPS without any further purification. 1H NMR (300 MHz, 
CDCl3) δ 7.96 (s, 1H, NH), 4.78 (s, 2H, CH2), 2.88 (s, 4H, CH2), 1.49 (s, 9H, CH3);
 13C 
NMR (75 MHz, CDCl3) δ 168.88, 165.06, 156.35, 82.63, 70.79, 28.11, 25.57. 
 
 
(4.29) 1-(N-Boc-(carboxymethoxy)amino)-heptane-7-((N-Boc-(amine)) 
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N-Boc-1,6-diaminohexane (183 l, 0.82 mmol), Boc-aminooxy-acetic acid NHS ester 
(250 mg, 0.82 mmol) and triethylamine (114 l, 0.82 mmol) in DMF (1 ml) were stirred 
at r.t. for 20 h.  MS: Found ([M+Na]+) 412.2, C18H35N3NaO6
+ requires 412.2. 1H NMR 
(500 MHz, CDCl3) δH 8.34 (s, 1H, H-4), 8.09 (s, 1H, H-14), 4.66 (s, 1H, H-7), 4.25 (s, 
2H, H-5), 3.24 (dt, J 6.7 Hz, J 6.7 Hz, 2H, H-13), 3.05 (dt, J 6.8 Hz, J 6.8 Hz, 2H, H-8), 
1.43 – 1.53 (m, 2H, H-12), 1.45 – 1.37 (m, 2H, H-9), 1.43 (s, 9H, H-1), 1.39 (s, 9H, H-
17), 1.35 – 1.23 (m, 4H, H-10, H-11). 13C NMR (126 MHz, CDCl3) δC 168.8 (C-3), 157.8 
(C-15), 156.0 (C-6), 82.6 (C-2), 78.9 (C-16), 75.9 (C-5), 40.3 (C-8), 38.7 (C-13), 29.8 
(C-9), 29.0 (C-12), 28.3 (C-1), 28.0 (C-17), 26.3 (C-10), 26.2 (C-11). 
 
 
(4.31) 6-(1-((carboxymethoxy)amino)-heptane-7-(((amino))) fluorescein 
maltoheptaose 
 
1-(N-Boc-(carboxymethoxy)amino)-heptane-7-((N-Boc-(amine)) (50 mg, 0.13 mmol) 
was stirred in TFA (200 l) for 15 min.  The TFA was removed under a stream of N2 
and maltoheptaose (75 mg, 0.065 mmol) in sodium acetate buffer (500 l, 0.1 M, pH 
4.0) was added and allowed to stir for 6 d.  The solution was purified by size exclusion 
chromatography (LH-20) before FITC (11.8 mg, 0.03 mmol) in DMF (1.2 ml) was added 
in sodium bicarbonate (1.2 ml, pH 8.5, 0.185 M) and the solution stirred for 24 h.  To 
purify the product it was applied directly to a size exclusion column (LH-20) yielding the 
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product as an orange oil (45 mg, 38%). HRMS: Found ([M+H] +) 1713.5601, 
C71H101N4O42S
+ requires 1713.5606. 
 
 
 
(5.1) O-(2-(t-Butoxycarbonyl-N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol 
  
 (t-Butoxycarbonyl-N′-methylaminooxyacetyl)-N-hydroxysuccinimide ester (180 mg, 
0.61 mmol), O-(2-aminoethyl)-O'-(2-azidoethyl)nonaethylene glycol (200 mg, 0.38 
mmol) and triethylamine (29 l, 0.21 mmol) were stirred in DMF (1 ml) for 48 h.  The 
product was concentrated under reduced pressure and taken into EtOAc (20 ml), 
washed with sat. aq. NaHCO3 (15 ml), sat. aq. NaCl (15 ml), dried (MgSO4) and 
concentrated under reduced pressure.  The resulting oil was purified by flash column 
chromatography (silica, 4:1 EtOAc‒MeOH) to afford a colourless oil (201 mg, 74%). 
HRMS: Found ([M+NH4]
+) 731.4433, C30H63N6O14
+ requires 731.4397; 1H NMR (500 
MHz, CDCl3) Η 8.04 (s, 1H, H-7), 4.32 (s, 2H, H-5), 3.71 – 3.61 (m, 38H, H-9, H-10, H-
11), 3.58 (t, J 5.6 Hz, 2H, ), 3.50 (t, J 5.6 Hz, 3H), 3.39 (t, J 5.1 Hz, 3H), 3.11 (s, 3H, H-
4), 1.50 (s, 9H, H-1). 13C NMR (126 MHz, MeOD) C 170.4 (C-3), 158.4 (C-6), 82.9 (C-
2), 73.8 (C-5), 70.7, 70.5, 70.4 (C-10, C-11, C-12, C-13), 51.0 (C-8), 39.2 (C-7), 37.0 
(C-4), 27.7 (C-1). 
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(5.3) O-(2-(N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-azidoethyl)nonaethylene 
glycol maltoheptaose 
 
O-(2-(t-Butoxycarbonyl-N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol (10 mg, 0.014 mmol) was stirred in TFA (200 l) for 30 
min before the TFA was removed under a stream of nitrogen.  The residue was taken 
into sodium acetate buffer (100 l, 0.1 M, pH 4.0) containing maltoheptaose (16.1 mg, 
0.014 mmol) and stirred for 7 days.  The solution was applied directly to a size 
exclusion column (LH-20) to yield the product as a colourless oil (16 mg, 15%).  HRMS: 
Found ([M+NH4+NH4]
2+) 891.8955, C67H129N7O47
2+ requires 891.8954; 1H NMR (500 
MHz, Deuterium Oxide) δ 5.34 (d, J 3.8 Hz, 6H, 6 x H-1'), 4.27 (s, 2H, H-8), 3.90 (t, J 
9.5 Hz, 7H, 7 x H-3'), 3.84 – 3.70 (m, 21H, 6 x H-5', 6 x H-6a', 6 x H-6b', H-5, H-6a, H-
6b), 3.70 – 3.47 (m, 56H, 5 x H-4', H-4, 6 x H-2', PEG-CH2), 3.37 (t, J4',3' = 9.6 Hz, J4',5' 
= 9.6 Hz, 1H, H-4'), 3.29 (t, J2,1 = 8.0 Hz, J2,3 = 8.0 Hz, 1H, H-2), 2.75 (s, 3H, H-7). 
 
 
(5.8) Benzyl 2,3-di-O-benzyl-(R)-4,6-O-benzylidene--D-glucopyranosyl-(1⟶4)-
2,3,6-tri-O-benzyl-O--D-glucopyranose 
 
Maltose (1.05 g, 2.92 mmol), ,-dimethoxy toluene (1.09 ml, 7.3 mmol) and p-
toluenesulfonic acid (0.06 g, 0.58 mmol) were dissolved in DMF (7.2 ml) and rotated on 
a rotary evaporator at 48°C and at 30 Torr for 6.5 h.  The solution was neutralised with 
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triethylamine and the solvent removed under reduced pressure.  The concentrate was 
taken up into DMF (7 ml) and TFA (0.1 ml) was stirred for 6 h 10 min.  The solution was 
neutralised with triethylamine and the solvent removed under reduced pressure.  The 
solid was purified by flash column chromatography (silica, 4:1 (v/v) CHCl3 –MeOH) to 
afford a white solid.  The solid and sodium hydride (60% in mineral oil) (1.17 g) were 
stirred in DMF (25 ml) at 0 °C.  Benzyl bromide (3.47 ml) was added dropwise and  the 
solution allowed to stir at r.t. for 20 h. Excess sodium hydride was quenched with 
methanol and diluted with Et2O (20 ml), washed with sat. aq. NaCl (20 ml), dried 
(MgSO4) and the solvent removed under reduced pressure.  The solid was purified by 
flash column chromatography (silica, 4:1→3:1 Hex-EtOAc) to afford a colourless oil 
(626 mg, 21%). HRMS: Found ([M+NH4]
+) 988.4654, C61H66NO11
+ requires 988.4631; 
IR (cm-1): 1740 (C O); 1H NMR (500 ΜΗz, CDCl3); Η   7.81 (m, 7H Ar-H), 7.69-7.38 
(m, 130H, Ar-H), 6.09 (d, J 3.8 Hz, 1H, H-1'), 6.03(d, J 3.9 Hz, 1H, H-1'), 5.78 (s, 1H, 
benzylidene acetal), 5.38 (d, J 11.8 Hz, 1H, Bn-H), 5.32-4.70 (m, 15H, Bn-H), 4.49-4.44 
(m, 2H), 4.36-4.01 (m, 5H), 3.92-3.87 (m, 4H), 3.79 (dd, J 9.4 Hz, J 4.2 Hz, 1H, H-2); 
13C NMR (75 MHz, CDCl3):  C = 139.3, 139.0, 139.0, 139.0, 138.5, 138.5, 138.5, 
138.2, 138.2, 138.0, 137.9, 137.7, 137.4, 129.3, 129.2, 129.1, 128.7, 128.7, 128.6, 
128.6, 128.5, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 
127.9, 127.8, 127.8, 127.7, 127.5, 127.4, 127.4, 126.9, 126.8, 126.3, 125.6 (42 x Ar-C), 
102.6 (C-1), 101.3 (benzylidene acetal-C), 97.5 (C-1'), 95.3 (C-1), 85.2, 82.4, 82.5, 
82.5, 82.6, 80.6, 79.1, 79.0, 79.0, 78.9, 77.7, 77.6, 77.4, 77.2, 75.4, 75.4, 74.9, 74.6, 
74.4, 74.1, 73.9, 73.9, 73.7, 73.6, 73.4, 73.1, 73.1, 72.3, 72.0, 71.2, 70.0, 69.4, 69.2, 
69.1, 68.9, 63.5, 29.9, 21.7. 
 
 
(5.9) Benzyl 2,3,6-tri-O-benzyl--D-glucopyranosyl-(1⟶4)-2,3,6-tri-O-benzyl-O--
D-glucopyranose 
 
TFA (2 ml, 23.38 mmol) was added dropwise to Benzyl 2,3-di-O-benzyl-(R)-4,6-O-
benzylidene--D-glucopyranosyl-(1⟶4)-2,3,6-tri-O-benzyl-O--D-glucopyranose (4.70 
g, 6.67 mmol), triethylsilane (4.20 ml, 23.38 mmol) and TFAA (2.23 ml, 14.03 mmol) in 
DCM (50 ml).  The solution was stirred for 20 h before dilution into EtOAc (200 ml) and 
190 
 
washing with sat. aq. NaHCO3 (200 ml), sat. aq. NaCl (200 ml), dried (MgSO4) and 
concentrated under reduced pressure.  The resulting oil was purified by flash column 
chromatography (silica, 3:1 Hex-EtOAc) to afford a colourless oil (2.8 g, 59%). HRMS: 
Found ([M+NH4]
+) 990.4820, C61H68NO11
+ requires 990.4787; 
Major isomer – 1H NMR (500 MHz, CDCl3) δ 7.52 – 7.13 (m, 35H, Ar-H), 5.77 (d, J1,2 = 
3.6 Hz, 1H, H-1), 5.73 (d, J 3.6 Hz, 1H, H-1'), 5.13 (d, J 11.7 Hz, 1H, Bn-H), 5.05 – 4.85 
(m, 5H, Bn-H), 4.84 – 4.36 (m, 9H, Bn-H), 4.19 – 4.09 (m, 1H, H-4), 3.92 (dd, J6a,6b = 
11.0 Hz, J6a,5 = 4.4 Hz, 1H, H-6a), 3.89 – 3.78 (m, 4H, H-3, H-3', H-5', H-6b), 3.73 – 
3.61 (m, 2H, H-4', H-5), 3.56 (m, 2H, H-6a', H-6b'), 3.53 – 3.47 (m, 1H, H-2), 3.49 (dd, 
J2,1 = 3.6 Hz, J2,3 = 9.7 Hz, 1H, H-2'), 2.69 – 2.61 (m, 1H, 4'-OH).  
13C NMR (126 MHz, 
CDCl3) δ 138.8, 138.6, 138.6, 138.2, 138.1, 138.0, 137.8, 137.7, 137.7, 137.2, 136.9 
(Ar-C), 133.9, 128.2, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 
127.6, 127.5, 127.5, 127.4, 127.4, 127.3, 127.2, 127.2, 127.1, 126.9, 126.9, 126.5, 
126.4 (Ar-CH), 99.6 (C-1'), 96.4 (C-1), 84.6 (C-3), 81.0 (C-3'), 80.0 (C-5), 78.8 (C-2), 
78.7 (C-2'), 75.0, 74.4, 74.0, 73.6, 73.3, 73.3, 73.1, (Bn-C), 72.9 (C-4), 72.8 (Bn-C), 
72.4, 72.2 (Bn-C), 71.1 (C-4'), 70.7 (C-5'), 69.5 (C-6'), 68.9 (C-6). 
Minor isomer – 1H NMR (500 MHz, CDCl3) δ 7.52 – 7.13 (m, 35H, Ar-H), 5.73 (d, J 3.6 
Hz, 1H, H-1'), 5.13 (d, J 11.7 Hz, 1H, Bn-H), 5.05 – 4.85 (m, 6H, Bn-H, H-1), 4.84 – 
4.36 (m, 9H, Bn-H), 4.23 (t, J 9.1 Hz, 1H, H-3), 4.19 – 4.09 (m, 1H, H-4), 4.03 – 3.98 
(m, 1H, H-5), 3.92 (dd, J6a,6b = 11.0 Hz, J6a,5 = 4.4 Hz, 1H, H-6a), 3.89 – 3.78 (m, 2H, H-
3', H-5'), 3.73 – 3.61 (m, 3H, H-2, H-4', H-6b), 3.56 (m, 2H, H-6a', H-6b'), 3.49 (dd, J2,1 
= 3.6 Hz, J2,3 = 9.7 Hz, 1H, H-2'), 2.69 – 2.61 (m, 1H, 4'-OH).
 13C NMR (126 MHz, 
CDCl3) δ 138.8, 138.6, 138.6, 138.2, 138.1, 138.0, 137.8, 137.7, 137.7, 137.2, 136.9 
(Ar-C), 133.9, 128.2, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 
127.6, 127.5, 127.5, 127.4, 127.4, 127.3, 127.2, 127.2, 127.1, 126.9, 126.9, 126.5, 
126.4 (Ar-CH), 99.6 (C-1'), 94.8 (C-1), 82.0 (C-2), 81.8 (C-3), 81.0 (C-3'), 78.7 (C-2'), 
75.0, 74.4, 74.0, 73.6, 73.3, 73.3, 73.1, (Bn-C), 72.8 (Bn-C), 72.6 (C-4), 72.4, 72.2 (Bn-
C), 71.1 (C-4'), 70.7 (C-5'), 70.5 (C-5), 69.5 (C-6'), 68.9 (C-6). 
 
 
(5.10) 2-(2-(2-chloroethoxy)ethoxy)ethoxypropargyl ether  
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A stirred solution of sodium hydride (0.94 g, 23.6 mmol) in THF (20 ml) had 2-[2-(2-
chloroethoxy)ethoxy]ethanol (2 g, 11.8 mmol) added dropwise at 0 °C.  After 30 min 
propargyl bromine (2.3 ml, 23.6 mmol) was added dropwise, the solution was stirred for 
1.5 h before more propargyl bromide (0.8 ml, 8.2 mmol) was added.  The resulting 
solution was stirred for 1.5 h before being diluted into EtOAc (200 ml), washed with 
H2O (200 ml), sat. aq. NaCl (200 ml), dried (MgSO4) and concentrated under reduced 
pressure to give a yellow oil.  The oil was purified by flash column chromatography 
(silica, 3:1 Hex-EtOAc) to afford a yellow oil (400 mg, 35%); HRMS: Found ([M+NH4]
+) 
224.1061, C9H19ClNO3
+ requires 224.1048; 1H NMR (500 MHz, CDCl3) δH 4.21 (d, J 2.5 
Hz, 2H, H-3), 3.77 (t, 2H J 6.0 Hz, 1H, H-8), 3.75 – 3.61 (m, 10H, H-4, H-5, H-6, H-7, 
H-9), 2.60 (t, J 2.5 Hz, 1H, H-1).  13C NMR (126 MHz, CDCl3) δC 79.8 (C-2), 74.9 (C-1), 
71.3 (C-8), 70.5, 70.3, 69.0 (C-4, C-5, C-6, C-7), 58.2 (C-3), 42.9 (C-9). 
 
 
(5.11) Benzyl 2,3,6-tri-O-benzyl-4-2-(2-(2-(ethoxy)ethoxy)ethoxypropargyl ether)-
-D-glucopyranosyl-(14)- 2,3,6-tri-O-benzyl--D-glucopyranoside 
 
To a stirred solution of Benzyl 2,3,6-tri-O-benzyl--D-glucopyranosyl-(1⟶4)-2,3,6-tri-
O-benzyl-O--D-glucopyranose (1.0 g, 1.02 mmol), 2-(2-(2-
chloroethoxy)ethoxy)ethoxypropargyl ether (426 mg, 2.04 mmol) and 
tetrabutylammonium iodide (37 mg, 0.10 mmol) in DMF (50 ml) sodium hydride (60% in 
oil) (70 mg, 1.73 mmol) was added at 0 °C.  The solution was diluted into EtOAc (200 
ml), washed with H2O (200 ml), sat. aq. NaCl (200 ml), dried (MgSO4) and 
concentrated under reduced pressure.  The oil was purified by flash column 
chromatography (silica, 3:1→2:1 Hex-EtOAc) to afford a colourless oil (422 mg, 36%); 
HRMS: Found ([M+NH4]
+) 1160.5770, C70H82NO14
+ requires 1160.5730;  
 - Major isomer: 1H NMR (500 MHz, CDCl3) δH 7.52 – 7.06 (m, 35H, Ar-H), 5.61 (d, 
J1',2' 3.7 Hz, 1H, H-1'), 5.03 (d, J 11.6 Hz, 1H, Bn-H), 4.99 – 4.89 (m, 3H, Bn-H), 4.83 
(m, 2H, H-1, Bn-H), 4.77 (d, J 11.7 Hz, 1H, Bn-H), 4.74 – 4.44 (m, 6H, Bn-H), 4.39 (d, J 
12.1 Hz, 1H, Bn-H), 4.35 (d, J 12.1 Hz, 1H, Bn-H), 4.14 (d, J 2.4 Hz, 2H, H-9), 4.12 (t, 
J3,2 10.0 Hz, J3,4 10.0 Hz, 1H, H-3), 4.04 (t, J4,3 10.0 Hz, J4,5 10.0 Hz, 1H, H-4), 3.90 
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(ddd, J5,4 10.0 Hz, J5,6a 5.9 Hz, J5,6b 3.7 Hz, 1H, H-5), 3.87 – 3.66 (m, 2H, H-3', H-5'), 
3.66 – 3.51 (m, 17H, H-2, H-4', H-6a', H-6b, H-6b', H-10, H-11, H-12, H-13 , H-14, H-
15), 3.51 – 3.39 (m, 2H, H-2', H-6b'), 2.40 (t, J 2.4 Hz, 1H, H-7); 13C NMR (126 MHz, 
CDCl3) δ 138.8, 138.4, 138.2, 138.0, 137.9, 137.4 (Ar-C), 128.3, 128.1, 128.1, 127.9, 
127.8, 127.8, 127.5, 127.5, 127.4, 126.9, 126.6, 126.5 (Ar-CH), 96.8 (C-1'), 95.2 (C-1), 
82.2 (C-3'), 81.6 (C-3), 79.1 (C-2'), 75.3, 74.6, 74.6, 74.4, 73.9, 73.3, 73.3, 73.2, 73.1, 
73.1 (7 x Bn-C, C-2, C-4, C-4'), 72.0 , 71.0, 70.9, 70.6, 70.5, 70.3, 70.3 (6 x PEG-C, C-
5, C5'), 69.2 (C-6'), 69.0 (C-6), 58.3 (C-9). 
 - Minor isomer: 1H NMR (500 MHz, CDCl3) δH 7.52 – 7.06 (m, 35H, Ar-H), 5.64 (d, 
J1,2 = 3.7 Hz, 1H, H-1), 5.61 (d, J1',2' = 3.7 Hz, 1H, H-1'), 5.03 (d, J 11.6 Hz, 1H, Bn-H), 
4.99 – 4.89 (m, 3H, Bn-H), 4.83 (m, 1H, Bn-H), 4.77 (d, J 11.7 Hz, 1H, Bn-H), 4.74 – 
4.44 (m, 6H, Bn-H), 4.39 (d, J 12.1 Hz, 1H, Bn-H), 4.35 (d, J 12.1 Hz, 1H, Bn-H), 4.14 
(d, J 2.4 Hz, 2H, H-9), 4.06 (t, J4,3 = 10.0 Hz, J4,5 = 10.0 Hz, 1H, H-4), 3.87 – 3.66 (m, 
4H, H-3', H-3, H-5', H-6a), 3.66 – 3.51 (m, 16H, H-4', H-5, H-6a', H-6b, H-10, H-11, H-
12, H-13 , H-14, H-15), 3.51 – 3.39 (m, 3H, H-2, H-2', H-6b'), 2.40 (t, J 2.4 Hz, 1H, H-7); 
13C NMR (126 MHz, CDCl3) δC 138.8, 138.4, 138.2, 138.0, 137.9, 137.4 (Ar-C), 128.3, 
128.1, 128.1, 127.9, 127.8, 127.8, 127.5, 127.5, 127.4, 126.9, 126.6, 126.5 (Ar-CH), 
96.8 (C-1, C-1'), 84.6 (C-3), 82.2 (C-3'), 79.6 (C-2), 79.1 (C-2'), 75.3, 74.6, 74.6, 74.4, 
73.9, 73.3, 73.3, 73.2, 73.1, 73.1 (7 x Bn-C, C-4, C-4', C-5), 72.0 , 71.0, 70.9, 70.6, 
70.5, 70.3, 70.3 (6 x PEG-C, C5'), 69.2 (C-6'), 68.2 (C-6), 58.3 (C-9). 
 
 
(5.16a) Ethyl (t-butoxycarbonyl-N-methylaminooxy)acetate152 
 
Sodium hydrogen carbonate (2.50 g, 30.0 mmol) and Di-tert-butyl dicarbonate (3.92 g, 
17.9 mmol) were added to N-methylhydroxylamine (1.25 g, 15.0 mmol) in THF‒H2O 
(27.5 ml, 10:1).  The solution was stirred for 20 h at r.t., diluted with H2O (25 ml), 
extracted with DCM (3 x 15 ml), dried (MgSO4) and concentrated under reduced 
pressure.  The resulting oil was added dropwise to sodium hydride (60% in oil, 1.44 g, 
36.1 mmol) in THF (15 ml) at 0 °C.  After stirring for 10 min 2-bromoethyl acetate (4.0 
ml, 36.1 mmol) was added dropwise.  The solution was stirred for 1 h and diluted with 
EtOAc (200 ml), washed with H2O (200 ml), sat. aq. NaCl (200 ml), dried (MgSO4) and 
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concentrated under reduced pressure.  The oil was purified by flash column 
chromatography (silica, 6:1→4:1 Hex-EtOAc) to afford a colourless oil (3.20 g, 66%).  
HRMS: Found ([M+Na]+) 256.1175, C10H19NNaO5+ requires 256.1155; 
1H NMR (500 
ΜΗz, CDCl3); Η = 4.44 (s, 2H, H-5), 4.22 (q, J 7.2 Hz, 2H, H-8), 3.20 (s, 1H, H-4), 1.48 
(s, 9H, H-1), 1.29 (t, J 7.2 Hz, 3H, H-7); 13C NMR (126 MHz, CDCl3) C = 169.3 (C-3), 
157.7 (C-6), 81.9 (C-2), 72.0 (C-5), 60.9 (C-7), 38.4 (C-4), 28.1 (C-1), 14.1 (C-8). 
 
 
(5.16b) (t-Butoxycarbonyl-N-methylaminooxy)acetic acid152 
 
Ethyl (t-butoxycarbonyl-N-methylaminooxy)acetate (3 g, 13.4 mmol) in 3M NaOH (2 ml) 
and THF (15 ml) was stirred for 3h.  The solution was diluted into EtOAc (100 ml), 
washed with 1M HCl (100 ml), H2O (100 ml), sat. aq. NaCl (100 ml), dried (MgSO4) and 
concentrated under reduced pressure.  The resulting oil was purified by flash column 
chromatography (silica, 50:50:1 Hex‒EtOAc‒AcOH) to afford a colourless oil (1.00 g, 
36%).  HRMS: Found ([M+Na]+) 228.0844, C8H15NNaO5+ requires 228.0842; 1H NMR 
(500 MHz, CDCl3) Η = 4.50 (s, 3H, H-4), 3.18 (s, 2H, H-5), 1.52 (s, 9H, H-1); 13C NMR 
(126 MHz, CDCl3) C 176.1 (C-3), 159.3 (C-6), 84.2 (C-5), 72.8 (C-2), 37.8 (C-4), 28.2 
(C-1). 
 
 
(5.17) (t-Butoxycarbonyl-N′-methylaminooxyacetyl)-N-hydroxysuccinimide 
ester152 
 
(t-Butoxycarbonyl-N-methylaminooxy)acetic acid with DCC (0.66 g, 5.85 mmol) and 
NHS (0.46 g, 7.32 mmol) were stirred in EtOAc (30 ml) for 2 h.  The product was then 
washed with 1% aq. NaHCO3 (30 ml), H2O (30 ml), sat. aq. NaCl (30 ml), dried (MgSO4) 
and concentrated under reduced pressure to give the product as a white solid (750 mg, 
51%).  HRMS: Found ([M+Na]+) 325.1009, C12H18N2NaO7+ requires 325.1006; 
1H NMR 
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(300 MHz, CDCl3) Η 4.80 (s, 2H, H-5), 3.19 (s, 3H, H-4), 2.86 (s, 2H, H-8), 1.50 (s, 9H, 
H-1); 13C NMR (75 MHz, CDCl3) C 168.6 (C-7), 165.0 (C-3), 157.7 (C-6), 82.4 (C-2), 
69.8 (C-5), 38.7 (C-4), 28.1 (C-1), 25.6 (C-8). 
 
 
(5.23) 6-(O-(2-thioureaethyl)-O′-(2-(t-Butoxycarbonyl-N′-methylaminooxyacetyl)-
aminoethyl nonaethylene glycol) fluorescein 
 
O-(2-(t-Butoxycarbonyl-N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol (50 mg, 0.07 mmol) and palladium on carbon (10 wt. %, 
30 mg) in MeOH (20 ml) were stirred stirred under an atmospher of H2 at r.t.p. for 3 h.  
The solution was then filtered and concentrated under reduced pressure.    The 
resulting oil was taken into sodium bicarbonate (1.2 ml, pH 8.5, 0.185 M) and FITC 
(12.4 mg, 0.03 mmol) in DMF (1.2 ml) was added and the solution stirred for 24 h.  To 
purify the product it was applied directly to a size exclusion column (LH-20) yielding the 
product as an orange oil (26 mg, 80%). HRMS: Found ([M+H]+) 1077.4597, 
C51H73N4O19S
+ requires 1077.4585. 
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(5.25) O-acetylmaltoheptaose81 
 
Triacetyl--cyclodextrin (10.0 g, 4.96 mmol) and sulfuric acid (1.2 ml, 22.5 mmol) in 
acetic anhydride (68.8 ml) were stirred at 60 °C o.n.  The solution was quenched with 
pyridine (40 ml) before concentration under reduced pressure.  The resulting oil was 
taken into EtOAc (250 ml), washed with H2O (100 ml), sat. aq. NaCl (100 ml), dried 
(MgSO4) and concentrated under reduced pressure to give a yellow foam.  The mixture 
was purified by flash column chromatography (silica, 4:1 EtOAc-Hex) to afford a white 
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solid (2.8 g, 28%); MS: Found ([M+Na+NH4]
2+) 1079.9, C88H122NNaO59
2+ requires 
1079.8;  
 - Major isomer: 1H-NMR (500 MHz, CDCl3) δH 6.20 (d, 1H, J1',2' 3.8 Hz, H-1'), 
5.46 (t, 1H, J2',3' 10.0 Hz, J3',4' 10.0 Hz, H-3'), 5.40 – 5.30 (m, 7H, 5 x H-3, H-1'', H-3''), 
5.30 – 5.20 (m, 5H, H-1), 5.03 (t, 1H, J3'',4'' 10.0 Hz, J4'',5'' 10.0 Hz , H-4''), 4.91 (dd, 1H, 
J1',2' 3.8 Hz, J2',3' 10.0 Hz, H-2'), 4.82 (dd, 1H, J1'',2'' 3.8 Hz, J2'',3'' 10.0 Hz, H-2'), 4.72 
– 4.64 (m, 5H, H-2), 4.51 – 4.39 (m, 7H, 5 x H-6, H-6', H-6''), 4.30 – 4.13 (m, 6H, 5 x H-
6, H-5'), 4.04 – 3.85 (m, 13H, H-4, H-4', H-5, H-5''), 2.21 – 1.81 (m, 69H, 7 x COCH3); 
13C-NMR (75 MHz, CDCl3) δ 169.7, 169.7, 169.6, 169.4, 168.9, 168.8, 168.6, 168.5, 
168.0 (23 x OCOCH3), 94.8, 94.7, 87.8 (C-1), 76.4, 76.0, 75.6, 72.1, 71.2, 70.7, 69.5, 
69.4, 69.2, 69.0, 68.7, 68.3, 68.1, 67.9, 67.4, 66.9, 61.3, 60.3, 59.4 (C2, C3, C4, C5, 
C6), 20.0, 19.9, 19.7, 19.6, 19.5, 19.4, 13.2 (23 x OCOCH3). 
 - Minor isomer: 1H-NMR (500 MHz, CDCl3) δH 5.71 (d, 1H, J1',2' 8 Hz, H-1' ), 5.46 
(t, 1H, J2',3' 10.0 Hz, J3',4' 10.0 Hz, H-3'), 5.40 – 5.30 (m, 7H, 5 x H-3, H-1'', H-3''), 5.30 – 
5.20 (m, 5H, H-1), 5.03 (t, 1H, J3'',4'' 10.0 Hz, J4'',5'' 10.0 Hz , H-4''), 4.89 (dd, 1H, J1',2' 
8.0 Hz, J2',3' 10.0 Hz, H-2'), 4.82 (dd, 1H, J1'',2'' 3.8 Hz, J2'',3'' 10.0 Hz, H-2'), 4.72 – 
4.64 (m, 5H, H-2), 4.51 – 4.39 (m, 7H, 5 x H-6, H-6', H-6''), 4.30 – 4.13 (m, 6H, 5 x H-6, 
H-5'), 4.04 – 3.85 (m, 13H, H-4, H-4', H-5, H-5''), 2.21 – 1.81 (m, 69H, 7 x COCH3); 
13C-
NMR (75 MHz, CDCl3) δ 169.7, 169.7, 169.6, 169.4, 168.9, 168.8, 168.6, 168.5, 168.0 
(23 x OCOCH3), 94.8, 94.7, 76.4, 76.0, 75.6, 72.1, 71.2, 70.7, 69.5, 69.4, 69.2, 69.0, 
68.7, 68.3, 68.1, 67.9, 67.4, 66.9, 61.3, 60.3, 59.4 (C2, C3, C4, C5, C6), 20.0, 19.9, 
19.7, 19.6, 19.5, 19.4, 13.2 (23 x OCOCH3). 
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(4.2) Maltoheptaose 
 
Per-acetylated maltoheptaose (2.3 g, 1.07 mmol) and sodium methoxide (230 mg, 1.17 
mmol) were stirred in methanol (23 ml) for 20 h.  The solution was neutralised with 
amberlite H-120 resin, filtered and concentrated under reduced pressure.  The residue 
was purified by size exclusion chromatography (LH-20) to produce a white solid (100 
mg, 8%).  MS: Found ([M+Na]+) 1175.4, C42H72NaO36
+ requires 1175.4; 
Major isomer  – 1H NMR (500 MHz, D2O) δ 5.41 (d, J1',2' = 3.4 Hz, 6H, H-1'), 5.24 (d, 
J1,2 = 3.8 Hz, 1H, H-1), 3.98 (m, 7H, H-3, 6 x H-3'), 3.92 – 3.75 (m, 21H, 6 x H-5', 6 x 
H-6a', 6 x H-6b', H-5, H-6a, H-6b), 3.65 (m, 13H, 5 x H-4', H-4, 6 x H-2', H-2), 3.44 (t, 
J4',3' = 9.5 Hz, J4',5' = 9.5 Hz, 1H, H-4'). 
Minor isomer  – 1H NMR (500 MHz, D2O) δ 5.41 (d, J1',2' = 3.4 Hz, 6H, H-1'), 4.67 (d, 
J1,2 = 8.0 Hz, 1H, H-1), 3.98 (m, 7H, H-3, 6 x H-3'), 3.92 – 3.75 (m, 21H, 6 x H-5', 6 x 
H-6a', 6 x H-6b', H-5, H-6a, H-6b), 3.65 (m, 12H, 5 x H-4', H-4, 6 x H-2'), 3.44 (t, J4',3' = 
9.5 Hz, J4',5' = 9.5 Hz, 1H, H-4'), 3.29 (t, J2,1 = 8.0 Hz, J2,3 = 8.0 Hz, 1H, H-2). 
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(5.26) Combined maltoheptaose and central fragments 
 
Benzyl 2,3,6-tri-O-benzyl-4-2-(2-(2-(ethoxy)ethoxy)ethoxypropargyl ether)--D-
glucopyranosyl-(14)- 2,3,6-tri-O-benzyl--D-glucopyranoside (12.6 mg, 11.0 mol) in 
DMF (600 l) had O-(2-(N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol maltoheptaose (16 mg, 9.2 mol) in H2O (10 l) added.  
Copper (II) sulphate (0.37 mg, 2.3 mol) in H2O (23l) was added followed by sodium-
D-ascorbate (0.91 mg, 4.6 mol) in H2O (46 l).  The solution was stirred for 20 h and 
the solution purified directly by size exclusion chromatography (H2O, LH-20) to give a 
colourless solid (21 mg, 79%).  HRMS: Found ([M+NH4+ NH4]
2+) 1463.6682, 
C137H207N7O61
2+ requires 1463.6667. 
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(5.29) The central fragment 
 
To a solution of Benzyl 2,3,6-tri-O-benzyl-4-2-(2-(2-(ethoxy)ethoxy)ethoxypropargyl 
ether)--D-glucopyranosyl-(14)- 2,3,6-tri-O-benzyl--D-glucopyranoside (106 mg, 93 
mol) and O-(2-(t-Butoxycarbonyl-N′-methylaminooxyacetyl)-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol (66 mg, 93 mol) in DMF (6.2 ml) was added copper (II) 
sulfate (3.69 mg, 23 mol) in water (239 l) and Na-L-Ascorbate (9.11 mg, 46 mol) in 
water (460 l).  The resulting solution was stirred for 24 h before being concentrated 
under reduced pressure.  The oil was purified by flash column chromatography (silica, 
4:1 EtOAc – MeOH) to afford a colourless oil (149 mg, 83%). HRMS: Found ([M+NH4]
+) 
1874.9841, C100H141N6O28
+ requires 1874.9841. 
Major isomer  1H NMR (500 MHz, CD3OD) δH 7.95 (s, 1H, H-20), 7.47 – 7.14 (m, 
35H, Ar-H), 5.57 (d, J1',2' = 3.6 Hz, 1H, H-1'), 4.98 – 4.64 (m, 7H, Bn-H), 4.64 – 4.39 (m, 
11H, H-1, H-22, H-19, Bn-H), 4.36 (s, 2H, H-11), 4.03 (t, J4,3 = 8.7 Hz, J4,5 = 8.7 Hz, 1H, 
H-4), 3.87 – 3.78 (m, 5H, H-3', H-4', H-5', H-18), 3.74 (t, J3,2 = 8.7 Hz, J3,4 = 8.7 Hz, 1H, 
H-3), 3.70 – 3.48 (m, 60H, H-2, H-5, H-6a, H-6b, H-6a', H-6b', H-14, H-16, H-17, H-23, 
H-24, H-25, H-26, H-27, H-28), 3.46 (t, J 5.5 Hz, 2H, H-15), 3.42 – 3.33 (m, 2H, H-2'), 
3.14 (s, 3H, H-10), 1.51 (s, 9H, H-7).  13C NMR (126 MHz, MeOD) δC 171.1 (C-9), 
159.2 (C-12), 140.3, 139.8, 139.7, 139.5, 139.1 (C-21, Bn-C), 129.5, 129.4, 129.4, 
129.3, 129.2, 129.1, 129.0, 129.0, 128.9, 128.8, 128.7, 128.7, 128.6, 128.3, 128.1, 
128.0 (Bn-CH), 125.6 (C-20), 103.7 (C-1), 97.6 (C-1'), 85.8 (C-3), 83.7 (C-2), 80.9 (C-
3'), 76.3 (C-2'), 74.9, 74.6, 74.4, 74.4, 74.2, 74.2, 72.5, 72.1, 71.8, 71.6, 71.6, 71.4, 
71.3, 71.2, 71.2, 70.8, 70.5, 70.3, 70.0 (C-4, C-4', C-5, C-5', C-6, C-6', C-11, C-14, C-
16, C-17, C-18, C-23, C-24, C-25, C-26, C-27, C-28, Bn-C), 65.1 (C-22), 51.4 (C-19), 
40.0 (C-15), 37.9 (C-10), 28.6 (C-7). 
Minor isomer : 1H NMR (500 MHz, CD3OD) δH 7.95 (s, 1H, H-20), 7.47 – 7.14 (m, 
35H, Ar-H), 5.61 (d, J1,2 = 3.5 Hz, 1H, H-1), 5.57 (d, J1',2' = 3.6 Hz, 1H, H-1'), 4.98 – 
4.64 (m, 7H, Bn-H), 4.64 – 4.39 (m, 10H, H-22, H-19, Bn-H), 4.36 (s, 2H, H-11), 3.95 – 
3.86 (m, 2H, H-4', H-5), 3.87 – 3.78 (m, 6H, H-3, H-3', H-4, H-5', H-18), 3.70 – 3.48 (m, 
60H, H-6a, H-6b, H-6a', H-6b', H-14, H-16, H-17, H-23, H-24, H-25, H-26, H-27, H-28), 
3.46 (t, J 5.5 Hz, 2H, H-15), 3.42 – 3.33 (m, 2H, H-2, H-2'), 3.14 (s, 3H, H-10), 1.51 (s, 
9H, H-7).  13C NMR (126 MHz, MeOD) δC 171.1 (C-9), 159.2 (C-12), 140.3, 139.8, 
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139.7, 139.5, 139.1 (C-21, Bn-C), 129.5, 129.4, 129.4, 129.3, 129.2, 129.1, 129.0, 
129.0, 128.9, 128.8, 128.7, 128.7, 128.6, 128.3, 128.1, 128.0 (Bn-CH), 125.6 (C-20), 
97.6 (C-1, C-1'), 80.9 (C-3, C-3'), 76.3 (C-2, C-2'), 74.9, 74.6, 74.4, 74.4, 74.2, 74.2, 
72.5, 72.1, 71.8, 71.6, 71.6, 71.4, 71.3, 71.2, 71.2, 70.8, 70.5, 70.3, 70.0 (C-4, C-4', C-
5, C-5', C-6, C-6', C-11, C-14, C-16, C-17, C-18, C-23, C-24, C-25, C-26, C-27, C-28, 
(Bn-C), 65.1 (C-22), 51.4 (C-19), 40.0 (C-15), 37.9 (C-10), 28.6 (C-7). 
 
 
7.2.3 SPPS 
 
7.2.3.1 General Reagents and Equipment  
All amino acids, resins and coupling reagents were purchased from Sigma Aldrich, 
VWR International and Cambridge Bioscience. All chemical compounds were used as 
received. Fritted polypropylene tubes (10 mL) purchased from Grace and Co were 
used as a vessel for all solid phase reactions. Agitation of the solid phase reaction 
mixture was achieved by rotation on a Stuart rotator which allowed multiple fritted 
polypropylene tubes to be spun simultaneously.  H-Gly-2-ClTrt (Sigma, loading: 1.1 
mmol/g) was used for solid phase peptide synthesis. 
Peptides were analysed using an Agilent 1290 affinity LC system equipped with an 
Ascentis Express 10 cm   2.1 mm, 2.7 μm ES-C18 peptide column (0.5 mL min−1) and 
ultraviolet (UV) detection at 220 nm - 280 nm. Gradient from 0.1% TFA/5% MeCN 
(vol/vol) in H2O to 0.1% TFA/95% MeCN in H2O over 5 min 40 s.  
 
 
7.2.4 General procedure for solid phase peptide synthesis  
 
Method One: Preparation of resin 
The resin was swollen in DMF for 1 h. HCTU (4.9 equiv) and an Fmoc-amino acid (5 
equiv) were dissolved in DMF (6 mL), followed by the addition of DIPEA (10 equiv).  
The solution was transferred to the swelled resin and the mixture was left to spin for 1 h 
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at room temperature. The resin was isolated by filtration and washed with DMF (3 × 6 
mL × 2 min spins). 
 
Method Two: Coupling reaction analysis  
A small sample of beads from the isolated Fmoc-amino acid-resin were exposed to 
TFA (100 l) for 2 minutes before the solution was quenched with methanol (1 mL). 
The solution was filtered and analysed by LCMS. If any starting material was detected 
method one was repeated. 
 
Method Three: Fmoc deprotection and peptide elongation  
The Fmoc-amino acid-resin was treated with piperidine (20% in DMF) (10 mL) and left 
to spin for 2 min at rt. This process was repeated five times before the amino acid resin 
was washed with DMF (5 × 10 mL × 2 min spins). The peptide sequence was 
elongated by repeating methods 1-3 (excluding the resin swelling step) until the correct 
peptide was synthesised.  
 
Method Four: Dde-protecting group removal and Fmoc-PEG-OH addition 
After elongation of the peptide to the desired length, a coupling step using a Boc-Gly-
OH residue was performed. After this coupling step, the resin was treated with a 
solution of hydrazine in DMF (2% v/v) (5 x 10 ml x 2 min spins).  The resin was then 
washed with DMF (5 × 10 mL × 2 min spins).  Methods 1-3 were then repeated for the 
addition of Fmoc-PEG-OH (12 equiv) but using HCTU (11.8 equiv) and DIPEA (24 
equiv). 
 
Method Five: Addition of Boc-Aoa-OH 
After addition of Fmoc-PEG-OH, a final coupling step using a Boc-Aoa-OH (9 equiv) 
residue was performed with DIPEA (18 equiv).  After methods 1-2 were repeated 
method six was followed. 
 
Method Six: Cleavage and isolation 
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The amino acid-resin was washed with DMF (3× 6 mL × 2 min spins), DCM (3 × 6 mL × 
2 min spins) and methanol (3 × 6 mL × 2 min spins). The resin was isolated by filtration 
before being dried under high vacuum for 3 h.  A cleavage cocktail consisting of HFIP 
(33% in H2O) (10 mL) was added to the resin and the mixture was left to spin for 2 h at 
rt. The resin was filtered and the peptide was analysed by LCMS before being 
dissolved in the minimal amount of water and freeze dried.  The peptide was purified by 
size exclusion chromatography (LH-20) before further purification by HPLC. 
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(5.10c) Trivalent ligand 
 
Yield (18 mg, 2%).  HRMS: Found ([M+NH4+H]
2+) 1268.6920, C112H197N23O40S
2+ 
requires 1268.6910. 
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8 Chapter VIII: Appendix 
 
8.1 pSAB2.2 
A pSAB2.2 vector was generated in a digest of pSAB2.0 with MfeI and re-ligated 
(Figure 8-1) by James Ross in the Turnbull laboratory.  This digestion removed the 
MBP gene (MalE), the CTA2 fusion protein as well as the additional terminator and 
promoter regions leaving the CTB gene downstream of the native tac promoter region 
of the pMAL-p5× plasmid.  On expression, this plasmid yielded a single mRNA 
containing the CTB gene.  This vector was produced by Dr. James Ross. 
 
Figure 8-1 The pSAB2.2 plasmid.  This plasmid is derived from the pSAB2.0 plasmid via 
digestion with MfeI.  When induced this plasmid should promote transcription of a mRNA 
containing the CTB gene (purple).  Figure produced with SnapGene. 
 
The maltoporin gene was ligated into the plasmid with the use of MfeI and HIND III 
restriction enzymes replacing the CTB gene. 
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